Sentence,Tags
Clustering of missense mutations in the ataxia - telangiectasia gene in a sporadic T - cell leukaemia .,"(('Clustering', 'O'), ('of', 'O'), ('missense', 'O'), ('mutations', 'O'), ('in', 'O'), ('the', 'O'), ('ataxia', 'B'), ('-', 'I'), ('telangiectasia', 'I'), ('gene', 'O'), ('in', 'O'), ('a', 'O'), ('sporadic', 'B'), ('T', 'I'), ('-', 'I'), ('cell', 'I'), ('leukaemia', 'I'), ('.', 'O'))"
Ataxia - telangiectasia ( A - T ) is a recessive multi - system disorder caused by mutations in the ATM gene at 11q22 - q23 ( ref . 3 ) .,"(('Ataxia', 'B'), ('-', 'I'), ('telangiectasia', 'I'), ('(', 'O'), ('A', 'B'), ('-', 'I'), ('T', 'I'), (')', 'O'), ('is', 'O'), ('a', 'O'), ('recessive', 'B'), ('multi', 'I'), ('-', 'I'), ('system', 'I'), ('disorder', 'I'), ('caused', 'O'), ('by', 'O'), ('mutations', 'O'), ('in', 'O'), ('the', 'O'), ('ATM', 'O'), ('gene', 'O'), ('at', 'O'), ('11q22', 'O'), ('-', 'O'), ('q23', 'O'), ('(', 'O'), ('ref', 'O'), ('.', 'O'), ('3', 'O'), (')', 'O'), ('.', 'O'))"
"The risk of cancer , especially lymphoid neoplasias , is substantially elevated in A - T patients and has long been associated with chromosomal instability .","(('The', 'O'), ('risk', 'O'), ('of', 'O'), ('cancer', 'B'), (',', 'O'), ('especially', 'O'), ('lymphoid', 'B'), ('neoplasias', 'I'), (',', 'O'), ('is', 'O'), ('substantially', 'O'), ('elevated', 'O'), ('in', 'O'), ('A', 'B'), ('-', 'I'), ('T', 'I'), ('patients', 'O'), ('and', 'O'), ('has', 'O'), ('long', 'O'), ('been', 'O'), ('associated', 'O'), ('with', 'O'), ('chromosomal', 'O'), ('instability', 'O'), ('.', 'O'))"
"By analysing tumour DNA from patients with sporadic T - cell prolymphocytic leukaemia ( T - PLL ) , a rare clonal malignancy with similarities to a mature T - cell leukaemia seen in A - T , we demonstrate a high frequency of ATM mutations in T - PLL .","(('By', 'O'), ('analysing', 'O'), ('tumour', 'B'), ('DNA', 'O'), ('from', 'O'), ('patients', 'O'), ('with', 'O'), ('sporadic', 'B'), ('T', 'I'), ('-', 'I'), ('cell', 'I'), ('prolymphocytic', 'I'), ('leukaemia', 'I'), ('(', 'O'), ('T', 'B'), ('-', 'I'), ('PLL', 'I'), (')', 'O'), (',', 'O'), ('a', 'O'), ('rare', 'O'), ('clonal', 'B'), ('malignancy', 'I'), ('with', 'O'), ('similarities', 'O'), ('to', 'O'), ('a', 'O'), ('mature', 'B'), ('T', 'I'), ('-', 'I'), ('cell', 'I'), ('leukaemia', 'I'), ('seen', 'O'), ('in', 'O'), ('A', 'B'), ('-', 'I'), ('T', 'I'), (',', 'O'), ('we', 'O'), ('demonstrate', 'O'), ('a', 'O'), ('high', 'O'), ('frequency', 'O'), ('of', 'O'), ('ATM', 'O'), ('mutations', 'O'), ('in', 'O'), ('T', 'B'), ('-', 'I'), ('PLL', 'I'), ('.', 'O'))"
"In marked contrast to the ATM mutation pattern in A - T , the most frequent nucleotide changes in this leukaemia were missense mutations .","(('In', 'O'), ('marked', 'O'), ('contrast', 'O'), ('to', 'O'), ('the', 'O'), ('ATM', 'O'), ('mutation', 'O'), ('pattern', 'O'), ('in', 'O'), ('A', 'B'), ('-', 'I'), ('T', 'I'), (',', 'O'), ('the', 'O'), ('most', 'O'), ('frequent', 'O'), ('nucleotide', 'O'), ('changes', 'O'), ('in', 'O'), ('this', 'O'), ('leukaemia', 'B'), ('were', 'O'), ('missense', 'O'), ('mutations', 'O'), ('.', 'O'))"
Two of seventeen mutated T - PLL samples had a previously reported A - T allele .,"(('Two', 'O'), ('of', 'O'), ('seventeen', 'O'), ('mutated', 'O'), ('T', 'B'), ('-', 'I'), ('PLL', 'I'), ('samples', 'O'), ('had', 'O'), ('a', 'O'), ('previously', 'O'), ('reported', 'O'), ('A', 'B'), ('-', 'I'), ('T', 'I'), ('allele', 'O'), ('.', 'O'))"
"In contrast , no mutations were detected in the p53 gene , suggesting that this tumour suppressor is not frequently altered in this leukaemia .","(('In', 'O'), ('contrast', 'O'), (',', 'O'), ('no', 'O'), ('mutations', 'O'), ('were', 'O'), ('detected', 'O'), ('in', 'O'), ('the', 'O'), ('p53', 'O'), ('gene', 'O'), (',', 'O'), ('suggesting', 'O'), ('that', 'O'), ('this', 'O'), ('tumour', 'B'), ('suppressor', 'O'), ('is', 'O'), ('not', 'O'), ('frequently', 'O'), ('altered', 'O'), ('in', 'O'), ('this', 'O'), ('leukaemia', 'B'), ('.', 'O'))"
Occasional missense mutations in ATM were also found in tumour DNA from patients with B - cell non - Hodgkins lymphomas ( B - NHL ) and a B - NHL cell line .,"(('Occasional', 'O'), ('missense', 'O'), ('mutations', 'O'), ('in', 'O'), ('ATM', 'O'), ('were', 'O'), ('also', 'O'), ('found', 'O'), ('in', 'O'), ('tumour', 'B'), ('DNA', 'O'), ('from', 'O'), ('patients', 'O'), ('with', 'O'), ('B', 'B'), ('-', 'I'), ('cell', 'I'), ('non', 'I'), ('-', 'I'), ('Hodgkins', 'I'), ('lymphomas', 'I'), ('(', 'O'), ('B', 'B'), ('-', 'I'), ('NHL', 'I'), (')', 'O'), ('and', 'O'), ('a', 'O'), ('B', 'B'), ('-', 'I'), ('NHL', 'I'), ('cell', 'O'), ('line', 'O'), ('.', 'O'))"
The evidence of a significant proportion of loss - of - function mutations and a complete absence of the normal copy of ATM in the majority of mutated tumours establishes somatic inactivation of this gene in the pathogenesis of sporadic T - PLL and suggests that ATM acts as a tumour suppressor .,"(('The', 'O'), ('evidence', 'O'), ('of', 'O'), ('a', 'O'), ('significant', 'O'), ('proportion', 'O'), ('of', 'O'), ('loss', 'O'), ('-', 'O'), ('of', 'O'), ('-', 'O'), ('function', 'O'), ('mutations', 'O'), ('and', 'O'), ('a', 'O'), ('complete', 'O'), ('absence', 'O'), ('of', 'O'), ('the', 'O'), ('normal', 'O'), ('copy', 'O'), ('of', 'O'), ('ATM', 'O'), ('in', 'O'), ('the', 'O'), ('majority', 'O'), ('of', 'O'), ('mutated', 'O'), ('tumours', 'B'), ('establishes', 'O'), ('somatic', 'O'), ('inactivation', 'O'), ('of', 'O'), ('this', 'O'), ('gene', 'O'), ('in', 'O'), ('the', 'O'), ('pathogenesis', 'O'), ('of', 'O'), ('sporadic', 'B'), ('T', 'I'), ('-', 'I'), ('PLL', 'I'), ('and', 'O'), ('suggests', 'O'), ('that', 'O'), ('ATM', 'O'), ('acts', 'O'), ('as', 'O'), ('a', 'O'), ('tumour', 'B'), ('suppressor', 'O'), ('.', 'O'))"
"As constitutional DNA was not available , a putative hereditary predisposition to T - PLL will require further investigation . .","(('As', 'O'), ('constitutional', 'O'), ('DNA', 'O'), ('was', 'O'), ('not', 'O'), ('available', 'O'), (',', 'O'), ('a', 'O'), ('putative', 'O'), ('hereditary', 'O'), ('predisposition', 'O'), ('to', 'O'), ('T', 'B'), ('-', 'I'), ('PLL', 'I'), ('will', 'O'), ('require', 'O'), ('further', 'O'), ('investigation', 'O'), ('.', 'O'), ('.', 'O'))"
Myotonic dystrophy protein kinase is involved in the modulation of the Ca2 + homeostasis in skeletal muscle cells .,"(('Myotonic', 'B'), ('dystrophy', 'I'), ('protein', 'O'), ('kinase', 'O'), ('is', 'O'), ('involved', 'O'), ('in', 'O'), ('the', 'O'), ('modulation', 'O'), ('of', 'O'), ('the', 'O'), ('Ca2', 'O'), ('+', 'O'), ('homeostasis', 'O'), ('in', 'O'), ('skeletal', 'O'), ('muscle', 'O'), ('cells', 'O'), ('.', 'O'))"
"Myotonic dystrophy ( DM ) , the most prevalent muscular disorder in adults , is caused by ( CTG ) n - repeat expansion in a gene encoding a protein kinase ( DM protein kinase ; DMPK ) and involves changes in cytoarchitecture and ion homeostasis .","(('Myotonic', 'B'), ('dystrophy', 'I'), ('(', 'O'), ('DM', 'B'), (')', 'O'), (',', 'O'), ('the', 'O'), ('most', 'O'), ('prevalent', 'O'), ('muscular', 'B'), ('disorder', 'I'), ('in', 'O'), ('adults', 'O'), (',', 'O'), ('is', 'O'), ('caused', 'O'), ('by', 'O'), ('(', 'O'), ('CTG', 'O'), (')', 'O'), ('n', 'O'), ('-', 'O'), ('repeat', 'O'), ('expansion', 'O'), ('in', 'O'), ('a', 'O'), ('gene', 'O'), ('encoding', 'O'), ('a', 'O'), ('protein', 'O'), ('kinase', 'O'), ('(', 'O'), ('DM', 'B'), ('protein', 'O'), ('kinase', 'O'), (';', 'O'), ('DMPK', 'O'), (')', 'O'), ('and', 'O'), ('involves', 'O'), ('changes', 'O'), ('in', 'O'), ('cytoarchitecture', 'O'), ('and', 'O'), ('ion', 'O'), ('homeostasis', 'O'), ('.', 'O'))"
Constitutional RB1 - gene mutations in patients with isolated unilateral retinoblastoma .,"(('Constitutional', 'O'), ('RB1', 'O'), ('-', 'O'), ('gene', 'O'), ('mutations', 'O'), ('in', 'O'), ('patients', 'O'), ('with', 'O'), ('isolated', 'O'), ('unilateral', 'B'), ('retinoblastoma', 'I'), ('.', 'O'))"
"In most patients with isolated unilateral retinoblastoma , tumor development is initiated by somatic inactivation of both alleles of the RB1 gene .","(('In', 'O'), ('most', 'O'), ('patients', 'O'), ('with', 'O'), ('isolated', 'O'), ('unilateral', 'B'), ('retinoblastoma', 'I'), (',', 'O'), ('tumor', 'B'), ('development', 'O'), ('is', 'O'), ('initiated', 'O'), ('by', 'O'), ('somatic', 'O'), ('inactivation', 'O'), ('of', 'O'), ('both', 'O'), ('alleles', 'O'), ('of', 'O'), ('the', 'O'), ('RB1', 'O'), ('gene', 'O'), ('.', 'O'))"
"However , some of these patients can transmit retinoblastoma predisposition to their offspring .","(('However', 'O'), (',', 'O'), ('some', 'O'), ('of', 'O'), ('these', 'O'), ('patients', 'O'), ('can', 'O'), ('transmit', 'O'), ('retinoblastoma', 'B'), ('predisposition', 'O'), ('to', 'O'), ('their', 'O'), ('offspring', 'O'), ('.', 'O'))"
"To determine the frequency and nature of constitutional RB1 - gene mutations in patients with isolated unilateral retinoblastoma , we analyzed DNA from peripheral blood and from tumor tissue .","(('To', 'O'), ('determine', 'O'), ('the', 'O'), ('frequency', 'O'), ('and', 'O'), ('nature', 'O'), ('of', 'O'), ('constitutional', 'O'), ('RB1', 'O'), ('-', 'O'), ('gene', 'O'), ('mutations', 'O'), ('in', 'O'), ('patients', 'O'), ('with', 'O'), ('isolated', 'O'), ('unilateral', 'B'), ('retinoblastoma', 'I'), (',', 'O'), ('we', 'O'), ('analyzed', 'O'), ('DNA', 'O'), ('from', 'O'), ('peripheral', 'O'), ('blood', 'O'), ('and', 'O'), ('from', 'O'), ('tumor', 'B'), ('tissue', 'O'), ('.', 'O'))"
The analysis of tumors from 54 ( 71 % ) of 76 informative patients showed loss of constitutional heterozygosity ( LOH ) at intragenic loci .,"(('The', 'O'), ('analysis', 'O'), ('of', 'O'), ('tumors', 'B'), ('from', 'O'), ('54', 'O'), ('(', 'O'), ('71', 'O'), ('%', 'O'), (')', 'O'), ('of', 'O'), ('76', 'O'), ('informative', 'O'), ('patients', 'O'), ('showed', 'O'), ('loss', 'O'), ('of', 'O'), ('constitutional', 'O'), ('heterozygosity', 'O'), ('(', 'O'), ('LOH', 'O'), (')', 'O'), ('at', 'O'), ('intragenic', 'O'), ('loci', 'O'), ('.', 'O'))"
"For 39 randomly selected tumors , SSCP , hetero - duplex analysis , sequencing , and Southern blot analysis were used to identify mutations .","(('For', 'O'), ('39', 'O'), ('randomly', 'O'), ('selected', 'O'), ('tumors', 'B'), (',', 'O'), ('SSCP', 'O'), (',', 'O'), ('hetero', 'O'), ('-', 'O'), ('duplex', 'O'), ('analysis', 'O'), (',', 'O'), ('sequencing', 'O'), (',', 'O'), ('and', 'O'), ('Southern', 'O'), ('blot', 'O'), ('analysis', 'O'), ('were', 'O'), ('used', 'O'), ('to', 'O'), ('identify', 'O'), ('mutations', 'O'), ('.', 'O'))"
Mutations were detected in 21 ( 91 % ) of 23 tumors with LOH .,"(('Mutations', 'O'), ('were', 'O'), ('detected', 'O'), ('in', 'O'), ('21', 'O'), ('(', 'O'), ('91', 'O'), ('%', 'O'), (')', 'O'), ('of', 'O'), ('23', 'O'), ('tumors', 'B'), ('with', 'O'), ('LOH', 'O'), ('.', 'O'))"
"In 6 ( 38 % ) of 16 tumors without LOH , one mutation was detected , and in 9 ( 56 % ) of the tumors without LOH , both mutations were found .","(('In', 'O'), ('6', 'O'), ('(', 'O'), ('38', 'O'), ('%', 'O'), (')', 'O'), ('of', 'O'), ('16', 'O'), ('tumors', 'B'), ('without', 'O'), ('LOH', 'O'), (',', 'O'), ('one', 'O'), ('mutation', 'O'), ('was', 'O'), ('detected', 'O'), (',', 'O'), ('and', 'O'), ('in', 'O'), ('9', 'O'), ('(', 'O'), ('56', 'O'), ('%', 'O'), (')', 'O'), ('of', 'O'), ('the', 'O'), ('tumors', 'B'), ('without', 'O'), ('LOH', 'O'), (',', 'O'), ('both', 'O'), ('mutations', 'O'), ('were', 'O'), ('found', 'O'), ('.', 'O'))"
"Thus , a total of 45 mutations were identified in tumors of 36 patients .","(('Thus', 'O'), (',', 'O'), ('a', 'O'), ('total', 'O'), ('of', 'O'), ('45', 'O'), ('mutations', 'O'), ('were', 'O'), ('identified', 'O'), ('in', 'O'), ('tumors', 'B'), ('of', 'O'), ('36', 'O'), ('patients', 'O'), ('.', 'O'))"
"In 2 patients without a detectable mutation in peripheral blood , mosaicism was suggested because 1 of the patients showed multifocal tumors and the other later developed bilateral retinoblastoma .","(('In', 'O'), ('2', 'O'), ('patients', 'O'), ('without', 'O'), ('a', 'O'), ('detectable', 'O'), ('mutation', 'O'), ('in', 'O'), ('peripheral', 'O'), ('blood', 'O'), (',', 'O'), ('mosaicism', 'O'), ('was', 'O'), ('suggested', 'O'), ('because', 'O'), ('1', 'O'), ('of', 'O'), ('the', 'O'), ('patients', 'O'), ('showed', 'O'), ('multifocal', 'O'), ('tumors', 'B'), ('and', 'O'), ('the', 'O'), ('other', 'O'), ('later', 'O'), ('developed', 'O'), ('bilateral', 'B'), ('retinoblastoma', 'I'), ('.', 'O'))"
"In conclusion , our results emphasize that the manifestation and transmissibility of retinoblastoma depend on the nature of the first mutation , its time in development , and the number and types of cells that are affected . .","(('In', 'O'), ('conclusion', 'O'), (',', 'O'), ('our', 'O'), ('results', 'O'), ('emphasize', 'O'), ('that', 'O'), ('the', 'O'), ('manifestation', 'O'), ('and', 'O'), ('transmissibility', 'O'), ('of', 'O'), ('retinoblastoma', 'B'), ('depend', 'O'), ('on', 'O'), ('the', 'O'), ('nature', 'O'), ('of', 'O'), ('the', 'O'), ('first', 'O'), ('mutation', 'O'), (',', 'O'), ('its', 'O'), ('time', 'O'), ('in', 'O'), ('development', 'O'), (',', 'O'), ('and', 'O'), ('the', 'O'), ('number', 'O'), ('and', 'O'), ('types', 'O'), ('of', 'O'), ('cells', 'O'), ('that', 'O'), ('are', 'O'), ('affected', 'O'), ('.', 'O'), ('.', 'O'))"
Hereditary deficiency of the fifth component of complement in man .,"(('Hereditary', 'B'), ('deficiency', 'I'), ('of', 'I'), ('the', 'I'), ('fifth', 'I'), ('component', 'I'), ('of', 'I'), ('complement', 'I'), ('in', 'O'), ('man', 'O'), ('.', 'O'))"
The first recognized human kindred with hereditary deficiency of the fifth component of complement ( C5 ) is described .,"(('The', 'O'), ('first', 'O'), ('recognized', 'O'), ('human', 'O'), ('kindred', 'O'), ('with', 'O'), ('hereditary', 'B'), ('deficiency', 'I'), ('of', 'I'), ('the', 'I'), ('fifth', 'I'), ('component', 'I'), ('of', 'I'), ('complement', 'I'), ('(', 'O'), ('C5', 'O'), (')', 'O'), ('is', 'O'), ('described', 'O'), ('.', 'O'))"
"The proband , a 20 - year - old black female with systemic lupus erythematosus since age 11 , lacked serum hemolytic complement activity , even during remission .","(('The', 'O'), ('proband', 'O'), (',', 'O'), ('a', 'O'), ('20', 'O'), ('-', 'O'), ('year', 'O'), ('-', 'O'), ('old', 'O'), ('black', 'O'), ('female', 'O'), ('with', 'O'), ('systemic', 'B'), ('lupus', 'I'), ('erythematosus', 'I'), ('since', 'O'), ('age', 'O'), ('11', 'O'), (',', 'O'), ('lacked', 'O'), ('serum', 'O'), ('hemolytic', 'O'), ('complement', 'O'), ('activity', 'O'), (',', 'O'), ('even', 'O'), ('during', 'O'), ('remission', 'O'), ('.', 'O'))"
"C5 levels of other family members were either normal or approximately half - normal , consistent with autosomal codominant inheritance of the gene determining C5 deficiency .","(('C5', 'O'), ('levels', 'O'), ('of', 'O'), ('other', 'O'), ('family', 'O'), ('members', 'O'), ('were', 'O'), ('either', 'O'), ('normal', 'O'), ('or', 'O'), ('approximately', 'O'), ('half', 'O'), ('-', 'O'), ('normal', 'O'), (',', 'O'), ('consistent', 'O'), ('with', 'O'), ('autosomal', 'O'), ('codominant', 'O'), ('inheritance', 'O'), ('of', 'O'), ('the', 'O'), ('gene', 'O'), ('determining', 'O'), ('C5', 'B'), ('deficiency', 'I'), ('.', 'O'))"
Normal hemolytic titers were restored to both homozygous C5 - deficient ( C5D ) sera by addition of highly purified human C5 .,"(('Normal', 'O'), ('hemolytic', 'O'), ('titers', 'O'), ('were', 'O'), ('restored', 'O'), ('to', 'O'), ('both', 'O'), ('homozygous', 'O'), ('C5', 'B'), ('-', 'I'), ('deficient', 'I'), ('(', 'O'), ('C5D', 'B'), (')', 'O'), ('sera', 'O'), ('by', 'O'), ('addition', 'O'), ('of', 'O'), ('highly', 'O'), ('purified', 'O'), ('human', 'O'), ('C5', 'O'), ('.', 'O'))"
"In specific C5 titrations , however , it was noted that when limited amounts of C5 were assayed in the presence of low dilutions of either C5D serum , curving rather than linear dose - response plots were consistently obtained , suggesting some inhibitory effect .","(('In', 'O'), ('specific', 'O'), ('C5', 'O'), ('titrations', 'O'), (',', 'O'), ('however', 'O'), (',', 'O'), ('it', 'O'), ('was', 'O'), ('noted', 'O'), ('that', 'O'), ('when', 'O'), ('limited', 'O'), ('amounts', 'O'), ('of', 'O'), ('C5', 'O'), ('were', 'O'), ('assayed', 'O'), ('in', 'O'), ('the', 'O'), ('presence', 'O'), ('of', 'O'), ('low', 'O'), ('dilutions', 'O'), ('of', 'O'), ('either', 'O'), ('C5D', 'B'), ('serum', 'O'), (',', 'O'), ('curving', 'O'), ('rather', 'O'), ('than', 'O'), ('linear', 'O'), ('dose', 'O'), ('-', 'O'), ('response', 'O'), ('plots', 'O'), ('were', 'O'), ('consistently', 'O'), ('obtained', 'O'), (',', 'O'), ('suggesting', 'O'), ('some', 'O'), ('inhibitory', 'O'), ('effect', 'O'), ('.', 'O'))"
"Further studies suggested that low dilutions of C5D serum contain a factor ( or factors ) interfering at some step in the hemolytic assay of C5 , rather than a true C5 inhibitor or inactivator .","(('Further', 'O'), ('studies', 'O'), ('suggested', 'O'), ('that', 'O'), ('low', 'O'), ('dilutions', 'O'), ('of', 'O'), ('C5D', 'B'), ('serum', 'O'), ('contain', 'O'), ('a', 'O'), ('factor', 'O'), ('(', 'O'), ('or', 'O'), ('factors', 'O'), (')', 'O'), ('interfering', 'O'), ('at', 'O'), ('some', 'O'), ('step', 'O'), ('in', 'O'), ('the', 'O'), ('hemolytic', 'O'), ('assay', 'O'), ('of', 'O'), ('C5', 'O'), (',', 'O'), ('rather', 'O'), ('than', 'O'), ('a', 'O'), ('true', 'O'), ('C5', 'O'), ('inhibitor', 'O'), ('or', 'O'), ('inactivator', 'O'), ('.', 'O'))"
"Of clinical interest are ( a ) the documentation of membranous glomerulonephritis , vasculitis , and arthritis in an individual lacking C5 ( and its biologic functions ) , and ( b ) a remarkable propensity to bacterial infections in the proband , even during periods of low - dose or alternate - day corticosteroid therapy .","(('Of', 'O'), ('clinical', 'O'), ('interest', 'O'), ('are', 'O'), ('(', 'O'), ('a', 'O'), (')', 'O'), ('the', 'O'), ('documentation', 'O'), ('of', 'O'), ('membranous', 'O'), ('glomerulonephritis', 'B'), (',', 'O'), ('vasculitis', 'B'), (',', 'O'), ('and', 'O'), ('arthritis', 'B'), ('in', 'O'), ('an', 'O'), ('individual', 'O'), ('lacking', 'O'), ('C5', 'O'), ('(', 'O'), ('and', 'O'), ('its', 'O'), ('biologic', 'O'), ('functions', 'O'), (')', 'O'), (',', 'O'), ('and', 'O'), ('(', 'O'), ('b', 'O'), (')', 'O'), ('a', 'O'), ('remarkable', 'O'), ('propensity', 'O'), ('to', 'O'), ('bacterial', 'B'), ('infections', 'I'), ('in', 'O'), ('the', 'O'), ('proband', 'O'), (',', 'O'), ('even', 'O'), ('during', 'O'), ('periods', 'O'), ('of', 'O'), ('low', 'O'), ('-', 'O'), ('dose', 'O'), ('or', 'O'), ('alternate', 'O'), ('-', 'O'), ('day', 'O'), ('corticosteroid', 'O'), ('therapy', 'O'), ('.', 'O'))"
Other observations indicate that the C5D state is compatible with normal coagulation function and the capacity to mount a neutrophilic leukocytosis during pyogenic infection . .,"(('Other', 'O'), ('observations', 'O'), ('indicate', 'O'), ('that', 'O'), ('the', 'O'), ('C5D', 'B'), ('state', 'O'), ('is', 'O'), ('compatible', 'O'), ('with', 'O'), ('normal', 'O'), ('coagulation', 'O'), ('function', 'O'), ('and', 'O'), ('the', 'O'), ('capacity', 'O'), ('to', 'O'), ('mount', 'O'), ('a', 'O'), ('neutrophilic', 'O'), ('leukocytosis', 'O'), ('during', 'O'), ('pyogenic', 'B'), ('infection', 'I'), ('.', 'O'), ('.', 'O'))"
"Susceptibility to ankylosing spondylitis in twins : the role of genes , HLA , and the environment .","(('Susceptibility', 'O'), ('to', 'O'), ('ankylosing', 'B'), ('spondylitis', 'I'), ('in', 'O'), ('twins', 'O'), (':', 'O'), ('the', 'O'), ('role', 'O'), ('of', 'O'), ('genes', 'O'), (',', 'O'), ('HLA', 'O'), (',', 'O'), ('and', 'O'), ('the', 'O'), ('environment', 'O'), ('.', 'O'))"
OBJECTIVE To determine the relative effects of genetic and environmental factors in susceptibility to ankylosing spondylitis ( AS ) .,"(('OBJECTIVE', 'O'), ('To', 'O'), ('determine', 'O'), ('the', 'O'), ('relative', 'O'), ('effects', 'O'), ('of', 'O'), ('genetic', 'O'), ('and', 'O'), ('environmental', 'O'), ('factors', 'O'), ('in', 'O'), ('susceptibility', 'O'), ('to', 'O'), ('ankylosing', 'B'), ('spondylitis', 'I'), ('(', 'O'), ('AS', 'B'), (')', 'O'), ('.', 'O'))"
METHODS Twins with AS were identified from the Royal National Hospital for Rheumatic Diseases database .,"(('METHODS', 'O'), ('Twins', 'O'), ('with', 'O'), ('AS', 'B'), ('were', 'O'), ('identified', 'O'), ('from', 'O'), ('the', 'O'), ('Royal', 'O'), ('National', 'O'), ('Hospital', 'O'), ('for', 'O'), ('Rheumatic', 'B'), ('Diseases', 'I'), ('database', 'O'), ('.', 'O'))"
"Genetic and environmental variance components were assessed with the program Mx , using data from this and previous studies of twins with AS .","(('Genetic', 'O'), ('and', 'O'), ('environmental', 'O'), ('variance', 'O'), ('components', 'O'), ('were', 'O'), ('assessed', 'O'), ('with', 'O'), ('the', 'O'), ('program', 'O'), ('Mx', 'O'), (',', 'O'), ('using', 'O'), ('data', 'O'), ('from', 'O'), ('this', 'O'), ('and', 'O'), ('previous', 'O'), ('studies', 'O'), ('of', 'O'), ('twins', 'O'), ('with', 'O'), ('AS', 'B'), ('.', 'O'))"
"CONCLUSION Susceptibility to AS is largely genetically determined , and the environmental trigger for the disease is probably ubiquitous .","(('CONCLUSION', 'O'), ('Susceptibility', 'O'), ('to', 'O'), ('AS', 'B'), ('is', 'O'), ('largely', 'O'), ('genetically', 'O'), ('determined', 'O'), (',', 'O'), ('and', 'O'), ('the', 'O'), ('environmental', 'O'), ('trigger', 'O'), ('for', 'O'), ('the', 'O'), ('disease', 'O'), ('is', 'O'), ('probably', 'O'), ('ubiquitous', 'O'), ('.', 'O'))"
HLA - B27 accounts for a minority of the overall genetic susceptibility to AS .,"(('HLA', 'O'), ('-', 'O'), ('B27', 'O'), ('accounts', 'O'), ('for', 'O'), ('a', 'O'), ('minority', 'O'), ('of', 'O'), ('the', 'O'), ('overall', 'O'), ('genetic', 'O'), ('susceptibility', 'O'), ('to', 'O'), ('AS', 'B'), ('.', 'O'))"
Germ - line mutations of the BRCA1 gene predispose women to early - onset breast and ovarian cancer by compromising the genes presumptive function as a tumor suppressor .,"(('Germ', 'O'), ('-', 'O'), ('line', 'O'), ('mutations', 'O'), ('of', 'O'), ('the', 'O'), ('BRCA1', 'O'), ('gene', 'O'), ('predispose', 'O'), ('women', 'O'), ('to', 'O'), ('early', 'O'), ('-', 'O'), ('onset', 'O'), ('breast', 'B'), ('and', 'I'), ('ovarian', 'I'), ('cancer', 'I'), ('by', 'O'), ('compromising', 'O'), ('the', 'O'), ('genes', 'O'), ('presumptive', 'O'), ('function', 'O'), ('as', 'O'), ('a', 'O'), ('tumor', 'B'), ('suppressor', 'O'), ('.', 'O'))"
This cell cycle - dependent colocalization of BARD1 and BRCA1 indicates a role for BARD1 in BRCA1 - mediated tumor suppression .,"(('This', 'O'), ('cell', 'O'), ('cycle', 'O'), ('-', 'O'), ('dependent', 'O'), ('colocalization', 'O'), ('of', 'O'), ('BARD1', 'O'), ('and', 'O'), ('BRCA1', 'O'), ('indicates', 'O'), ('a', 'O'), ('role', 'O'), ('for', 'O'), ('BARD1', 'O'), ('in', 'O'), ('BRCA1', 'O'), ('-', 'O'), ('mediated', 'O'), ('tumor', 'B'), ('suppression', 'O'), ('.', 'O'))"
Recent studies have shown that hereditary hemochromatosis ( HH ) is likely to be caused by homozygosity for a Cys282Tyr mutation in the HFE gene located 4 .,"(('Recent', 'O'), ('studies', 'O'), ('have', 'O'), ('shown', 'O'), ('that', 'O'), ('hereditary', 'B'), ('hemochromatosis', 'I'), ('(', 'O'), ('HH', 'B'), (')', 'O'), ('is', 'O'), ('likely', 'O'), ('to', 'O'), ('be', 'O'), ('caused', 'O'), ('by', 'O'), ('homozygosity', 'O'), ('for', 'O'), ('a', 'O'), ('Cys282Tyr', 'O'), ('mutation', 'O'), ('in', 'O'), ('the', 'O'), ('HFE', 'O'), ('gene', 'O'), ('located', 'O'), ('4', 'O'), ('.', 'O'))"
"Comparisons with allele frequencies based on prevalence estimates of HH showed some disagreements with the RFLP data , particularly in Finns .","(('Comparisons', 'O'), ('with', 'O'), ('allele', 'O'), ('frequencies', 'O'), ('based', 'O'), ('on', 'O'), ('prevalence', 'O'), ('estimates', 'O'), ('of', 'O'), ('HH', 'B'), ('showed', 'O'), ('some', 'O'), ('disagreements', 'O'), ('with', 'O'), ('the', 'O'), ('RFLP', 'O'), ('data', 'O'), (',', 'O'), ('particularly', 'O'), ('in', 'O'), ('Finns', 'O'), ('.', 'O'))"
The newly described HFE marker provides a new approach to the screening of HH as well as studies of the relationship between the HFE Tyr allele and different disorders including cancer,"(('The', 'O'), ('newly', 'O'), ('described', 'O'), ('HFE', 'O'), ('marker', 'O'), ('provides', 'O'), ('a', 'O'), ('new', 'O'), ('approach', 'O'), ('to', 'O'), ('the', 'O'), ('screening', 'O'), ('of', 'O'), ('HH', 'B'), ('as', 'O'), ('well', 'O'), ('as', 'O'), ('studies', 'O'), ('of', 'O'), ('the', 'O'), ('relationship', 'O'), ('between', 'O'), ('the', 'O'), ('HFE', 'O'), ('Tyr', 'O'), ('allele', 'O'), ('and', 'O'), ('different', 'O'), ('disorders', 'O'), ('including', 'O'), ('cancer', 'B'))"
Autosomal dominant neurohypophyseal diabetes insipidus associated with a missense mutation encoding Gly23 - - > Val in neurophysin II .,"(('Autosomal', 'B'), ('dominant', 'I'), ('neurohypophyseal', 'I'), ('diabetes', 'I'), ('insipidus', 'I'), ('associated', 'O'), ('with', 'O'), ('a', 'O'), ('missense', 'O'), ('mutation', 'O'), ('encoding', 'O'), ('Gly23', 'O'), ('-', 'O'), ('-', 'O'), ('>', 'O'), ('Val', 'O'), ('in', 'O'), ('neurophysin', 'O'), ('II', 'O'), ('.', 'O'))"
Autosomal dominant neurohypophyseal diabetes insipidus ( ADNDI ) is an inherited disease caused by progressive degeneration of the magnocellular neurons of the hypothalamus leading to decreased ability to produce the hormone arginine vasopressin ( AVP ) .,"(('Autosomal', 'B'), ('dominant', 'I'), ('neurohypophyseal', 'I'), ('diabetes', 'I'), ('insipidus', 'I'), ('(', 'O'), ('ADNDI', 'B'), (')', 'O'), ('is', 'O'), ('an', 'O'), ('inherited', 'B'), ('disease', 'I'), ('caused', 'O'), ('by', 'O'), ('progressive', 'O'), ('degeneration', 'O'), ('of', 'O'), ('the', 'O'), ('magnocellular', 'O'), ('neurons', 'O'), ('of', 'O'), ('the', 'O'), ('hypothalamus', 'O'), ('leading', 'O'), ('to', 'O'), ('decreased', 'O'), ('ability', 'O'), ('to', 'O'), ('produce', 'O'), ('the', 'O'), ('hormone', 'O'), ('arginine', 'O'), ('vasopressin', 'O'), ('(', 'O'), ('AVP', 'O'), (')', 'O'), ('.', 'O'))"
"Affected individuals are not symptomatic at birth , but usually develop diabetes insipidus at 1 - 6 yr of age .","(('Affected', 'O'), ('individuals', 'O'), ('are', 'O'), ('not', 'O'), ('symptomatic', 'O'), ('at', 'O'), ('birth', 'O'), (',', 'O'), ('but', 'O'), ('usually', 'O'), ('develop', 'O'), ('diabetes', 'B'), ('insipidus', 'I'), ('at', 'O'), ('1', 'O'), ('-', 'O'), ('6', 'O'), ('yr', 'O'), ('of', 'O'), ('age', 'O'), ('.', 'O'))"
"This mutation may be valuable for developing models of dominantly inherited neurodegeneration , as the early age of onset of symptoms suggests that this mutation may be particularly deleterious to the magnocellular neuron . .","(('This', 'O'), ('mutation', 'O'), ('may', 'O'), ('be', 'O'), ('valuable', 'O'), ('for', 'O'), ('developing', 'O'), ('models', 'O'), ('of', 'O'), ('dominantly', 'B'), ('inherited', 'I'), ('neurodegeneration', 'I'), (',', 'O'), ('as', 'O'), ('the', 'O'), ('early', 'O'), ('age', 'O'), ('of', 'O'), ('onset', 'O'), ('of', 'O'), ('symptoms', 'O'), ('suggests', 'O'), ('that', 'O'), ('this', 'O'), ('mutation', 'O'), ('may', 'O'), ('be', 'O'), ('particularly', 'O'), ('deleterious', 'O'), ('to', 'O'), ('the', 'O'), ('magnocellular', 'O'), ('neuron', 'O'), ('.', 'O'), ('.', 'O'))"
Frequent inactivation of PTEN / MMAC1 in primary prostate cancer .,"(('Frequent', 'O'), ('inactivation', 'O'), ('of', 'O'), ('PTEN', 'O'), ('/', 'O'), ('MMAC1', 'O'), ('in', 'O'), ('primary', 'O'), ('prostate', 'B'), ('cancer', 'I'), ('.', 'O'))"
"Sporadic prostate carcinoma is the most common male cancer in the Western world , yet many of the major genetic events involved in the progression of this often fatal cancer remain to be elucidated .","(('Sporadic', 'B'), ('prostate', 'I'), ('carcinoma', 'I'), ('is', 'O'), ('the', 'O'), ('most', 'O'), ('common', 'O'), ('male', 'B'), ('cancer', 'I'), ('in', 'O'), ('the', 'O'), ('Western', 'O'), ('world', 'O'), (',', 'O'), ('yet', 'O'), ('many', 'O'), ('of', 'O'), ('the', 'O'), ('major', 'O'), ('genetic', 'O'), ('events', 'O'), ('involved', 'O'), ('in', 'O'), ('the', 'O'), ('progression', 'O'), ('of', 'O'), ('this', 'O'), ('often', 'O'), ('fatal', 'O'), ('cancer', 'B'), ('remain', 'O'), ('to', 'O'), ('be', 'O'), ('elucidated', 'O'), ('.', 'O'))"
Numerous cytogenetic and allelotype studies have reported frequent loss of heterozygosity on chromosomal arm 10q in sporadic prostate cancer .,"(('Numerous', 'O'), ('cytogenetic', 'O'), ('and', 'O'), ('allelotype', 'O'), ('studies', 'O'), ('have', 'O'), ('reported', 'O'), ('frequent', 'O'), ('loss', 'O'), ('of', 'O'), ('heterozygosity', 'O'), ('on', 'O'), ('chromosomal', 'O'), ('arm', 'O'), ('10q', 'O'), ('in', 'O'), ('sporadic', 'B'), ('prostate', 'I'), ('cancer', 'I'), ('.', 'O'))"
"A new tumor suppressor gene , PTEN / MMAC1 , was isolated recently at this region of chromosome 10q23 and found to be inactivated by mutation in three prostate cancer cell lines .","(('A', 'O'), ('new', 'O'), ('tumor', 'B'), ('suppressor', 'O'), ('gene', 'O'), (',', 'O'), ('PTEN', 'O'), ('/', 'O'), ('MMAC1', 'O'), (',', 'O'), ('was', 'O'), ('isolated', 'O'), ('recently', 'O'), ('at', 'O'), ('this', 'O'), ('region', 'O'), ('of', 'O'), ('chromosome', 'O'), ('10q23', 'O'), ('and', 'O'), ('found', 'O'), ('to', 'O'), ('be', 'O'), ('inactivated', 'O'), ('by', 'O'), ('mutation', 'O'), ('in', 'O'), ('three', 'O'), ('prostate', 'B'), ('cancer', 'I'), ('cell', 'O'), ('lines', 'O'), ('.', 'O'))"
We screened 80 prostate tumors by microsatellite analysis and found chromosome 10q23 to be deleted in 23 cases .,"(('We', 'O'), ('screened', 'O'), ('80', 'O'), ('prostate', 'B'), ('tumors', 'I'), ('by', 'O'), ('microsatellite', 'O'), ('analysis', 'O'), ('and', 'O'), ('found', 'O'), ('chromosome', 'O'), ('10q23', 'O'), ('to', 'O'), ('be', 'O'), ('deleted', 'O'), ('in', 'O'), ('23', 'O'), ('cases', 'O'), ('.', 'O'))"
The identification of the second mutational event in 10 ( 43 % ) tumors establishes PTEN / MMAC1 as a main inactivation target of 10q loss in sporadic prostate cancer . .,"(('The', 'O'), ('identification', 'O'), ('of', 'O'), ('the', 'O'), ('second', 'O'), ('mutational', 'O'), ('event', 'O'), ('in', 'O'), ('10', 'O'), ('(', 'O'), ('43', 'O'), ('%', 'O'), (')', 'O'), ('tumors', 'B'), ('establishes', 'O'), ('PTEN', 'O'), ('/', 'O'), ('MMAC1', 'O'), ('as', 'O'), ('a', 'O'), ('main', 'O'), ('inactivation', 'O'), ('target', 'O'), ('of', 'O'), ('10q', 'O'), ('loss', 'O'), ('in', 'O'), ('sporadic', 'B'), ('prostate', 'I'), ('cancer', 'I'), ('.', 'O'), ('.', 'O'))"
Risk reversals in predictive testing for Huntington disease .,"(('Risk', 'O'), ('reversals', 'O'), ('in', 'O'), ('predictive', 'O'), ('testing', 'O'), ('for', 'O'), ('Huntington', 'B'), ('disease', 'I'), ('.', 'O'))"
The first predictive testing for Huntington disease ( HD ) was based on analysis of linked polymorphic DNA markers to estimate the likelihood of inheriting the mutation for HD .,"(('The', 'O'), ('first', 'O'), ('predictive', 'O'), ('testing', 'O'), ('for', 'O'), ('Huntington', 'B'), ('disease', 'I'), ('(', 'O'), ('HD', 'B'), (')', 'O'), ('was', 'O'), ('based', 'O'), ('on', 'O'), ('analysis', 'O'), ('of', 'O'), ('linked', 'O'), ('polymorphic', 'O'), ('DNA', 'O'), ('markers', 'O'), ('to', 'O'), ('estimate', 'O'), ('the', 'O'), ('likelihood', 'O'), ('of', 'O'), ('inheriting', 'O'), ('the', 'O'), ('mutation', 'O'), ('for', 'O'), ('HD', 'B'), ('.', 'O'))"
"With direct tests for the HD mutation , we have assessed the accuracy of results obtained by linkage approaches when requested to do so by the test individuals .","(('With', 'O'), ('direct', 'O'), ('tests', 'O'), ('for', 'O'), ('the', 'O'), ('HD', 'B'), ('mutation', 'O'), (',', 'O'), ('we', 'O'), ('have', 'O'), ('assessed', 'O'), ('the', 'O'), ('accuracy', 'O'), ('of', 'O'), ('results', 'O'), ('obtained', 'O'), ('by', 'O'), ('linkage', 'O'), ('approaches', 'O'), ('when', 'O'), ('requested', 'O'), ('to', 'O'), ('do', 'O'), ('so', 'O'), ('by', 'O'), ('the', 'O'), ('test', 'O'), ('individuals', 'O'), ('.', 'O'))"
A novel common missense mutation G301C in the N - acetylgalactosamine - 6 - sulfate sulfatase gene in mucopolysaccharidosis IVA .,"(('A', 'O'), ('novel', 'O'), ('common', 'O'), ('missense', 'O'), ('mutation', 'O'), ('G301C', 'O'), ('in', 'O'), ('the', 'O'), ('N', 'O'), ('-', 'O'), ('acetylgalactosamine', 'O'), ('-', 'O'), ('6', 'O'), ('-', 'O'), ('sulfate', 'O'), ('sulfatase', 'O'), ('gene', 'O'), ('in', 'O'), ('mucopolysaccharidosis', 'B'), ('IVA', 'I'), ('.', 'O'))"
Mucopolysaccharidosis IVA ( MPS IVA ) is an autosomal recessive lysosomal storage disorder caused by a genetic defect in N - acetylgalactosamine - 6 - sulfate sulfatase ( GALNS ) .,"(('Mucopolysaccharidosis', 'B'), ('IVA', 'I'), ('(', 'O'), ('MPS', 'B'), ('IVA', 'I'), (')', 'O'), ('is', 'O'), ('an', 'O'), ('autosomal', 'B'), ('recessive', 'I'), ('lysosomal', 'I'), ('storage', 'I'), ('disorder', 'I'), ('caused', 'O'), ('by', 'O'), ('a', 'O'), ('genetic', 'B'), ('defect', 'I'), ('in', 'O'), ('N', 'O'), ('-', 'O'), ('acetylgalactosamine', 'O'), ('-', 'O'), ('6', 'O'), ('-', 'O'), ('sulfate', 'O'), ('sulfatase', 'O'), ('(', 'O'), ('GALNS', 'O'), (')', 'O'), ('.', 'O'))"
"To characterize the mutational spectrum in various ethnic groups , mutations in the GALNS gene in Colombian MPS IVA patients were investigated , and genetic backgrounds were extensively analyzed to identify racial origin , based on mitochondrial DNA ( mtDNA ) lineages .","(('To', 'O'), ('characterize', 'O'), ('the', 'O'), ('mutational', 'O'), ('spectrum', 'O'), ('in', 'O'), ('various', 'O'), ('ethnic', 'O'), ('groups', 'O'), (',', 'O'), ('mutations', 'O'), ('in', 'O'), ('the', 'O'), ('GALNS', 'O'), ('gene', 'O'), ('in', 'O'), ('Colombian', 'O'), ('MPS', 'B'), ('IVA', 'I'), ('patients', 'O'), ('were', 'O'), ('investigated', 'O'), (',', 'O'), ('and', 'O'), ('genetic', 'O'), ('backgrounds', 'O'), ('were', 'O'), ('extensively', 'O'), ('analyzed', 'O'), ('to', 'O'), ('identify', 'O'), ('racial', 'O'), ('origin', 'O'), (',', 'O'), ('based', 'O'), ('on', 'O'), ('mitochondrial', 'O'), ('DNA', 'O'), ('(', 'O'), ('mtDNA', 'O'), (')', 'O'), ('lineages', 'O'), ('.', 'O'))"
Three novel missense mutations never identified previously in other populations and found in 16 out of 19 Colombian MPS IVA unrelated alleles account for 84 .,"(('Three', 'O'), ('novel', 'O'), ('missense', 'O'), ('mutations', 'O'), ('never', 'O'), ('identified', 'O'), ('previously', 'O'), ('in', 'O'), ('other', 'O'), ('populations', 'O'), ('and', 'O'), ('found', 'O'), ('in', 'O'), ('16', 'O'), ('out', 'O'), ('of', 'O'), ('19', 'O'), ('Colombian', 'O'), ('MPS', 'B'), ('IVA', 'I'), ('unrelated', 'O'), ('alleles', 'O'), ('account', 'O'), ('for', 'O'), ('84', 'O'), ('.', 'O'))"
Low frequency of BRCA1 germline mutations in 45 German breast / ovarian cancer families .,"(('Low', 'O'), ('frequency', 'O'), ('of', 'O'), ('BRCA1', 'O'), ('germline', 'O'), ('mutations', 'O'), ('in', 'O'), ('45', 'O'), ('German', 'O'), ('breast', 'B'), ('/', 'I'), ('ovarian', 'I'), ('cancer', 'I'), ('families', 'O'), ('.', 'O'))"
In this study we investigated 45 German breast / ovarian cancer families for germline mutations in the BRCA1 gene .,"(('In', 'O'), ('this', 'O'), ('study', 'O'), ('we', 'O'), ('investigated', 'O'), ('45', 'O'), ('German', 'O'), ('breast', 'B'), ('/', 'I'), ('ovarian', 'I'), ('cancer', 'I'), ('families', 'O'), ('for', 'O'), ('germline', 'O'), ('mutations', 'O'), ('in', 'O'), ('the', 'O'), ('BRCA1', 'O'), ('gene', 'O'), ('.', 'O'))"
"We identified four germline mutations in three breast cancer families and in one breast - ovarian cancer family . among these were one frameshift mutation , one nonsense mutation , one novel splice site mutation , and one missense mutation .","(('We', 'O'), ('identified', 'O'), ('four', 'O'), ('germline', 'O'), ('mutations', 'O'), ('in', 'O'), ('three', 'O'), ('breast', 'B'), ('cancer', 'I'), ('families', 'O'), ('and', 'O'), ('in', 'O'), ('one', 'O'), ('breast', 'B'), ('-', 'I'), ('ovarian', 'I'), ('cancer', 'I'), ('family', 'O'), ('.', 'O'), ('among', 'O'), ('these', 'O'), ('were', 'O'), ('one', 'O'), ('frameshift', 'O'), ('mutation', 'O'), (',', 'O'), ('one', 'O'), ('nonsense', 'O'), ('mutation', 'O'), (',', 'O'), ('one', 'O'), ('novel', 'O'), ('splice', 'O'), ('site', 'O'), ('mutation', 'O'), (',', 'O'), ('and', 'O'), ('one', 'O'), ('missense', 'O'), ('mutation', 'O'), ('.', 'O'))"
These findings show that BRCA1 is implicated in a small fraction of breast / ovarian cancer families suggesting the involvement of another susceptibility gene ( s ),"(('These', 'O'), ('findings', 'O'), ('show', 'O'), ('that', 'O'), ('BRCA1', 'O'), ('is', 'O'), ('implicated', 'O'), ('in', 'O'), ('a', 'O'), ('small', 'O'), ('fraction', 'O'), ('of', 'O'), ('breast', 'B'), ('/', 'I'), ('ovarian', 'I'), ('cancer', 'I'), ('families', 'O'), ('suggesting', 'O'), ('the', 'O'), ('involvement', 'O'), ('of', 'O'), ('another', 'O'), ('susceptibility', 'O'), ('gene', 'O'), ('(', 'O'), ('s', 'O'), (')', 'O'))"
Paternal transmission of congenital myotonic dystrophy .,"(('Paternal', 'O'), ('transmission', 'O'), ('of', 'O'), ('congenital', 'B'), ('myotonic', 'I'), ('dystrophy', 'I'), ('.', 'O'))"
We report a rare case of paternally transmitted congenital myotonic dystrophy ( DM ) .,"(('We', 'O'), ('report', 'O'), ('a', 'O'), ('rare', 'O'), ('case', 'O'), ('of', 'O'), ('paternally', 'O'), ('transmitted', 'O'), ('congenital', 'B'), ('myotonic', 'I'), ('dystrophy', 'I'), ('(', 'O'), ('DM', 'B'), (')', 'O'), ('.', 'O'))"
"The proband is a 23 year old , mentally retarded male who suffers severe muscular weakness .","(('The', 'O'), ('proband', 'O'), ('is', 'O'), ('a', 'O'), ('23', 'O'), ('year', 'O'), ('old', 'O'), (',', 'O'), ('mentally', 'B'), ('retarded', 'I'), ('male', 'O'), ('who', 'O'), ('suffers', 'O'), ('severe', 'O'), ('muscular', 'B'), ('weakness', 'I'), ('.', 'O'))"
His two sibs suffer from childhood onset DM .,"(('His', 'O'), ('two', 'O'), ('sibs', 'O'), ('suffer', 'O'), ('from', 'O'), ('childhood', 'O'), ('onset', 'O'), ('DM', 'B'), ('.', 'O'))"
"Their late father had the adult type of DM , with onset around 30 years .","(('Their', 'O'), ('late', 'O'), ('father', 'O'), ('had', 'O'), ('the', 'O'), ('adult', 'O'), ('type', 'O'), ('of', 'O'), ('DM', 'B'), (',', 'O'), ('with', 'O'), ('onset', 'O'), ('around', 'O'), ('30', 'O'), ('years', 'O'), ('.', 'O'))"
Only six other cases of paternal transmission of congenital DM have been reported recently .,"(('Only', 'O'), ('six', 'O'), ('other', 'O'), ('cases', 'O'), ('of', 'O'), ('paternal', 'O'), ('transmission', 'O'), ('of', 'O'), ('congenital', 'B'), ('DM', 'I'), ('have', 'O'), ('been', 'O'), ('reported', 'O'), ('recently', 'O'), ('.', 'O'))"
We review the sex related effects on transmission of congenital DM .,"(('We', 'O'), ('review', 'O'), ('the', 'O'), ('sex', 'O'), ('related', 'O'), ('effects', 'O'), ('on', 'O'), ('transmission', 'O'), ('of', 'O'), ('congenital', 'B'), ('DM', 'I'), ('.', 'O'))"
Decreased fertility of males with adult onset DM and contraction of the repeat upon male transmission contribute to the almost absent occurrence of paternal transmission of congenital DM .,"(('Decreased', 'O'), ('fertility', 'O'), ('of', 'O'), ('males', 'O'), ('with', 'O'), ('adult', 'O'), ('onset', 'O'), ('DM', 'B'), ('and', 'O'), ('contraction', 'O'), ('of', 'O'), ('the', 'O'), ('repeat', 'O'), ('upon', 'O'), ('male', 'O'), ('transmission', 'O'), ('contribute', 'O'), ('to', 'O'), ('the', 'O'), ('almost', 'O'), ('absent', 'O'), ('occurrence', 'O'), ('of', 'O'), ('paternal', 'O'), ('transmission', 'O'), ('of', 'O'), ('congenital', 'B'), ('DM', 'I'), ('.', 'O'))"
"Also the fathers of the reported congenitally affected children showed , on average , shorter CTG repeat lengths and hence less severe clinical symptoms than the mothers of children with congenital DM .","(('Also', 'O'), ('the', 'O'), ('fathers', 'O'), ('of', 'O'), ('the', 'O'), ('reported', 'O'), ('congenitally', 'O'), ('affected', 'O'), ('children', 'O'), ('showed', 'O'), (',', 'O'), ('on', 'O'), ('average', 'O'), (',', 'O'), ('shorter', 'O'), ('CTG', 'O'), ('repeat', 'O'), ('lengths', 'O'), ('and', 'O'), ('hence', 'O'), ('less', 'O'), ('severe', 'O'), ('clinical', 'O'), ('symptoms', 'O'), ('than', 'O'), ('the', 'O'), ('mothers', 'O'), ('of', 'O'), ('children', 'O'), ('with', 'O'), ('congenital', 'B'), ('DM', 'I'), ('.', 'O'))"
We conclude that paternal transmission of congenital DM is rare and preferentially occurs with onset of DM past 30 years in the father . .,"(('We', 'O'), ('conclude', 'O'), ('that', 'O'), ('paternal', 'O'), ('transmission', 'O'), ('of', 'O'), ('congenital', 'B'), ('DM', 'I'), ('is', 'O'), ('rare', 'O'), ('and', 'O'), ('preferentially', 'O'), ('occurs', 'O'), ('with', 'O'), ('onset', 'O'), ('of', 'O'), ('DM', 'B'), ('past', 'O'), ('30', 'O'), ('years', 'O'), ('in', 'O'), ('the', 'O'), ('father', 'O'), ('.', 'O'), ('.', 'O'))"
The RB1 gene mutation in a child with ectopic intracranial retinoblastoma .,"(('The', 'O'), ('RB1', 'O'), ('gene', 'O'), ('mutation', 'O'), ('in', 'O'), ('a', 'O'), ('child', 'O'), ('with', 'O'), ('ectopic', 'B'), ('intracranial', 'I'), ('retinoblastoma', 'I'), ('.', 'O'))"
The RB1 gene mutation was investigated in a child with ectopic intracranial retinoblastoma using DNA obtained from both the pineal and retinal tumours of the patient .,"(('The', 'O'), ('RB1', 'O'), ('gene', 'O'), ('mutation', 'O'), ('was', 'O'), ('investigated', 'O'), ('in', 'O'), ('a', 'O'), ('child', 'O'), ('with', 'O'), ('ectopic', 'B'), ('intracranial', 'I'), ('retinoblastoma', 'I'), ('using', 'O'), ('DNA', 'O'), ('obtained', 'O'), ('from', 'O'), ('both', 'O'), ('the', 'O'), ('pineal', 'B'), ('and', 'I'), ('retinal', 'I'), ('tumours', 'I'), ('of', 'O'), ('the', 'O'), ('patient', 'O'), ('.', 'O'))"
A nonsense mutation in exon 17 ( codon 556 ) of the RB1 gene was found to be present homozygously in both the retinal and the pineal tumours .,"(('A', 'O'), ('nonsense', 'O'), ('mutation', 'O'), ('in', 'O'), ('exon', 'O'), ('17', 'O'), ('(', 'O'), ('codon', 'O'), ('556', 'O'), (')', 'O'), ('of', 'O'), ('the', 'O'), ('RB1', 'O'), ('gene', 'O'), ('was', 'O'), ('found', 'O'), ('to', 'O'), ('be', 'O'), ('present', 'O'), ('homozygously', 'O'), ('in', 'O'), ('both', 'O'), ('the', 'O'), ('retinal', 'B'), ('and', 'I'), ('the', 'I'), ('pineal', 'I'), ('tumours', 'I'), ('.', 'O'))"
The mutation is in an area of the gene that encodes the protein - binding region known as the pocket region and has been detected in other cases of retinoblastoma . .,"(('The', 'O'), ('mutation', 'O'), ('is', 'O'), ('in', 'O'), ('an', 'O'), ('area', 'O'), ('of', 'O'), ('the', 'O'), ('gene', 'O'), ('that', 'O'), ('encodes', 'O'), ('the', 'O'), ('protein', 'O'), ('-', 'O'), ('binding', 'O'), ('region', 'O'), ('known', 'O'), ('as', 'O'), ('the', 'O'), ('pocket', 'O'), ('region', 'O'), ('and', 'O'), ('has', 'O'), ('been', 'O'), ('detected', 'O'), ('in', 'O'), ('other', 'O'), ('cases', 'O'), ('of', 'O'), ('retinoblastoma', 'B'), ('.', 'O'), ('.', 'O'))"
Appreciable beta hexosaminidase A ( hex A ) activity has been detected in cultured skin fibroblasts and melanoma tissue from healthy individuals previously reported as having deficiency of hex A activity indistinguishable from that of patients with Tay - Sachs disease ( TSD ) .,"(('Appreciable', 'O'), ('beta', 'O'), ('hexosaminidase', 'O'), ('A', 'O'), ('(', 'O'), ('hex', 'O'), ('A', 'O'), (')', 'O'), ('activity', 'O'), ('has', 'O'), ('been', 'O'), ('detected', 'O'), ('in', 'O'), ('cultured', 'O'), ('skin', 'O'), ('fibroblasts', 'O'), ('and', 'O'), ('melanoma', 'B'), ('tissue', 'O'), ('from', 'O'), ('healthy', 'O'), ('individuals', 'O'), ('previously', 'O'), ('reported', 'O'), ('as', 'O'), ('having', 'O'), ('deficiency', 'B'), ('of', 'I'), ('hex', 'I'), ('A', 'I'), ('activity', 'O'), ('indistinguishable', 'O'), ('from', 'O'), ('that', 'O'), ('of', 'O'), ('patients', 'O'), ('with', 'O'), ('Tay', 'B'), ('-', 'I'), ('Sachs', 'I'), ('disease', 'I'), ('(', 'O'), ('TSD', 'B'), (')', 'O'), ('.', 'O'))"
Previous family studies suggested that these individuals may be compound heterozygotes for the common mutant TSD gene and a rare ( allelic ) mutant gene .,"(('Previous', 'O'), ('family', 'O'), ('studies', 'O'), ('suggested', 'O'), ('that', 'O'), ('these', 'O'), ('individuals', 'O'), ('may', 'O'), ('be', 'O'), ('compound', 'O'), ('heterozygotes', 'O'), ('for', 'O'), ('the', 'O'), ('common', 'O'), ('mutant', 'O'), ('TSD', 'B'), ('gene', 'O'), ('and', 'O'), ('a', 'O'), ('rare', 'O'), ('(', 'O'), ('allelic', 'O'), (')', 'O'), ('mutant', 'O'), ('gene', 'O'), ('.', 'O'))"
Heterozygotes for the rare mutant may be indistinguishable from heterozygotes for the common TSD mutant .,"(('Heterozygotes', 'O'), ('for', 'O'), ('the', 'O'), ('rare', 'O'), ('mutant', 'O'), ('may', 'O'), ('be', 'O'), ('indistinguishable', 'O'), ('from', 'O'), ('heterozygotes', 'O'), ('for', 'O'), ('the', 'O'), ('common', 'O'), ('TSD', 'B'), ('mutant', 'O'), ('.', 'O'))"
"However , direct visualization and quantitation of hex A by the methods described may prevent false - positive prenatal diagnosis of TSD in fetuses having the incomplete hex A deficiency of the type described in the four healthy individuals","(('However', 'O'), (',', 'O'), ('direct', 'O'), ('visualization', 'O'), ('and', 'O'), ('quantitation', 'O'), ('of', 'O'), ('hex', 'O'), ('A', 'O'), ('by', 'O'), ('the', 'O'), ('methods', 'O'), ('described', 'O'), ('may', 'O'), ('prevent', 'O'), ('false', 'O'), ('-', 'O'), ('positive', 'O'), ('prenatal', 'O'), ('diagnosis', 'O'), ('of', 'O'), ('TSD', 'B'), ('in', 'O'), ('fetuses', 'O'), ('having', 'O'), ('the', 'O'), ('incomplete', 'O'), ('hex', 'B'), ('A', 'I'), ('deficiency', 'I'), ('of', 'O'), ('the', 'O'), ('type', 'O'), ('described', 'O'), ('in', 'O'), ('the', 'O'), ('four', 'O'), ('healthy', 'O'), ('individuals', 'O'))"
The tumor suppressor gene Smad4 / Dpc4 is required for gastrulation and later for anterior development of the mouse embryo .,"(('The', 'O'), ('tumor', 'B'), ('suppressor', 'O'), ('gene', 'O'), ('Smad4', 'O'), ('/', 'O'), ('Dpc4', 'O'), ('is', 'O'), ('required', 'O'), ('for', 'O'), ('gastrulation', 'O'), ('and', 'O'), ('later', 'O'), ('for', 'O'), ('anterior', 'O'), ('development', 'O'), ('of', 'O'), ('the', 'O'), ('mouse', 'O'), ('embryo', 'O'), ('.', 'O'))"
"Mutations in the SMAD4 / DPC4 tumor suppressor gene , a key signal transducer in most TGFbeta - related pathways , are involved in 50 % of pancreatic cancers .","(('Mutations', 'O'), ('in', 'O'), ('the', 'O'), ('SMAD4', 'O'), ('/', 'O'), ('DPC4', 'O'), ('tumor', 'B'), ('suppressor', 'O'), ('gene', 'O'), (',', 'O'), ('a', 'O'), ('key', 'O'), ('signal', 'O'), ('transducer', 'O'), ('in', 'O'), ('most', 'O'), ('TGFbeta', 'O'), ('-', 'O'), ('related', 'O'), ('pathways', 'O'), (',', 'O'), ('are', 'O'), ('involved', 'O'), ('in', 'O'), ('50', 'O'), ('%', 'O'), ('of', 'O'), ('pancreatic', 'B'), ('cancers', 'I'), ('.', 'O'))"
Growth retardation of the Smad4 - deficient embryos results from reduced cell proliferation rather than increased apoptosis .,"(('Growth', 'B'), ('retardation', 'I'), ('of', 'O'), ('the', 'O'), ('Smad4', 'O'), ('-', 'O'), ('deficient', 'O'), ('embryos', 'O'), ('results', 'O'), ('from', 'O'), ('reduced', 'O'), ('cell', 'O'), ('proliferation', 'O'), ('rather', 'O'), ('than', 'O'), ('increased', 'O'), ('apoptosis', 'O'), ('.', 'O'))"
Aggregation of mutant Smad4 ES cells with wild - type tetraploid morulae rescues the gastrulation defect .,"(('Aggregation', 'O'), ('of', 'O'), ('mutant', 'O'), ('Smad4', 'O'), ('ES', 'O'), ('cells', 'O'), ('with', 'O'), ('wild', 'O'), ('-', 'O'), ('type', 'O'), ('tetraploid', 'O'), ('morulae', 'O'), ('rescues', 'O'), ('the', 'O'), ('gastrulation', 'B'), ('defect', 'I'), ('.', 'O'))"
These results indicate that Smad4 is initially required for the differentiation of the visceral endoderm and that the gastrulation defect in the epiblast is secondary and non - cell autonomous .,"(('These', 'O'), ('results', 'O'), ('indicate', 'O'), ('that', 'O'), ('Smad4', 'O'), ('is', 'O'), ('initially', 'O'), ('required', 'O'), ('for', 'O'), ('the', 'O'), ('differentiation', 'O'), ('of', 'O'), ('the', 'O'), ('visceral', 'O'), ('endoderm', 'O'), ('and', 'O'), ('that', 'O'), ('the', 'O'), ('gastrulation', 'B'), ('defect', 'I'), ('in', 'O'), ('the', 'O'), ('epiblast', 'O'), ('is', 'O'), ('secondary', 'O'), ('and', 'O'), ('non', 'O'), ('-', 'O'), ('cell', 'O'), ('autonomous', 'O'), ('.', 'O'))"
Prevalence of p16 and CDK4 germline mutations in 48 melanoma - prone families in France .,"(('Prevalence', 'O'), ('of', 'O'), ('p16', 'O'), ('and', 'O'), ('CDK4', 'O'), ('germline', 'O'), ('mutations', 'O'), ('in', 'O'), ('48', 'O'), ('melanoma', 'B'), ('-', 'O'), ('prone', 'O'), ('families', 'O'), ('in', 'O'), ('France', 'O'), ('.', 'O'))"
The French Familial Melanoma Study Group .,"(('The', 'O'), ('French', 'O'), ('Familial', 'B'), ('Melanoma', 'I'), ('Study', 'O'), ('Group', 'O'), ('.', 'O'))"
"Germline mutations in the p16 and CDK4 genes have been reported in a subset of melanoma pedigrees , but their prevalence is not well known .","(('Germline', 'O'), ('mutations', 'O'), ('in', 'O'), ('the', 'O'), ('p16', 'O'), ('and', 'O'), ('CDK4', 'O'), ('genes', 'O'), ('have', 'O'), ('been', 'O'), ('reported', 'O'), ('in', 'O'), ('a', 'O'), ('subset', 'O'), ('of', 'O'), ('melanoma', 'B'), ('pedigrees', 'O'), (',', 'O'), ('but', 'O'), ('their', 'O'), ('prevalence', 'O'), ('is', 'O'), ('not', 'O'), ('well', 'O'), ('known', 'O'), ('.', 'O'))"
"We searched for such germline mutations in 48 French melanoma - prone families selected according to two major criteria families with at least three affected members ( n = 20 ) or families with two affected members , one of them affected before the age of 50 ( n = 28 ) , and one additional minor criterion .","(('We', 'O'), ('searched', 'O'), ('for', 'O'), ('such', 'O'), ('germline', 'O'), ('mutations', 'O'), ('in', 'O'), ('48', 'O'), ('French', 'O'), ('melanoma', 'B'), ('-', 'O'), ('prone', 'O'), ('families', 'O'), ('selected', 'O'), ('according', 'O'), ('to', 'O'), ('two', 'O'), ('major', 'O'), ('criteria', 'O'), ('families', 'O'), ('with', 'O'), ('at', 'O'), ('least', 'O'), ('three', 'O'), ('affected', 'O'), ('members', 'O'), ('(', 'O'), ('n', 'O'), ('=', 'O'), ('20', 'O'), (')', 'O'), ('or', 'O'), ('families', 'O'), ('with', 'O'), ('two', 'O'), ('affected', 'O'), ('members', 'O'), (',', 'O'), ('one', 'O'), ('of', 'O'), ('them', 'O'), ('affected', 'O'), ('before', 'O'), ('the', 'O'), ('age', 'O'), ('of', 'O'), ('50', 'O'), ('(', 'O'), ('n', 'O'), ('=', 'O'), ('28', 'O'), (')', 'O'), (',', 'O'), ('and', 'O'), ('one', 'O'), ('additional', 'O'), ('minor', 'O'), ('criterion', 'O'), ('.', 'O'))"
"In summary , our results show frequent involvement of the p16 gene in familial melanoma and confirm the role of the CDK4 gene as a melanoma - predisposing gene . .","(('In', 'O'), ('summary', 'O'), (',', 'O'), ('our', 'O'), ('results', 'O'), ('show', 'O'), ('frequent', 'O'), ('involvement', 'O'), ('of', 'O'), ('the', 'O'), ('p16', 'O'), ('gene', 'O'), ('in', 'O'), ('familial', 'B'), ('melanoma', 'I'), ('and', 'O'), ('confirm', 'O'), ('the', 'O'), ('role', 'O'), ('of', 'O'), ('the', 'O'), ('CDK4', 'O'), ('gene', 'O'), ('as', 'O'), ('a', 'O'), ('melanoma', 'B'), ('-', 'O'), ('predisposing', 'O'), ('gene', 'O'), ('.', 'O'), ('.', 'O'))"
Progression of somatic CTG repeat length heterogeneity in the blood cells of myotonic dystrophy patients .,"(('Progression', 'O'), ('of', 'O'), ('somatic', 'O'), ('CTG', 'O'), ('repeat', 'O'), ('length', 'O'), ('heterogeneity', 'O'), ('in', 'O'), ('the', 'O'), ('blood', 'O'), ('cells', 'O'), ('of', 'O'), ('myotonic', 'B'), ('dystrophy', 'I'), ('patients', 'O'), ('.', 'O'))"
The genetic basis of myotonic dystrophy ( DM ) is the expansion of an unstable CTG repeat in the 34 UTR of the DM protein kinase gene on chromosome 19 .,"(('The', 'O'), ('genetic', 'O'), ('basis', 'O'), ('of', 'O'), ('myotonic', 'B'), ('dystrophy', 'I'), ('(', 'O'), ('DM', 'B'), (')', 'O'), ('is', 'O'), ('the', 'O'), ('expansion', 'O'), ('of', 'O'), ('an', 'O'), ('unstable', 'O'), ('CTG', 'O'), ('repeat', 'O'), ('in', 'O'), ('the', 'O'), ('34', 'O'), ('UTR', 'O'), ('of', 'O'), ('the', 'O'), ('DM', 'B'), ('protein', 'O'), ('kinase', 'O'), ('gene', 'O'), ('on', 'O'), ('chromosome', 'O'), ('19', 'O'), ('.', 'O'))"
"One of the principal features of the DM mutation is an extraordinarily high level of somatic mosaicism , due to an extremely high degree of somatic instability both within and between different tissues .","(('One', 'O'), ('of', 'O'), ('the', 'O'), ('principal', 'O'), ('features', 'O'), ('of', 'O'), ('the', 'O'), ('DM', 'B'), ('mutation', 'O'), ('is', 'O'), ('an', 'O'), ('extraordinarily', 'O'), ('high', 'O'), ('level', 'O'), ('of', 'O'), ('somatic', 'O'), ('mosaicism', 'O'), (',', 'O'), ('due', 'O'), ('to', 'O'), ('an', 'O'), ('extremely', 'O'), ('high', 'O'), ('degree', 'O'), ('of', 'O'), ('somatic', 'O'), ('instability', 'O'), ('both', 'O'), ('within', 'O'), ('and', 'O'), ('between', 'O'), ('different', 'O'), ('tissues', 'O'), ('.', 'O'))"
"In order to further characterize the dynamics of DM CTG repeat somatic instability , we have studied repeat length changes over time in 111 myotonic dystrophy patients with varying clinical severity and CTG repeat size over time intervals of 1 - 7 years .","(('In', 'O'), ('order', 'O'), ('to', 'O'), ('further', 'O'), ('characterize', 'O'), ('the', 'O'), ('dynamics', 'O'), ('of', 'O'), ('DM', 'B'), ('CTG', 'O'), ('repeat', 'O'), ('somatic', 'O'), ('instability', 'O'), (',', 'O'), ('we', 'O'), ('have', 'O'), ('studied', 'O'), ('repeat', 'O'), ('length', 'O'), ('changes', 'O'), ('over', 'O'), ('time', 'O'), ('in', 'O'), ('111', 'O'), ('myotonic', 'B'), ('dystrophy', 'I'), ('patients', 'O'), ('with', 'O'), ('varying', 'O'), ('clinical', 'O'), ('severity', 'O'), ('and', 'O'), ('CTG', 'O'), ('repeat', 'O'), ('size', 'O'), ('over', 'O'), ('time', 'O'), ('intervals', 'O'), ('of', 'O'), ('1', 'O'), ('-', 'O'), ('7', 'O'), ('years', 'O'), ('.', 'O'))"
Aspartylglucosaminuria among Palestinian Arabs .,"(('Aspartylglucosaminuria', 'B'), ('among', 'O'), ('Palestinian', 'O'), ('Arabs', 'O'), ('.', 'O'))"
Aspartylglucosaminuria ( AGU ) is a rare disorder of glycoprotein metabolism caused by the deficiency of the lysosomal enzyme aspartylglucosaminidase ( AGA ) .,"(('Aspartylglucosaminuria', 'B'), ('(', 'O'), ('AGU', 'B'), (')', 'O'), ('is', 'O'), ('a', 'O'), ('rare', 'O'), ('disorder', 'B'), ('of', 'I'), ('glycoprotein', 'I'), ('metabolism', 'I'), ('caused', 'O'), ('by', 'O'), ('the', 'O'), ('deficiency', 'B'), ('of', 'I'), ('the', 'I'), ('lysosomal', 'I'), ('enzyme', 'I'), ('aspartylglucosaminidase', 'I'), ('(', 'O'), ('AGA', 'O'), (')', 'O'), ('.', 'O'))"
AGU is inherited as an autosomal recessive trait and occurs with a high frequency in Finland because of a founder effect .,"(('AGU', 'B'), ('is', 'O'), ('inherited', 'O'), ('as', 'O'), ('an', 'O'), ('autosomal', 'O'), ('recessive', 'O'), ('trait', 'O'), ('and', 'O'), ('occurs', 'O'), ('with', 'O'), ('a', 'O'), ('high', 'O'), ('frequency', 'O'), ('in', 'O'), ('Finland', 'O'), ('because', 'O'), ('of', 'O'), ('a', 'O'), ('founder', 'O'), ('effect', 'O'), ('.', 'O'))"
"While very few patients with AGU have been reported from non - Finnish origin , we diagnosed the disorder in 8 patients originating from 3 unrelated families , all Palestinian Arabs from the region of Jerusalem .","(('While', 'O'), ('very', 'O'), ('few', 'O'), ('patients', 'O'), ('with', 'O'), ('AGU', 'B'), ('have', 'O'), ('been', 'O'), ('reported', 'O'), ('from', 'O'), ('non', 'O'), ('-', 'O'), ('Finnish', 'O'), ('origin', 'O'), (',', 'O'), ('we', 'O'), ('diagnosed', 'O'), ('the', 'O'), ('disorder', 'O'), ('in', 'O'), ('8', 'O'), ('patients', 'O'), ('originating', 'O'), ('from', 'O'), ('3', 'O'), ('unrelated', 'O'), ('families', 'O'), (',', 'O'), ('all', 'O'), ('Palestinian', 'O'), ('Arabs', 'O'), ('from', 'O'), ('the', 'O'), ('region', 'O'), ('of', 'O'), ('Jerusalem', 'O'), ('.', 'O'))"
"The clinical diagnosis of AGU is often difficult , in particular early in the course of the disease , and most of the patients are diagnosed after the age of 5 years .","(('The', 'O'), ('clinical', 'O'), ('diagnosis', 'O'), ('of', 'O'), ('AGU', 'B'), ('is', 'O'), ('often', 'O'), ('difficult', 'O'), (',', 'O'), ('in', 'O'), ('particular', 'O'), ('early', 'O'), ('in', 'O'), ('the', 'O'), ('course', 'O'), ('of', 'O'), ('the', 'O'), ('disease', 'O'), (',', 'O'), ('and', 'O'), ('most', 'O'), ('of', 'O'), ('the', 'O'), ('patients', 'O'), ('are', 'O'), ('diagnosed', 'O'), ('after', 'O'), ('the', 'O'), ('age', 'O'), ('of', 'O'), ('5', 'O'), ('years', 'O'), ('.', 'O'))"
Detection of heterozygous carriers of the ataxia - telangiectasia ( ATM ) gene by G2 phase chromosomal radiosensitivity of peripheral blood lymphocytes .,"(('Detection', 'O'), ('of', 'O'), ('heterozygous', 'O'), ('carriers', 'O'), ('of', 'O'), ('the', 'O'), ('ataxia', 'B'), ('-', 'I'), ('telangiectasia', 'I'), ('(', 'O'), ('ATM', 'O'), (')', 'O'), ('gene', 'O'), ('by', 'O'), ('G2', 'O'), ('phase', 'O'), ('chromosomal', 'O'), ('radiosensitivity', 'O'), ('of', 'O'), ('peripheral', 'O'), ('blood', 'O'), ('lymphocytes', 'O'), ('.', 'O'))"
"In ataxia - telangiectasia ( A - T ) patients , mutations in a single gene , ATM , result in an autosomal recessive syndrome that embraces a variety of clinical features and manifests extreme radiosensitivity and a strong pre - disposition to malignancy .","(('In', 'O'), ('ataxia', 'B'), ('-', 'I'), ('telangiectasia', 'I'), ('(', 'O'), ('A', 'B'), ('-', 'I'), ('T', 'I'), (')', 'O'), ('patients', 'O'), (',', 'O'), ('mutations', 'O'), ('in', 'O'), ('a', 'O'), ('single', 'O'), ('gene', 'O'), (',', 'O'), ('ATM', 'O'), (',', 'O'), ('result', 'O'), ('in', 'O'), ('an', 'O'), ('autosomal', 'B'), ('recessive', 'I'), ('syndrome', 'I'), ('that', 'O'), ('embraces', 'O'), ('a', 'O'), ('variety', 'O'), ('of', 'O'), ('clinical', 'O'), ('features', 'O'), ('and', 'O'), ('manifests', 'O'), ('extreme', 'O'), ('radiosensitivity', 'O'), ('and', 'O'), ('a', 'O'), ('strong', 'O'), ('pre', 'O'), ('-', 'O'), ('disposition', 'O'), ('to', 'O'), ('malignancy', 'B'), ('.', 'O'))"
Heterozygotes for the ATM gene have no clinical expression of A - T but may be cancer prone with a moderate increase in in vitro radiosensitivity .,"(('Heterozygotes', 'O'), ('for', 'O'), ('the', 'O'), ('ATM', 'O'), ('gene', 'O'), ('have', 'O'), ('no', 'O'), ('clinical', 'O'), ('expression', 'O'), ('of', 'O'), ('A', 'B'), ('-', 'I'), ('T', 'I'), ('but', 'O'), ('may', 'O'), ('be', 'O'), ('cancer', 'B'), ('prone', 'O'), ('with', 'O'), ('a', 'O'), ('moderate', 'O'), ('increase', 'O'), ('in', 'O'), ('in', 'O'), ('vitro', 'O'), ('radiosensitivity', 'O'), ('.', 'O'))"
"We performed a blind chromosomal analysis on G2 - phase lymphocytes from 7 unrelated A - T patients , 13 obligate A - T heterozygotes ( parents of the patients ) , and 14 normal controls following X - irradiation with 1 Gy in order to evaluate this cytogenetic method as a tool for detection of ATM carriers .","(('We', 'O'), ('performed', 'O'), ('a', 'O'), ('blind', 'O'), ('chromosomal', 'O'), ('analysis', 'O'), ('on', 'O'), ('G2', 'O'), ('-', 'O'), ('phase', 'O'), ('lymphocytes', 'O'), ('from', 'O'), ('7', 'O'), ('unrelated', 'O'), ('A', 'B'), ('-', 'I'), ('T', 'I'), ('patients', 'O'), (',', 'O'), ('13', 'O'), ('obligate', 'O'), ('A', 'B'), ('-', 'I'), ('T', 'I'), ('heterozygotes', 'O'), ('(', 'O'), ('parents', 'O'), ('of', 'O'), ('the', 'O'), ('patients', 'O'), (')', 'O'), (',', 'O'), ('and', 'O'), ('14', 'O'), ('normal', 'O'), ('controls', 'O'), ('following', 'O'), ('X', 'O'), ('-', 'O'), ('irradiation', 'O'), ('with', 'O'), ('1', 'O'), ('Gy', 'O'), ('in', 'O'), ('order', 'O'), ('to', 'O'), ('evaluate', 'O'), ('this', 'O'), ('cytogenetic', 'O'), ('method', 'O'), ('as', 'O'), ('a', 'O'), ('tool', 'O'), ('for', 'O'), ('detection', 'O'), ('of', 'O'), ('ATM', 'O'), ('carriers', 'O'), ('.', 'O'))"
Both A - T homozygotes and heterozygotes showed significantly increased levels of radiation - induced chromatid damage relative to that of normal controls .,"(('Both', 'O'), ('A', 'B'), ('-', 'I'), ('T', 'I'), ('homozygotes', 'O'), ('and', 'O'), ('heterozygotes', 'O'), ('showed', 'O'), ('significantly', 'O'), ('increased', 'O'), ('levels', 'O'), ('of', 'O'), ('radiation', 'O'), ('-', 'O'), ('induced', 'O'), ('chromatid', 'O'), ('damage', 'O'), ('relative', 'O'), ('to', 'O'), ('that', 'O'), ('of', 'O'), ('normal', 'O'), ('controls', 'O'), ('.', 'O'))"
These results show that the G2 - phase chromosomal radiosensitivity assay can be used for the detection of A - T heterozygotes .,"(('These', 'O'), ('results', 'O'), ('show', 'O'), ('that', 'O'), ('the', 'O'), ('G2', 'O'), ('-', 'O'), ('phase', 'O'), ('chromosomal', 'O'), ('radiosensitivity', 'O'), ('assay', 'O'), ('can', 'O'), ('be', 'O'), ('used', 'O'), ('for', 'O'), ('the', 'O'), ('detection', 'O'), ('of', 'O'), ('A', 'B'), ('-', 'I'), ('T', 'I'), ('heterozygotes', 'O'), ('.', 'O'))"
"In combination with molecular genetic analyses , this test may be of value in studies of familial and sporadic cancers aimed at determination of the potential involvement of ATM mutations in tumor risk or development . .","(('In', 'O'), ('combination', 'O'), ('with', 'O'), ('molecular', 'O'), ('genetic', 'O'), ('analyses', 'O'), (',', 'O'), ('this', 'O'), ('test', 'O'), ('may', 'O'), ('be', 'O'), ('of', 'O'), ('value', 'O'), ('in', 'O'), ('studies', 'O'), ('of', 'O'), ('familial', 'B'), ('and', 'I'), ('sporadic', 'I'), ('cancers', 'I'), ('aimed', 'O'), ('at', 'O'), ('determination', 'O'), ('of', 'O'), ('the', 'O'), ('potential', 'O'), ('involvement', 'O'), ('of', 'O'), ('ATM', 'O'), ('mutations', 'O'), ('in', 'O'), ('tumor', 'B'), ('risk', 'O'), ('or', 'O'), ('development', 'O'), ('.', 'O'), ('.', 'O'))"
Ataxia - telangiectasia : identification and detection of founder - effect mutations in the ATM gene in ethnic populations .,"(('Ataxia', 'B'), ('-', 'I'), ('telangiectasia', 'I'), (':', 'O'), ('identification', 'O'), ('and', 'O'), ('detection', 'O'), ('of', 'O'), ('founder', 'O'), ('-', 'O'), ('effect', 'O'), ('mutations', 'O'), ('in', 'O'), ('the', 'O'), ('ATM', 'O'), ('gene', 'O'), ('in', 'O'), ('ethnic', 'O'), ('populations', 'O'), ('.', 'O'))"
"To facilitate the evaluation of ATM heterozygotes for susceptibility to other diseases , such as breast cancer , we have attempted to define the most common mutations and their frequencies in ataxia - telangiectasia ( A - T ) homozygotes from 10 ethnic populations .","(('To', 'O'), ('facilitate', 'O'), ('the', 'O'), ('evaluation', 'O'), ('of', 'O'), ('ATM', 'O'), ('heterozygotes', 'O'), ('for', 'O'), ('susceptibility', 'O'), ('to', 'O'), ('other', 'O'), ('diseases', 'O'), (',', 'O'), ('such', 'O'), ('as', 'O'), ('breast', 'B'), ('cancer', 'I'), (',', 'O'), ('we', 'O'), ('have', 'O'), ('attempted', 'O'), ('to', 'O'), ('define', 'O'), ('the', 'O'), ('most', 'O'), ('common', 'O'), ('mutations', 'O'), ('and', 'O'), ('their', 'O'), ('frequencies', 'O'), ('in', 'O'), ('ataxia', 'B'), ('-', 'I'), ('telangiectasia', 'I'), ('(', 'O'), ('A', 'B'), ('-', 'I'), ('T', 'I'), (')', 'O'), ('homozygotes', 'O'), ('from', 'O'), ('10', 'O'), ('ethnic', 'O'), ('populations', 'O'), ('.', 'O'))"
These assays should facilitate screening for A - T heterozygotes in the populations studied . .,"(('These', 'O'), ('assays', 'O'), ('should', 'O'), ('facilitate', 'O'), ('screening', 'O'), ('for', 'O'), ('A', 'B'), ('-', 'I'), ('T', 'I'), ('heterozygotes', 'O'), ('in', 'O'), ('the', 'O'), ('populations', 'O'), ('studied', 'O'), ('.', 'O'), ('.', 'O'))"
The von Hippel - Lindau tumor suppressor gene is required for cell cycle exit upon serum withdrawal .,"(('The', 'O'), ('von', 'B'), ('Hippel', 'I'), ('-', 'I'), ('Lindau', 'I'), ('tumor', 'I'), ('suppressor', 'O'), ('gene', 'O'), ('is', 'O'), ('required', 'O'), ('for', 'O'), ('cell', 'O'), ('cycle', 'O'), ('exit', 'O'), ('upon', 'O'), ('serum', 'O'), ('withdrawal', 'O'), ('.', 'O'))"
The inactivation of the von Hippel - Lindau ( VHL ) tumor suppressor gene predisposes affected individuals to the human VHL cancer syndrome and is associated with sporadic renal cell carcinomas ( RCC ) and brain hemangioblastomas .,"(('The', 'O'), ('inactivation', 'O'), ('of', 'O'), ('the', 'O'), ('von', 'B'), ('Hippel', 'I'), ('-', 'I'), ('Lindau', 'I'), ('(', 'I'), ('VHL', 'I'), (')', 'I'), ('tumor', 'I'), ('suppressor', 'O'), ('gene', 'O'), ('predisposes', 'O'), ('affected', 'O'), ('individuals', 'O'), ('to', 'O'), ('the', 'O'), ('human', 'O'), ('VHL', 'B'), ('cancer', 'I'), ('syndrome', 'I'), ('and', 'O'), ('is', 'O'), ('associated', 'O'), ('with', 'O'), ('sporadic', 'B'), ('renal', 'I'), ('cell', 'I'), ('carcinomas', 'I'), ('(', 'O'), ('RCC', 'B'), (')', 'O'), ('and', 'O'), ('brain', 'B'), ('hemangioblastomas', 'I'), ('.', 'O'))"
VHL - negative 786 - 0 RCC cells are tumorigenic in nude mice which is suppressed by the reintroduction of VHL .,"(('VHL', 'O'), ('-', 'O'), ('negative', 'O'), ('786', 'O'), ('-', 'O'), ('0', 'O'), ('RCC', 'B'), ('cells', 'O'), ('are', 'O'), ('tumorigenic', 'O'), ('in', 'O'), ('nude', 'O'), ('mice', 'O'), ('which', 'O'), ('is', 'O'), ('suppressed', 'O'), ('by', 'O'), ('the', 'O'), ('reintroduction', 'O'), ('of', 'O'), ('VHL', 'B'), ('.', 'O'))"
"The 786 - 0 cell line , like many cancer cells , fails to exit the cell cycle upon serum withdrawal .","(('The', 'O'), ('786', 'O'), ('-', 'O'), ('0', 'O'), ('cell', 'O'), ('line', 'O'), (',', 'O'), ('like', 'O'), ('many', 'O'), ('cancer', 'B'), ('cells', 'O'), (',', 'O'), ('fails', 'O'), ('to', 'O'), ('exit', 'O'), ('the', 'O'), ('cell', 'O'), ('cycle', 'O'), ('upon', 'O'), ('serum', 'O'), ('withdrawal', 'O'), ('.', 'O'))"
"Here , it is shown that reintroduction of the wild - type VHL gene restores the ability of VHL - negative RCC cancer cells to exit the cell cycle and enter G0 / quiescence in low serum .","(('Here', 'O'), (',', 'O'), ('it', 'O'), ('is', 'O'), ('shown', 'O'), ('that', 'O'), ('reintroduction', 'O'), ('of', 'O'), ('the', 'O'), ('wild', 'O'), ('-', 'O'), ('type', 'O'), ('VHL', 'B'), ('gene', 'O'), ('restores', 'O'), ('the', 'O'), ('ability', 'O'), ('of', 'O'), ('VHL', 'O'), ('-', 'O'), ('negative', 'O'), ('RCC', 'B'), ('cancer', 'I'), ('cells', 'O'), ('to', 'O'), ('exit', 'O'), ('the', 'O'), ('cell', 'O'), ('cycle', 'O'), ('and', 'O'), ('enter', 'O'), ('G0', 'O'), ('/', 'O'), ('quiescence', 'O'), ('in', 'O'), ('low', 'O'), ('serum', 'O'), ('.', 'O'))"
Both VHL - positive and VHL - negative RCC cells exit the cell cycle by contact inhibition .,"(('Both', 'O'), ('VHL', 'O'), ('-', 'O'), ('positive', 'O'), ('and', 'O'), ('VHL', 'O'), ('-', 'O'), ('negative', 'O'), ('RCC', 'B'), ('cells', 'O'), ('exit', 'O'), ('the', 'O'), ('cell', 'O'), ('cycle', 'O'), ('by', 'O'), ('contact', 'O'), ('inhibition', 'O'), ('.', 'O'))"
"The cyclin - dependent kinase inhibitor , p27 , accumulates upon serum withdrawal , only in the presence of VHL , as a result of the stabilization of the protein .","(('The', 'O'), ('cyclin', 'O'), ('-', 'O'), ('dependent', 'O'), ('kinase', 'O'), ('inhibitor', 'O'), (',', 'O'), ('p27', 'O'), (',', 'O'), ('accumulates', 'O'), ('upon', 'O'), ('serum', 'O'), ('withdrawal', 'O'), (',', 'O'), ('only', 'O'), ('in', 'O'), ('the', 'O'), ('presence', 'O'), ('of', 'O'), ('VHL', 'B'), (',', 'O'), ('as', 'O'), ('a', 'O'), ('result', 'O'), ('of', 'O'), ('the', 'O'), ('stabilization', 'O'), ('of', 'O'), ('the', 'O'), ('protein', 'O'), ('.', 'O'))"
"We propose that the loss of wild - type VHL gene results in a specific cellular defect in serum - dependent growth control , which may initiate tumor formation .","(('We', 'O'), ('propose', 'O'), ('that', 'O'), ('the', 'O'), ('loss', 'O'), ('of', 'O'), ('wild', 'O'), ('-', 'O'), ('type', 'O'), ('VHL', 'B'), ('gene', 'O'), ('results', 'O'), ('in', 'O'), ('a', 'O'), ('specific', 'O'), ('cellular', 'O'), ('defect', 'O'), ('in', 'O'), ('serum', 'O'), ('-', 'O'), ('dependent', 'O'), ('growth', 'O'), ('control', 'O'), (',', 'O'), ('which', 'O'), ('may', 'O'), ('initiate', 'O'), ('tumor', 'B'), ('formation', 'O'), ('.', 'O'))"
"This is corrected by the reintroduction of wild - type VHL , implicating VHL as the first tumor suppressor involved in the regulation of cell cycle exit , which is consistent with its gatekeeper function in the kidney . .","(('This', 'O'), ('is', 'O'), ('corrected', 'O'), ('by', 'O'), ('the', 'O'), ('reintroduction', 'O'), ('of', 'O'), ('wild', 'O'), ('-', 'O'), ('type', 'O'), ('VHL', 'B'), (',', 'O'), ('implicating', 'O'), ('VHL', 'B'), ('as', 'O'), ('the', 'O'), ('first', 'O'), ('tumor', 'B'), ('suppressor', 'O'), ('involved', 'O'), ('in', 'O'), ('the', 'O'), ('regulation', 'O'), ('of', 'O'), ('cell', 'O'), ('cycle', 'O'), ('exit', 'O'), (',', 'O'), ('which', 'O'), ('is', 'O'), ('consistent', 'O'), ('with', 'O'), ('its', 'O'), ('gatekeeper', 'O'), ('function', 'O'), ('in', 'O'), ('the', 'O'), ('kidney', 'O'), ('.', 'O'), ('.', 'O'))"
Piebaldism with deafness : molecular evidence for an expanded syndrome .,"(('Piebaldism', 'B'), ('with', 'O'), ('deafness', 'B'), (':', 'O'), ('molecular', 'O'), ('evidence', 'O'), ('for', 'O'), ('an', 'O'), ('expanded', 'O'), ('syndrome', 'O'), ('.', 'O'))"
"In a South African girl of Xhosa stock with severe piebaldism and profound congenital sensorineural deafness we identified a novel missense substitution at a highly conserved residue in the intracellular kinase domain of the KIT proto - oncogene , R796G .","(('In', 'O'), ('a', 'O'), ('South', 'O'), ('African', 'O'), ('girl', 'O'), ('of', 'O'), ('Xhosa', 'O'), ('stock', 'O'), ('with', 'O'), ('severe', 'O'), ('piebaldism', 'B'), ('and', 'O'), ('profound', 'O'), ('congenital', 'O'), ('sensorineural', 'B'), ('deafness', 'I'), ('we', 'O'), ('identified', 'O'), ('a', 'O'), ('novel', 'O'), ('missense', 'O'), ('substitution', 'O'), ('at', 'O'), ('a', 'O'), ('highly', 'O'), ('conserved', 'O'), ('residue', 'O'), ('in', 'O'), ('the', 'O'), ('intracellular', 'O'), ('kinase', 'O'), ('domain', 'O'), ('of', 'O'), ('the', 'O'), ('KIT', 'O'), ('proto', 'O'), ('-', 'O'), ('oncogene', 'O'), (',', 'O'), ('R796G', 'O'), ('.', 'O'))"
"Though auditory anomalies have been observed in mice with dominant white spotting ( W ) due to KIT mutations , deafness is not typical in human piebaldism .","(('Though', 'O'), ('auditory', 'B'), ('anomalies', 'I'), ('have', 'O'), ('been', 'O'), ('observed', 'O'), ('in', 'O'), ('mice', 'O'), ('with', 'O'), ('dominant', 'O'), ('white', 'O'), ('spotting', 'O'), ('(', 'O'), ('W', 'O'), (')', 'O'), ('due', 'O'), ('to', 'O'), ('KIT', 'O'), ('mutations', 'O'), (',', 'O'), ('deafness', 'B'), ('is', 'O'), ('not', 'O'), ('typical', 'O'), ('in', 'O'), ('human', 'O'), ('piebaldism', 'B'), ('.', 'O'))"
"Thus , the occurrence of sensorineural deafness in this patient extends considerably the phenotypic range of piebaldism due to KIT gene mutation in humans and tightens the clinical similarity between piebaldism and the various forms of Waardenburg syndrome . .","(('Thus', 'O'), (',', 'O'), ('the', 'O'), ('occurrence', 'O'), ('of', 'O'), ('sensorineural', 'B'), ('deafness', 'I'), ('in', 'O'), ('this', 'O'), ('patient', 'O'), ('extends', 'O'), ('considerably', 'O'), ('the', 'O'), ('phenotypic', 'O'), ('range', 'O'), ('of', 'O'), ('piebaldism', 'B'), ('due', 'O'), ('to', 'O'), ('KIT', 'O'), ('gene', 'O'), ('mutation', 'O'), ('in', 'O'), ('humans', 'O'), ('and', 'O'), ('tightens', 'O'), ('the', 'O'), ('clinical', 'O'), ('similarity', 'O'), ('between', 'O'), ('piebaldism', 'B'), ('and', 'O'), ('the', 'O'), ('various', 'O'), ('forms', 'O'), ('of', 'O'), ('Waardenburg', 'B'), ('syndrome', 'I'), ('.', 'O'), ('.', 'O'))"
Cycloheximide facilitates the identification of aberrant transcripts resulting from a novel splice - site mutation in COL17A1 in a patient with generalized atrophic benign epidermolysis bullosa .,"(('Cycloheximide', 'O'), ('facilitates', 'O'), ('the', 'O'), ('identification', 'O'), ('of', 'O'), ('aberrant', 'O'), ('transcripts', 'O'), ('resulting', 'O'), ('from', 'O'), ('a', 'O'), ('novel', 'O'), ('splice', 'O'), ('-', 'O'), ('site', 'O'), ('mutation', 'O'), ('in', 'O'), ('COL17A1', 'O'), ('in', 'O'), ('a', 'O'), ('patient', 'O'), ('with', 'O'), ('generalized', 'O'), ('atrophic', 'B'), ('benign', 'I'), ('epidermolysis', 'I'), ('bullosa', 'I'), ('.', 'O'))"
"Patients with generalized atrophic benign epidermolysis bullosa often show decreased expression of type XVII collagen , a transmembrane hemidesmosomal protein encoded by COL17A1 .","(('Patients', 'O'), ('with', 'O'), ('generalized', 'O'), ('atrophic', 'B'), ('benign', 'I'), ('epidermolysis', 'I'), ('bullosa', 'I'), ('often', 'O'), ('show', 'O'), ('decreased', 'O'), ('expression', 'O'), ('of', 'O'), ('type', 'O'), ('XVII', 'O'), ('collagen', 'O'), (',', 'O'), ('a', 'O'), ('transmembrane', 'O'), ('hemidesmosomal', 'O'), ('protein', 'O'), ('encoded', 'O'), ('by', 'O'), ('COL17A1', 'O'), ('.', 'O'))"
"This report documents a novel splice - site mutation in COL17A1 in a patient with generalized atrophic benign epidermolysis bullosa , and applies a new methodology to define and characterize the resulting mRNA splice variants .","(('This', 'O'), ('report', 'O'), ('documents', 'O'), ('a', 'O'), ('novel', 'O'), ('splice', 'O'), ('-', 'O'), ('site', 'O'), ('mutation', 'O'), ('in', 'O'), ('COL17A1', 'O'), ('in', 'O'), ('a', 'O'), ('patient', 'O'), ('with', 'O'), ('generalized', 'O'), ('atrophic', 'B'), ('benign', 'I'), ('epidermolysis', 'I'), ('bullosa', 'I'), (',', 'O'), ('and', 'O'), ('applies', 'O'), ('a', 'O'), ('new', 'O'), ('methodology', 'O'), ('to', 'O'), ('define', 'O'), ('and', 'O'), ('characterize', 'O'), ('the', 'O'), ('resulting', 'O'), ('mRNA', 'O'), ('splice', 'O'), ('variants', 'O'), ('.', 'O'))"
A deletion mutation in COL17A1 in five Austrian families with generalized atrophic benign epidermolysis bullosa represents propagation of an ancestral allele .,"(('A', 'O'), ('deletion', 'O'), ('mutation', 'O'), ('in', 'O'), ('COL17A1', 'O'), ('in', 'O'), ('five', 'O'), ('Austrian', 'O'), ('families', 'O'), ('with', 'O'), ('generalized', 'O'), ('atrophic', 'B'), ('benign', 'I'), ('epidermolysis', 'I'), ('bullosa', 'I'), ('represents', 'O'), ('propagation', 'O'), ('of', 'O'), ('an', 'O'), ('ancestral', 'O'), ('allele', 'O'), ('.', 'O'))"
"Patients with generalized atrophic benign epidermolysis bullosa , a usually nonlethal form of junctional epidermolysis bullosa , have generalized blistering , nail dystrophy , patchy alopecia , and dental abnormalities .","(('Patients', 'O'), ('with', 'O'), ('generalized', 'O'), ('atrophic', 'B'), ('benign', 'I'), ('epidermolysis', 'I'), ('bullosa', 'I'), (',', 'O'), ('a', 'O'), ('usually', 'O'), ('nonlethal', 'O'), ('form', 'O'), ('of', 'O'), ('junctional', 'B'), ('epidermolysis', 'I'), ('bullosa', 'I'), (',', 'O'), ('have', 'O'), ('generalized', 'O'), ('blistering', 'B'), (',', 'O'), ('nail', 'B'), ('dystrophy', 'I'), (',', 'O'), ('patchy', 'B'), ('alopecia', 'I'), (',', 'O'), ('and', 'O'), ('dental', 'B'), ('abnormalities', 'I'), ('.', 'O'))"
"Recently , we reported five Austrian families with generalized atrophic benign epidermolysis bullosa who share the same COL17A1 mutation .","(('Recently', 'O'), (',', 'O'), ('we', 'O'), ('reported', 'O'), ('five', 'O'), ('Austrian', 'O'), ('families', 'O'), ('with', 'O'), ('generalized', 'O'), ('atrophic', 'B'), ('benign', 'I'), ('epidermolysis', 'I'), ('bullosa', 'I'), ('who', 'O'), ('share', 'O'), ('the', 'O'), ('same', 'O'), ('COL17A1', 'O'), ('mutation', 'O'), ('.', 'O'))"
"ATM mutations and phenotypes in ataxia - telangiectasia families in the British Isles : expression of mutant ATM and the risk of leukemia , lymphoma , and breast cancer .","(('ATM', 'O'), ('mutations', 'O'), ('and', 'O'), ('phenotypes', 'O'), ('in', 'O'), ('ataxia', 'B'), ('-', 'I'), ('telangiectasia', 'I'), ('families', 'O'), ('in', 'O'), ('the', 'O'), ('British', 'O'), ('Isles', 'O'), (':', 'O'), ('expression', 'O'), ('of', 'O'), ('mutant', 'O'), ('ATM', 'O'), ('and', 'O'), ('the', 'O'), ('risk', 'O'), ('of', 'O'), ('leukemia', 'B'), (',', 'O'), ('lymphoma', 'B'), (',', 'O'), ('and', 'O'), ('breast', 'B'), ('cancer', 'I'), ('.', 'O'))"
We report the spectrum of 59 ATM mutations observed in ataxia - telangiectasia ( A - T ) patients in the British Isles .,"(('We', 'O'), ('report', 'O'), ('the', 'O'), ('spectrum', 'O'), ('of', 'O'), ('59', 'O'), ('ATM', 'O'), ('mutations', 'O'), ('observed', 'O'), ('in', 'O'), ('ataxia', 'B'), ('-', 'I'), ('telangiectasia', 'I'), ('(', 'O'), ('A', 'B'), ('-', 'I'), ('T', 'I'), (')', 'O'), ('patients', 'O'), ('in', 'O'), ('the', 'O'), ('British', 'O'), ('Isles', 'O'), ('.', 'O'))"
"Of 51 ATM mutations identified in families native to the British Isles , 11 were founder mutations , and 2 of these 11 conferred a milder clinical phenotype with respect to both cerebellar degeneration and cellular features .","(('Of', 'O'), ('51', 'O'), ('ATM', 'O'), ('mutations', 'O'), ('identified', 'O'), ('in', 'O'), ('families', 'O'), ('native', 'O'), ('to', 'O'), ('the', 'O'), ('British', 'O'), ('Isles', 'O'), (',', 'O'), ('11', 'O'), ('were', 'O'), ('founder', 'O'), ('mutations', 'O'), (',', 'O'), ('and', 'O'), ('2', 'O'), ('of', 'O'), ('these', 'O'), ('11', 'O'), ('conferred', 'O'), ('a', 'O'), ('milder', 'O'), ('clinical', 'O'), ('phenotype', 'O'), ('with', 'O'), ('respect', 'O'), ('to', 'O'), ('both', 'O'), ('cerebellar', 'B'), ('degeneration', 'I'), ('and', 'O'), ('cellular', 'O'), ('features', 'O'), ('.', 'O'))"
"We report , in two A - T families , an ATM mutation ( 7271T - - > G ) that may be associated with an increased risk of breast cancer in both homozygotes and heterozygotes ( relative risk 12 . 7 ; P = . 0025 ) , although there is a less severe A - T phenotype in terms of the degree of cerebellar degeneration .","(('We', 'O'), ('report', 'O'), (',', 'O'), ('in', 'O'), ('two', 'O'), ('A', 'B'), ('-', 'I'), ('T', 'I'), ('families', 'O'), (',', 'O'), ('an', 'O'), ('ATM', 'O'), ('mutation', 'O'), ('(', 'O'), ('7271T', 'O'), ('-', 'O'), ('-', 'O'), ('>', 'O'), ('G', 'O'), (')', 'O'), ('that', 'O'), ('may', 'O'), ('be', 'O'), ('associated', 'O'), ('with', 'O'), ('an', 'O'), ('increased', 'O'), ('risk', 'O'), ('of', 'O'), ('breast', 'B'), ('cancer', 'I'), ('in', 'O'), ('both', 'O'), ('homozygotes', 'O'), ('and', 'O'), ('heterozygotes', 'O'), ('(', 'O'), ('relative', 'O'), ('risk', 'O'), ('12', 'O'), ('.', 'O'), ('7', 'O'), (';', 'O'), ('P', 'O'), ('=', 'O'), ('.', 'O'), ('0025', 'O'), (')', 'O'), (',', 'O'), ('although', 'O'), ('there', 'O'), ('is', 'O'), ('a', 'O'), ('less', 'O'), ('severe', 'O'), ('A', 'B'), ('-', 'I'), ('T', 'I'), ('phenotype', 'O'), ('in', 'O'), ('terms', 'O'), ('of', 'O'), ('the', 'O'), ('degree', 'O'), ('of', 'O'), ('cerebellar', 'B'), ('degeneration', 'I'), ('.', 'O'))"
"In addition , we have studied 18 A - T patients , in 15 families , who developed leukemia , lymphoma , preleukemic T - cell proliferation , or Hodgkin lymphoma , mostly in childhood .","(('In', 'O'), ('addition', 'O'), (',', 'O'), ('we', 'O'), ('have', 'O'), ('studied', 'O'), ('18', 'O'), ('A', 'B'), ('-', 'I'), ('T', 'I'), ('patients', 'O'), (',', 'O'), ('in', 'O'), ('15', 'O'), ('families', 'O'), (',', 'O'), ('who', 'O'), ('developed', 'O'), ('leukemia', 'B'), (',', 'O'), ('lymphoma', 'B'), (',', 'O'), ('preleukemic', 'O'), ('T', 'O'), ('-', 'O'), ('cell', 'O'), ('proliferation', 'O'), (',', 'O'), ('or', 'O'), ('Hodgkin', 'B'), ('lymphoma', 'I'), (',', 'O'), ('mostly', 'O'), ('in', 'O'), ('childhood', 'O'), ('.', 'O'))"
"We also show that 25 % of all A - T patients carried in - frame deletions or missense mutations , many of which were also associated with expression of mutant ATM protein .","(('We', 'O'), ('also', 'O'), ('show', 'O'), ('that', 'O'), ('25', 'O'), ('%', 'O'), ('of', 'O'), ('all', 'O'), ('A', 'B'), ('-', 'I'), ('T', 'I'), ('patients', 'O'), ('carried', 'O'), ('in', 'O'), ('-', 'O'), ('frame', 'O'), ('deletions', 'O'), ('or', 'O'), ('missense', 'O'), ('mutations', 'O'), (',', 'O'), ('many', 'O'), ('of', 'O'), ('which', 'O'), ('were', 'O'), ('also', 'O'), ('associated', 'O'), ('with', 'O'), ('expression', 'O'), ('of', 'O'), ('mutant', 'O'), ('ATM', 'O'), ('protein', 'O'), ('.', 'O'))"
The DMPK gene of severely affected myotonic dystrophy patients is hypermethylated proximal to the largely expanded CTG repeat .,"(('The', 'O'), ('DMPK', 'O'), ('gene', 'O'), ('of', 'O'), ('severely', 'O'), ('affected', 'O'), ('myotonic', 'B'), ('dystrophy', 'I'), ('patients', 'O'), ('is', 'O'), ('hypermethylated', 'O'), ('proximal', 'O'), ('to', 'O'), ('the', 'O'), ('largely', 'O'), ('expanded', 'O'), ('CTG', 'O'), ('repeat', 'O'), ('.', 'O'))"
"Using methylation - sensitive restriction enzymes , we characterized the methylation pattern on the 5 side of the CTG repeat in the DMPK gene of normal individuals and of patients affected with myotonic dystrophy , showing expansions of the repetitive sequence .","(('Using', 'O'), ('methylation', 'O'), ('-', 'O'), ('sensitive', 'O'), ('restriction', 'O'), ('enzymes', 'O'), (',', 'O'), ('we', 'O'), ('characterized', 'O'), ('the', 'O'), ('methylation', 'O'), ('pattern', 'O'), ('on', 'O'), ('the', 'O'), ('5', 'O'), ('side', 'O'), ('of', 'O'), ('the', 'O'), ('CTG', 'O'), ('repeat', 'O'), ('in', 'O'), ('the', 'O'), ('DMPK', 'O'), ('gene', 'O'), ('of', 'O'), ('normal', 'O'), ('individuals', 'O'), ('and', 'O'), ('of', 'O'), ('patients', 'O'), ('affected', 'O'), ('with', 'O'), ('myotonic', 'B'), ('dystrophy', 'I'), (',', 'O'), ('showing', 'O'), ('expansions', 'O'), ('of', 'O'), ('the', 'O'), ('repetitive', 'O'), ('sequence', 'O'), ('.', 'O'))"
The hemochromatosis gene product complexes with the transferrin receptor and lowers its affinity for ligand binding .,"(('The', 'O'), ('hemochromatosis', 'B'), ('gene', 'O'), ('product', 'O'), ('complexes', 'O'), ('with', 'O'), ('the', 'O'), ('transferrin', 'O'), ('receptor', 'O'), ('and', 'O'), ('lowers', 'O'), ('its', 'O'), ('affinity', 'O'), ('for', 'O'), ('ligand', 'O'), ('binding', 'O'), ('.', 'O'))"
We recently reported the positional cloning of a candidate gene for hereditary hemochromatosis called HFE .,"(('We', 'O'), ('recently', 'O'), ('reported', 'O'), ('the', 'O'), ('positional', 'O'), ('cloning', 'O'), ('of', 'O'), ('a', 'O'), ('candidate', 'O'), ('gene', 'O'), ('for', 'O'), ('hereditary', 'B'), ('hemochromatosis', 'I'), ('called', 'O'), ('HFE', 'O'), ('.', 'O'))"
"These results establish a molecular link between HFE and a key protein involved in iron transport , the TfR , and raise the possibility that alterations in this regulatory mechanism may play a role in the pathogenesis of hereditary hemochromatosis . .","(('These', 'O'), ('results', 'O'), ('establish', 'O'), ('a', 'O'), ('molecular', 'O'), ('link', 'O'), ('between', 'O'), ('HFE', 'O'), ('and', 'O'), ('a', 'O'), ('key', 'O'), ('protein', 'O'), ('involved', 'O'), ('in', 'O'), ('iron', 'O'), ('transport', 'O'), (',', 'O'), ('the', 'O'), ('TfR', 'O'), (',', 'O'), ('and', 'O'), ('raise', 'O'), ('the', 'O'), ('possibility', 'O'), ('that', 'O'), ('alterations', 'O'), ('in', 'O'), ('this', 'O'), ('regulatory', 'O'), ('mechanism', 'O'), ('may', 'O'), ('play', 'O'), ('a', 'O'), ('role', 'O'), ('in', 'O'), ('the', 'O'), ('pathogenesis', 'O'), ('of', 'O'), ('hereditary', 'B'), ('hemochromatosis', 'I'), ('.', 'O'), ('.', 'O'))"
The UBE3A gene encodes the E6 - AP ubiquitin - protein ligase and has recently been shown to be mutated in Angelman syndrome patients who lack 15q11 - q13 deletions or chromosome 15 paternal uniparental disomy .,"(('The', 'O'), ('UBE3A', 'O'), ('gene', 'O'), ('encodes', 'O'), ('the', 'O'), ('E6', 'O'), ('-', 'O'), ('AP', 'O'), ('ubiquitin', 'O'), ('-', 'O'), ('protein', 'O'), ('ligase', 'O'), ('and', 'O'), ('has', 'O'), ('recently', 'O'), ('been', 'O'), ('shown', 'O'), ('to', 'O'), ('be', 'O'), ('mutated', 'O'), ('in', 'O'), ('Angelman', 'B'), ('syndrome', 'I'), ('patients', 'O'), ('who', 'O'), ('lack', 'O'), ('15q11', 'O'), ('-', 'O'), ('q13', 'O'), ('deletions', 'O'), ('or', 'O'), ('chromosome', 'O'), ('15', 'O'), ('paternal', 'O'), ('uniparental', 'B'), ('disomy', 'I'), ('.', 'O'))"
"Mutation spectrum and genotype - phenotype analyses in Cowden disease and Bannayan - Zonana syndrome , two hamartoma syndromes with germline PTEN mutation .","(('Mutation', 'O'), ('spectrum', 'O'), ('and', 'O'), ('genotype', 'O'), ('-', 'O'), ('phenotype', 'O'), ('analyses', 'O'), ('in', 'O'), ('Cowden', 'B'), ('disease', 'I'), ('and', 'O'), ('Bannayan', 'B'), ('-', 'I'), ('Zonana', 'I'), ('syndrome', 'I'), (',', 'O'), ('two', 'O'), ('hamartoma', 'B'), ('syndromes', 'I'), ('with', 'O'), ('germline', 'O'), ('PTEN', 'O'), ('mutation', 'O'), ('.', 'O'))"
"The tumour suppressor gene PTEN , which maps to 10q23 .","(('The', 'O'), ('tumour', 'B'), ('suppressor', 'O'), ('gene', 'O'), ('PTEN', 'O'), (',', 'O'), ('which', 'O'), ('maps', 'O'), ('to', 'O'), ('10q23', 'O'), ('.', 'O'))"
"Somatic PTEN deletions and mutations were observed in sporadic breast , brain , prostate and kidney cancer cell lines and in several primary tumours such as endometrial carcinomas , malignant melanoma and thyroid tumours .","(('Somatic', 'O'), ('PTEN', 'O'), ('deletions', 'O'), ('and', 'O'), ('mutations', 'O'), ('were', 'O'), ('observed', 'O'), ('in', 'O'), ('sporadic', 'B'), ('breast', 'I'), (',', 'I'), ('brain', 'I'), (',', 'I'), ('prostate', 'I'), ('and', 'I'), ('kidney', 'I'), ('cancer', 'I'), ('cell', 'O'), ('lines', 'O'), ('and', 'O'), ('in', 'O'), ('several', 'O'), ('primary', 'O'), ('tumours', 'B'), ('such', 'O'), ('as', 'O'), ('endometrial', 'B'), ('carcinomas', 'I'), (',', 'O'), ('malignant', 'B'), ('melanoma', 'I'), ('and', 'O'), ('thyroid', 'B'), ('tumours', 'I'), ('.', 'O'))"
"In addition , PTEN was identified as the susceptibility gene for two hamartoma syndromes Cowden disease ( CD ; MIM 158350 ) and Bannayan - Zonana ( BZS ) or Ruvalcaba - Riley - Smith syndrome ( MIM 153480 ) .","(('In', 'O'), ('addition', 'O'), (',', 'O'), ('PTEN', 'O'), ('was', 'O'), ('identified', 'O'), ('as', 'O'), ('the', 'O'), ('susceptibility', 'O'), ('gene', 'O'), ('for', 'O'), ('two', 'O'), ('hamartoma', 'B'), ('syndromes', 'I'), ('Cowden', 'B'), ('disease', 'I'), ('(', 'O'), ('CD', 'B'), (';', 'O'), ('MIM', 'O'), ('158350', 'O'), (')', 'O'), ('and', 'O'), ('Bannayan', 'B'), ('-', 'I'), ('Zonana', 'I'), ('(', 'I'), ('BZS', 'I'), (')', 'I'), ('or', 'I'), ('Ruvalcaba', 'I'), ('-', 'I'), ('Riley', 'I'), ('-', 'I'), ('Smith', 'I'), ('syndrome', 'I'), ('(', 'O'), ('MIM', 'O'), ('153480', 'O'), (')', 'O'), ('.', 'O'))"
The first was an association noted in the group of CD families with breast disease .,"(('The', 'O'), ('first', 'O'), ('was', 'O'), ('an', 'O'), ('association', 'O'), ('noted', 'O'), ('in', 'O'), ('the', 'O'), ('group', 'O'), ('of', 'O'), ('CD', 'B'), ('families', 'O'), ('with', 'O'), ('breast', 'B'), ('disease', 'I'), ('.', 'O'))"
"Specifically and more directly , an association was also observed between the presence of a PTEN mutation and malignant breast disease .","(('Specifically', 'O'), ('and', 'O'), ('more', 'O'), ('directly', 'O'), (',', 'O'), ('an', 'O'), ('association', 'O'), ('was', 'O'), ('also', 'O'), ('observed', 'O'), ('between', 'O'), ('the', 'O'), ('presence', 'O'), ('of', 'O'), ('a', 'O'), ('PTEN', 'O'), ('mutation', 'O'), ('and', 'O'), ('malignant', 'B'), ('breast', 'I'), ('disease', 'I'), ('.', 'O'))"
Molecular defects leading to human complement component C6 deficiency in an African - American family .,"(('Molecular', 'O'), ('defects', 'O'), ('leading', 'O'), ('to', 'O'), ('human', 'O'), ('complement', 'B'), ('component', 'I'), ('C6', 'I'), ('deficiency', 'I'), ('in', 'O'), ('an', 'O'), ('African', 'O'), ('-', 'O'), ('American', 'O'), ('family', 'O'), ('.', 'O'))"
Complement component C6 deficiency ( C6D ) was diagnosed in a 16 - year - old African - American male with meningococcal meningitis .,"(('Complement', 'B'), ('component', 'I'), ('C6', 'I'), ('deficiency', 'I'), ('(', 'O'), ('C6D', 'B'), (')', 'O'), ('was', 'O'), ('diagnosed', 'O'), ('in', 'O'), ('a', 'O'), ('16', 'O'), ('-', 'O'), ('year', 'O'), ('-', 'O'), ('old', 'O'), ('African', 'O'), ('-', 'O'), ('American', 'O'), ('male', 'O'), ('with', 'O'), ('meningococcal', 'B'), ('meningitis', 'I'), ('.', 'O'))"
"The patients father and two brothers also had C6D , but gave no history of meningitis or other neisserial infection .","(('The', 'O'), ('patients', 'O'), ('father', 'O'), ('and', 'O'), ('two', 'O'), ('brothers', 'O'), ('also', 'O'), ('had', 'O'), ('C6D', 'B'), (',', 'O'), ('but', 'O'), ('gave', 'O'), ('no', 'O'), ('history', 'O'), ('of', 'O'), ('meningitis', 'B'), ('or', 'O'), ('other', 'O'), ('neisserial', 'B'), ('infection', 'I'), ('.', 'O'))"
"Mutations in PAX6 are responsible for human aniridia and have also been found in patients with Peters anomaly , with congenital cataracts , with autosomal dominant keratitis , and with isolated foveal hypoplasia .","(('Mutations', 'O'), ('in', 'O'), ('PAX6', 'O'), ('are', 'O'), ('responsible', 'O'), ('for', 'O'), ('human', 'O'), ('aniridia', 'B'), ('and', 'O'), ('have', 'O'), ('also', 'O'), ('been', 'O'), ('found', 'O'), ('in', 'O'), ('patients', 'O'), ('with', 'O'), ('Peters', 'B'), ('anomaly', 'I'), (',', 'O'), ('with', 'O'), ('congenital', 'B'), ('cataracts', 'I'), (',', 'O'), ('with', 'O'), ('autosomal', 'B'), ('dominant', 'I'), ('keratitis', 'I'), (',', 'O'), ('and', 'O'), ('with', 'O'), ('isolated', 'B'), ('foveal', 'I'), ('hypoplasia', 'I'), ('.', 'O'))"
"No locus other than chromosome 11p13 has been implicated in aniridia , and PAX6 is clearly the major , if not only , gene responsible .","(('No', 'O'), ('locus', 'O'), ('other', 'O'), ('than', 'O'), ('chromosome', 'O'), ('11p13', 'O'), ('has', 'O'), ('been', 'O'), ('implicated', 'O'), ('in', 'O'), ('aniridia', 'B'), (',', 'O'), ('and', 'O'), ('PAX6', 'O'), ('is', 'O'), ('clearly', 'O'), ('the', 'O'), ('major', 'O'), (',', 'O'), ('if', 'O'), ('not', 'O'), ('only', 'O'), (',', 'O'), ('gene', 'O'), ('responsible', 'O'), ('.', 'O'))"
Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families .,"(('Genetic', 'O'), ('heterogeneity', 'O'), ('and', 'O'), ('penetrance', 'O'), ('analysis', 'O'), ('of', 'O'), ('the', 'O'), ('BRCA1', 'O'), ('and', 'O'), ('BRCA2', 'O'), ('genes', 'O'), ('in', 'O'), ('breast', 'B'), ('cancer', 'I'), ('families', 'O'), ('.', 'O'))"
The Breast Cancer Linkage Consortium .,"(('The', 'O'), ('Breast', 'B'), ('Cancer', 'I'), ('Linkage', 'O'), ('Consortium', 'O'), ('.', 'O'))"
"The contribution of BRCA1 and BRCA2 to inherited breast cancer was assessed by linkage and mutation analysis in 237 families , each with at least four cases of breast cancer , collected by the Breast Cancer Linkage Consortium .","(('The', 'O'), ('contribution', 'O'), ('of', 'O'), ('BRCA1', 'O'), ('and', 'O'), ('BRCA2', 'O'), ('to', 'O'), ('inherited', 'B'), ('breast', 'I'), ('cancer', 'I'), ('was', 'O'), ('assessed', 'O'), ('by', 'O'), ('linkage', 'O'), ('and', 'O'), ('mutation', 'O'), ('analysis', 'O'), ('in', 'O'), ('237', 'O'), ('families', 'O'), (',', 'O'), ('each', 'O'), ('with', 'O'), ('at', 'O'), ('least', 'O'), ('four', 'O'), ('cases', 'O'), ('of', 'O'), ('breast', 'B'), ('cancer', 'I'), (',', 'O'), ('collected', 'O'), ('by', 'O'), ('the', 'O'), ('Breast', 'B'), ('Cancer', 'I'), ('Linkage', 'O'), ('Consortium', 'O'), ('.', 'O'))"
Families were included without regard to the occurrence of ovarian or other cancers .,"(('Families', 'O'), ('were', 'O'), ('included', 'O'), ('without', 'O'), ('regard', 'O'), ('to', 'O'), ('the', 'O'), ('occurrence', 'O'), ('of', 'O'), ('ovarian', 'B'), ('or', 'I'), ('other', 'I'), ('cancers', 'I'), ('.', 'O'))"
"The majority ( 81 % ) of the breast - ovarian cancer families were due to BRCA1 , with most others ( 14 % ) due to BRCA2 .","(('The', 'O'), ('majority', 'O'), ('(', 'O'), ('81', 'O'), ('%', 'O'), (')', 'O'), ('of', 'O'), ('the', 'O'), ('breast', 'B'), ('-', 'I'), ('ovarian', 'I'), ('cancer', 'I'), ('families', 'O'), ('were', 'O'), ('due', 'O'), ('to', 'O'), ('BRCA1', 'O'), (',', 'O'), ('with', 'O'), ('most', 'O'), ('others', 'O'), ('(', 'O'), ('14', 'O'), ('%', 'O'), (')', 'O'), ('due', 'O'), ('to', 'O'), ('BRCA2', 'O'), ('.', 'O'))"
"Conversely , the majority of families with male and female breast cancer were due to BRCA2 ( 76 % ) .","(('Conversely', 'O'), (',', 'O'), ('the', 'O'), ('majority', 'O'), ('of', 'O'), ('families', 'O'), ('with', 'O'), ('male', 'B'), ('and', 'I'), ('female', 'I'), ('breast', 'I'), ('cancer', 'I'), ('were', 'O'), ('due', 'O'), ('to', 'O'), ('BRCA2', 'O'), ('(', 'O'), ('76', 'O'), ('%', 'O'), (')', 'O'), ('.', 'O'))"
The largest proportion ( 67 % ) of families due to other genes was found in families with four or five cases of female breast cancer only .,"(('The', 'O'), ('largest', 'O'), ('proportion', 'O'), ('(', 'O'), ('67', 'O'), ('%', 'O'), (')', 'O'), ('of', 'O'), ('families', 'O'), ('due', 'O'), ('to', 'O'), ('other', 'O'), ('genes', 'O'), ('was', 'O'), ('found', 'O'), ('in', 'O'), ('families', 'O'), ('with', 'O'), ('four', 'O'), ('or', 'O'), ('five', 'O'), ('cases', 'O'), ('of', 'O'), ('female', 'O'), ('breast', 'B'), ('cancer', 'I'), ('only', 'O'), ('.', 'O'))"
The estimated cumulative risk of breast cancer reached 28 % ( 95 % CI 9 % - 44 % ) by age 50 years and 84 % ( 95 % CI 43 % - 95 % ) by age 70 years .,"(('The', 'O'), ('estimated', 'O'), ('cumulative', 'O'), ('risk', 'O'), ('of', 'O'), ('breast', 'B'), ('cancer', 'I'), ('reached', 'O'), ('28', 'O'), ('%', 'O'), ('(', 'O'), ('95', 'O'), ('%', 'O'), ('CI', 'O'), ('9', 'O'), ('%', 'O'), ('-', 'O'), ('44', 'O'), ('%', 'O'), (')', 'O'), ('by', 'O'), ('age', 'O'), ('50', 'O'), ('years', 'O'), ('and', 'O'), ('84', 'O'), ('%', 'O'), ('(', 'O'), ('95', 'O'), ('%', 'O'), ('CI', 'O'), ('43', 'O'), ('%', 'O'), ('-', 'O'), ('95', 'O'), ('%', 'O'), (')', 'O'), ('by', 'O'), ('age', 'O'), ('70', 'O'), ('years', 'O'), ('.', 'O'))"
The corresponding ovarian cancer risks were 0 .,"(('The', 'O'), ('corresponding', 'O'), ('ovarian', 'B'), ('cancer', 'I'), ('risks', 'O'), ('were', 'O'), ('0', 'O'), ('.', 'O'))"
"The lifetime risk of breast cancer appears similar to the risk in BRCA1 carriers , but there was some suggestion of a lower risk in BRCA2 carriers < 50 years of age .","(('The', 'O'), ('lifetime', 'O'), ('risk', 'O'), ('of', 'O'), ('breast', 'B'), ('cancer', 'I'), ('appears', 'O'), ('similar', 'O'), ('to', 'O'), ('the', 'O'), ('risk', 'O'), ('in', 'O'), ('BRCA1', 'O'), ('carriers', 'O'), (',', 'O'), ('but', 'O'), ('there', 'O'), ('was', 'O'), ('some', 'O'), ('suggestion', 'O'), ('of', 'O'), ('a', 'O'), ('lower', 'O'), ('risk', 'O'), ('in', 'O'), ('BRCA2', 'O'), ('carriers', 'O'), ('<', 'O'), ('50', 'O'), ('years', 'O'), ('of', 'O'), ('age', 'O'), ('.', 'O'))"
Eye movement abnormalities correlate with genotype in autosomal dominant cerebellar ataxia type I .,"(('Eye', 'B'), ('movement', 'I'), ('abnormalities', 'I'), ('correlate', 'O'), ('with', 'O'), ('genotype', 'O'), ('in', 'O'), ('autosomal', 'O'), ('dominant', 'O'), ('cerebellar', 'B'), ('ataxia', 'I'), ('type', 'I'), ('I', 'I'), ('.', 'O'))"
"We compared horizontal eye movements ( visually guided saccades , antisaccades , and smooth pursuit ) in control subjects ( n = 14 ) and patients with three forms of autosomal dominant cerebellar ataxias type I spinocerebellar ataxias 1 and 2 ( SCA1 , n = 11 ; SCA2 , n = 10 ) and SCA3 / Machado - Joseph disease ( MJD ) ( n = 16 ) .","(('We', 'O'), ('compared', 'O'), ('horizontal', 'O'), ('eye', 'O'), ('movements', 'O'), ('(', 'O'), ('visually', 'O'), ('guided', 'O'), ('saccades', 'O'), (',', 'O'), ('antisaccades', 'O'), (',', 'O'), ('and', 'O'), ('smooth', 'O'), ('pursuit', 'O'), (')', 'O'), ('in', 'O'), ('control', 'O'), ('subjects', 'O'), ('(', 'O'), ('n', 'O'), ('=', 'O'), ('14', 'O'), (')', 'O'), ('and', 'O'), ('patients', 'O'), ('with', 'O'), ('three', 'O'), ('forms', 'O'), ('of', 'O'), ('autosomal', 'O'), ('dominant', 'O'), ('cerebellar', 'B'), ('ataxias', 'I'), ('type', 'I'), ('I', 'I'), ('spinocerebellar', 'B'), ('ataxias', 'I'), ('1', 'I'), ('and', 'I'), ('2', 'I'), ('(', 'O'), ('SCA1', 'B'), (',', 'O'), ('n', 'O'), ('=', 'O'), ('11', 'O'), (';', 'O'), ('SCA2', 'B'), (',', 'O'), ('n', 'O'), ('=', 'O'), ('10', 'O'), (')', 'O'), ('and', 'O'), ('SCA3', 'B'), ('/', 'O'), ('Machado', 'B'), ('-', 'I'), ('Joseph', 'I'), ('disease', 'I'), ('(', 'O'), ('MJD', 'B'), (')', 'O'), ('(', 'O'), ('n', 'O'), ('=', 'O'), ('16', 'O'), (')', 'O'), ('.', 'O'))"
"In SCA3 , gaze - evoked nystagmus was often present as was saccade hypometria and smooth pursuit gain was markedly decreased .","(('In', 'O'), ('SCA3', 'B'), (',', 'O'), ('gaze', 'B'), ('-', 'I'), ('evoked', 'I'), ('nystagmus', 'I'), ('was', 'O'), ('often', 'O'), ('present', 'O'), ('as', 'O'), ('was', 'O'), ('saccade', 'O'), ('hypometria', 'O'), ('and', 'O'), ('smooth', 'O'), ('pursuit', 'O'), ('gain', 'O'), ('was', 'O'), ('markedly', 'O'), ('decreased', 'O'), ('.', 'O'))"
"Three major criteria , saccade amplitude , saccade velocity , and presence of gaze - evoked nystagmus , permitted the correct assignment of 90 % of the SCA1 , 90 % of the SCA2 , and 93 % of the patients with SCA3 to their genetically confirmed patient group and , therefore , may help orient diagnoses of SCA1 , SCA2 , and SCA3 at early clinical stages of the diseases . .","(('Three', 'O'), ('major', 'O'), ('criteria', 'O'), (',', 'O'), ('saccade', 'O'), ('amplitude', 'O'), (',', 'O'), ('saccade', 'O'), ('velocity', 'O'), (',', 'O'), ('and', 'O'), ('presence', 'O'), ('of', 'O'), ('gaze', 'B'), ('-', 'I'), ('evoked', 'I'), ('nystagmus', 'I'), (',', 'O'), ('permitted', 'O'), ('the', 'O'), ('correct', 'O'), ('assignment', 'O'), ('of', 'O'), ('90', 'O'), ('%', 'O'), ('of', 'O'), ('the', 'O'), ('SCA1', 'B'), (',', 'O'), ('90', 'O'), ('%', 'O'), ('of', 'O'), ('the', 'O'), ('SCA2', 'B'), (',', 'O'), ('and', 'O'), ('93', 'O'), ('%', 'O'), ('of', 'O'), ('the', 'O'), ('patients', 'O'), ('with', 'O'), ('SCA3', 'B'), ('to', 'O'), ('their', 'O'), ('genetically', 'O'), ('confirmed', 'O'), ('patient', 'O'), ('group', 'O'), ('and', 'O'), (',', 'O'), ('therefore', 'O'), (',', 'O'), ('may', 'O'), ('help', 'O'), ('orient', 'O'), ('diagnoses', 'O'), ('of', 'O'), ('SCA1', 'B'), (',', 'O'), ('SCA2', 'B'), (',', 'O'), ('and', 'O'), ('SCA3', 'B'), ('at', 'O'), ('early', 'O'), ('clinical', 'O'), ('stages', 'O'), ('of', 'O'), ('the', 'O'), ('diseases', 'O'), ('.', 'O'), ('.', 'O'))"
Genetic basis and molecular mechanism for idiopathic ventricular fibrillation .,"(('Genetic', 'O'), ('basis', 'O'), ('and', 'O'), ('molecular', 'O'), ('mechanism', 'O'), ('for', 'O'), ('idiopathic', 'B'), ('ventricular', 'I'), ('fibrillation', 'I'), ('.', 'O'))"
"Ventricular fibrillation causes more than 300 , 000 sudden deaths each year in the USA alone .","(('Ventricular', 'B'), ('fibrillation', 'I'), ('causes', 'O'), ('more', 'O'), ('than', 'O'), ('300', 'O'), (',', 'O'), ('000', 'O'), ('sudden', 'O'), ('deaths', 'O'), ('each', 'O'), ('year', 'O'), ('in', 'O'), ('the', 'O'), ('USA', 'O'), ('alone', 'O'), ('.', 'O'))"
"In approximately 5 - 12 % of these cases , there are no demonstrable cardiac or non - cardiac causes to account for the episode , which is therefore classified as idiopathic ventricular fibrillation ( IVF ) .","(('In', 'O'), ('approximately', 'O'), ('5', 'O'), ('-', 'O'), ('12', 'O'), ('%', 'O'), ('of', 'O'), ('these', 'O'), ('cases', 'O'), (',', 'O'), ('there', 'O'), ('are', 'O'), ('no', 'O'), ('demonstrable', 'O'), ('cardiac', 'O'), ('or', 'O'), ('non', 'O'), ('-', 'O'), ('cardiac', 'O'), ('causes', 'O'), ('to', 'O'), ('account', 'O'), ('for', 'O'), ('the', 'O'), ('episode', 'O'), (',', 'O'), ('which', 'O'), ('is', 'O'), ('therefore', 'O'), ('classified', 'O'), ('as', 'O'), ('idiopathic', 'B'), ('ventricular', 'I'), ('fibrillation', 'I'), ('(', 'O'), ('IVF', 'B'), (')', 'O'), ('.', 'O'))"
A distinct group of IVF patients has been found to present with a characteristic electrocardiographic pattern .,"(('A', 'O'), ('distinct', 'O'), ('group', 'O'), ('of', 'O'), ('IVF', 'B'), ('patients', 'O'), ('has', 'O'), ('been', 'O'), ('found', 'O'), ('to', 'O'), ('present', 'O'), ('with', 'O'), ('a', 'O'), ('characteristic', 'O'), ('electrocardiographic', 'O'), ('pattern', 'O'), ('.', 'O'))"
"Because of the small size of most pedigrees and the high incidence of sudden death , however , molecular genetic studies of IVF have not yet been done .","(('Because', 'O'), ('of', 'O'), ('the', 'O'), ('small', 'O'), ('size', 'O'), ('of', 'O'), ('most', 'O'), ('pedigrees', 'O'), ('and', 'O'), ('the', 'O'), ('high', 'O'), ('incidence', 'O'), ('of', 'O'), ('sudden', 'B'), ('death', 'I'), (',', 'O'), ('however', 'O'), (',', 'O'), ('molecular', 'O'), ('genetic', 'O'), ('studies', 'O'), ('of', 'O'), ('IVF', 'B'), ('have', 'O'), ('not', 'O'), ('yet', 'O'), ('been', 'O'), ('done', 'O'), ('.', 'O'))"
"Because IVF causes cardiac rhythm disturbance , we investigated whether malfunction of ion channels could cause the disorder by studying mutations in the cardiac sodium channel gene SCN5A .","(('Because', 'O'), ('IVF', 'B'), ('causes', 'O'), ('cardiac', 'O'), ('rhythm', 'O'), ('disturbance', 'O'), (',', 'O'), ('we', 'O'), ('investigated', 'O'), ('whether', 'O'), ('malfunction', 'O'), ('of', 'O'), ('ion', 'O'), ('channels', 'O'), ('could', 'O'), ('cause', 'O'), ('the', 'O'), ('disorder', 'O'), ('by', 'O'), ('studying', 'O'), ('mutations', 'O'), ('in', 'O'), ('the', 'O'), ('cardiac', 'O'), ('sodium', 'O'), ('channel', 'O'), ('gene', 'O'), ('SCN5A', 'O'), ('.', 'O'))"
"We have now identified a missense mutation , a splice - donor mutation , and a frameshift mutation in the coding region of SCN5A in three IVF families .","(('We', 'O'), ('have', 'O'), ('now', 'O'), ('identified', 'O'), ('a', 'O'), ('missense', 'O'), ('mutation', 'O'), (',', 'O'), ('a', 'O'), ('splice', 'O'), ('-', 'O'), ('donor', 'O'), ('mutation', 'O'), (',', 'O'), ('and', 'O'), ('a', 'O'), ('frameshift', 'O'), ('mutation', 'O'), ('in', 'O'), ('the', 'O'), ('coding', 'O'), ('region', 'O'), ('of', 'O'), ('SCN5A', 'O'), ('in', 'O'), ('three', 'O'), ('IVF', 'B'), ('families', 'O'), ('.', 'O'))"
Our results indicate that mutations in cardiac ion - channel genes contribute to the risk of developing IVF . .,"(('Our', 'O'), ('results', 'O'), ('indicate', 'O'), ('that', 'O'), ('mutations', 'O'), ('in', 'O'), ('cardiac', 'O'), ('ion', 'O'), ('-', 'O'), ('channel', 'O'), ('genes', 'O'), ('contribute', 'O'), ('to', 'O'), ('the', 'O'), ('risk', 'O'), ('of', 'O'), ('developing', 'O'), ('IVF', 'B'), ('.', 'O'), ('.', 'O'))"
"Molecular heterogeneity in mucopolysaccharidosis IVA in Australia and Northern Ireland : nine novel mutations including T312S , a common allele that confers a mild phenotype .","(('Molecular', 'O'), ('heterogeneity', 'O'), ('in', 'O'), ('mucopolysaccharidosis', 'B'), ('IVA', 'I'), ('in', 'O'), ('Australia', 'O'), ('and', 'O'), ('Northern', 'O'), ('Ireland', 'O'), (':', 'O'), ('nine', 'O'), ('novel', 'O'), ('mutations', 'O'), ('including', 'O'), ('T312S', 'O'), (',', 'O'), ('a', 'O'), ('common', 'O'), ('allele', 'O'), ('that', 'O'), ('confers', 'O'), ('a', 'O'), ('mild', 'O'), ('phenotype', 'O'), ('.', 'O'))"
Mucopolysaccharidosis IVA ( MPS IVA ) is an autosomal recessive lysosomal storage disorder caused by a genetic defect in N - acetylgalactosamine - 6 - sulfate sulfatase ( GALNS ) .,"(('Mucopolysaccharidosis', 'B'), ('IVA', 'I'), ('(', 'O'), ('MPS', 'B'), ('IVA', 'I'), (')', 'O'), ('is', 'O'), ('an', 'O'), ('autosomal', 'B'), ('recessive', 'I'), ('lysosomal', 'I'), ('storage', 'I'), ('disorder', 'I'), ('caused', 'O'), ('by', 'O'), ('a', 'O'), ('genetic', 'B'), ('defect', 'I'), ('in', 'O'), ('N', 'O'), ('-', 'O'), ('acetylgalactosamine', 'O'), ('-', 'O'), ('6', 'O'), ('-', 'O'), ('sulfate', 'O'), ('sulfatase', 'O'), ('(', 'O'), ('GALNS', 'O'), (')', 'O'), ('.', 'O'))"
Previous studies of patients from a British - Irish population showed that the I113F mutation is the most common single mutation among MPS IVA patients and produces a severe clinical phenotype .,"(('Previous', 'O'), ('studies', 'O'), ('of', 'O'), ('patients', 'O'), ('from', 'O'), ('a', 'O'), ('British', 'O'), ('-', 'O'), ('Irish', 'O'), ('population', 'O'), ('showed', 'O'), ('that', 'O'), ('the', 'O'), ('I113F', 'O'), ('mutation', 'O'), ('is', 'O'), ('the', 'O'), ('most', 'O'), ('common', 'O'), ('single', 'O'), ('mutation', 'O'), ('among', 'O'), ('MPS', 'B'), ('IVA', 'I'), ('patients', 'O'), ('and', 'O'), ('produces', 'O'), ('a', 'O'), ('severe', 'O'), ('clinical', 'O'), ('phenotype', 'O'), ('.', 'O'))"
"We studied mutations in the GALNS gene from 23 additional MPS IVA patients ( 15 from Australia , 8 from Northern Ireland ) , with various clinical phenotypes ( severe , 16 cases ; intermediate , 4 cases ; mild , 3 cases ) .","(('We', 'O'), ('studied', 'O'), ('mutations', 'O'), ('in', 'O'), ('the', 'O'), ('GALNS', 'O'), ('gene', 'O'), ('from', 'O'), ('23', 'O'), ('additional', 'O'), ('MPS', 'B'), ('IVA', 'I'), ('patients', 'O'), ('(', 'O'), ('15', 'O'), ('from', 'O'), ('Australia', 'O'), (',', 'O'), ('8', 'O'), ('from', 'O'), ('Northern', 'O'), ('Ireland', 'O'), (')', 'O'), (',', 'O'), ('with', 'O'), ('various', 'O'), ('clinical', 'O'), ('phenotypes', 'O'), ('(', 'O'), ('severe', 'O'), (',', 'O'), ('16', 'O'), ('cases', 'O'), (';', 'O'), ('intermediate', 'O'), (',', 'O'), ('4', 'O'), ('cases', 'O'), (';', 'O'), ('mild', 'O'), (',', 'O'), ('3', 'O'), ('cases', 'O'), (')', 'O'), ('.', 'O'))"
These data provide further evidence for extensive allelic heterogeneity in MPS IVA in British - Irish patients and provide evidence for their transmission to Australia by British - Irish migrants . .,"(('These', 'O'), ('data', 'O'), ('provide', 'O'), ('further', 'O'), ('evidence', 'O'), ('for', 'O'), ('extensive', 'O'), ('allelic', 'O'), ('heterogeneity', 'O'), ('in', 'O'), ('MPS', 'B'), ('IVA', 'I'), ('in', 'O'), ('British', 'O'), ('-', 'O'), ('Irish', 'O'), ('patients', 'O'), ('and', 'O'), ('provide', 'O'), ('evidence', 'O'), ('for', 'O'), ('their', 'O'), ('transmission', 'O'), ('to', 'O'), ('Australia', 'O'), ('by', 'O'), ('British', 'O'), ('-', 'O'), ('Irish', 'O'), ('migrants', 'O'), ('.', 'O'), ('.', 'O'))"
"Identification of constitutional WT1 mutations , in patients with isolated diffuse mesangial sclerosis , and analysis of genotype / phenotype correlations by use of a computerized mutation database .","(('Identification', 'O'), ('of', 'O'), ('constitutional', 'O'), ('WT1', 'O'), ('mutations', 'O'), (',', 'O'), ('in', 'O'), ('patients', 'O'), ('with', 'O'), ('isolated', 'O'), ('diffuse', 'B'), ('mesangial', 'I'), ('sclerosis', 'I'), (',', 'O'), ('and', 'O'), ('analysis', 'O'), ('of', 'O'), ('genotype', 'O'), ('/', 'O'), ('phenotype', 'O'), ('correlations', 'O'), ('by', 'O'), ('use', 'O'), ('of', 'O'), ('a', 'O'), ('computerized', 'O'), ('mutation', 'O'), ('database', 'O'), ('.', 'O'))"
"Constitutional mutations of the WT1 gene , encoding a zinc - finger transcription factor involved in renal and gonadal development , are found in most patients with Denys - Drash syndrome ( DDS ) , or diffuse mesangial sclerosis ( DMS ) associated with pseudohermaphroditism and / or Wilms tumor ( WT ) .","(('Constitutional', 'O'), ('mutations', 'O'), ('of', 'O'), ('the', 'O'), ('WT1', 'O'), ('gene', 'O'), (',', 'O'), ('encoding', 'O'), ('a', 'O'), ('zinc', 'O'), ('-', 'O'), ('finger', 'O'), ('transcription', 'O'), ('factor', 'O'), ('involved', 'O'), ('in', 'O'), ('renal', 'O'), ('and', 'O'), ('gonadal', 'O'), ('development', 'O'), (',', 'O'), ('are', 'O'), ('found', 'O'), ('in', 'O'), ('most', 'O'), ('patients', 'O'), ('with', 'O'), ('Denys', 'B'), ('-', 'I'), ('Drash', 'I'), ('syndrome', 'I'), ('(', 'O'), ('DDS', 'B'), (')', 'O'), (',', 'O'), ('or', 'O'), ('diffuse', 'B'), ('mesangial', 'I'), ('sclerosis', 'I'), ('(', 'O'), ('DMS', 'B'), (')', 'O'), ('associated', 'O'), ('with', 'O'), ('pseudohermaphroditism', 'B'), ('and', 'O'), ('/', 'O'), ('or', 'O'), ('Wilms', 'B'), ('tumor', 'I'), ('(', 'O'), ('WT', 'B'), (')', 'O'), ('.', 'O'))"
"Most mutations in DDS patients lie in exon 8 or exon 9 , encoding zinc finger 2 or zinc finger 3 , respectively , with a hot spot ( R394W ) in exon 9 .","(('Most', 'O'), ('mutations', 'O'), ('in', 'O'), ('DDS', 'B'), ('patients', 'O'), ('lie', 'O'), ('in', 'O'), ('exon', 'O'), ('8', 'O'), ('or', 'O'), ('exon', 'O'), ('9', 'O'), (',', 'O'), ('encoding', 'O'), ('zinc', 'O'), ('finger', 'O'), ('2', 'O'), ('or', 'O'), ('zinc', 'O'), ('finger', 'O'), ('3', 'O'), (',', 'O'), ('respectively', 'O'), (',', 'O'), ('with', 'O'), ('a', 'O'), ('hot', 'O'), ('spot', 'O'), ('(', 'O'), ('R394W', 'O'), (')', 'O'), ('in', 'O'), ('exon', 'O'), ('9', 'O'), ('.', 'O'))"
"We analyzed a series of 24 patients , 10 with isolated DMS ( IDMS ) , 10 with DDS , and 4 with urogenital abnormalities and / or WT .","(('We', 'O'), ('analyzed', 'O'), ('a', 'O'), ('series', 'O'), ('of', 'O'), ('24', 'O'), ('patients', 'O'), (',', 'O'), ('10', 'O'), ('with', 'O'), ('isolated', 'B'), ('DMS', 'I'), ('(', 'O'), ('IDMS', 'B'), (')', 'O'), (',', 'O'), ('10', 'O'), ('with', 'O'), ('DDS', 'B'), (',', 'O'), ('and', 'O'), ('4', 'O'), ('with', 'O'), ('urogenital', 'B'), ('abnormalities', 'I'), ('and', 'O'), ('/', 'O'), ('or', 'O'), ('WT', 'B'), ('.', 'O'))"
Two mutations associated with IDMS are different from those described in DDS patients .,"(('Two', 'O'), ('mutations', 'O'), ('associated', 'O'), ('with', 'O'), ('IDMS', 'B'), ('are', 'O'), ('different', 'O'), ('from', 'O'), ('those', 'O'), ('described', 'O'), ('in', 'O'), ('DDS', 'B'), ('patients', 'O'), ('.', 'O'))"
The 185delAG mutation in BRCA1 is detected in Ashkenazi Jews both in familial breast and ovarian cancer and in the general population .,"(('The', 'O'), ('185delAG', 'O'), ('mutation', 'O'), ('in', 'O'), ('BRCA1', 'O'), ('is', 'O'), ('detected', 'O'), ('in', 'O'), ('Ashkenazi', 'O'), ('Jews', 'O'), ('both', 'O'), ('in', 'O'), ('familial', 'B'), ('breast', 'I'), ('and', 'I'), ('ovarian', 'I'), ('cancer', 'I'), ('and', 'O'), ('in', 'O'), ('the', 'O'), ('general', 'O'), ('population', 'O'), ('.', 'O'))"
BRCA1 allelic patterns were determined for four of these individuals and for 12 additional non - Ashkenazi 185delAG mutation carriers who had breast / ovarian cancer .,"(('BRCA1', 'O'), ('allelic', 'O'), ('patterns', 'O'), ('were', 'O'), ('determined', 'O'), ('for', 'O'), ('four', 'O'), ('of', 'O'), ('these', 'O'), ('individuals', 'O'), ('and', 'O'), ('for', 'O'), ('12', 'O'), ('additional', 'O'), ('non', 'O'), ('-', 'O'), ('Ashkenazi', 'O'), ('185delAG', 'O'), ('mutation', 'O'), ('carriers', 'O'), ('who', 'O'), ('had', 'O'), ('breast', 'B'), ('/', 'I'), ('ovarian', 'I'), ('cancer', 'I'), ('.', 'O'))"
Crystal structure of the hemochromatosis protein HFE and characterization of its interaction with transferrin receptor .,"(('Crystal', 'O'), ('structure', 'O'), ('of', 'O'), ('the', 'O'), ('hemochromatosis', 'B'), ('protein', 'O'), ('HFE', 'O'), ('and', 'O'), ('characterization', 'O'), ('of', 'O'), ('its', 'O'), ('interaction', 'O'), ('with', 'O'), ('transferrin', 'O'), ('receptor', 'O'), ('.', 'O'))"
HFE is an MHC - related protein that is mutated in the iron - overload disease hereditary hemochromatosis .,"(('HFE', 'O'), ('is', 'O'), ('an', 'O'), ('MHC', 'O'), ('-', 'O'), ('related', 'O'), ('protein', 'O'), ('that', 'O'), ('is', 'O'), ('mutated', 'O'), ('in', 'O'), ('the', 'O'), ('iron', 'B'), ('-', 'I'), ('overload', 'I'), ('disease', 'I'), ('hereditary', 'B'), ('hemochromatosis', 'I'), ('.', 'O'))"
6 A crystal structure of HFE reveals the locations of hemochromatosis mutations and a patch of histidines that could be involved in pH - dependent interactions .,"(('6', 'O'), ('A', 'O'), ('crystal', 'O'), ('structure', 'O'), ('of', 'O'), ('HFE', 'O'), ('reveals', 'O'), ('the', 'O'), ('locations', 'O'), ('of', 'O'), ('hemochromatosis', 'B'), ('mutations', 'O'), ('and', 'O'), ('a', 'O'), ('patch', 'O'), ('of', 'O'), ('histidines', 'O'), ('that', 'O'), ('could', 'O'), ('be', 'O'), ('involved', 'O'), ('in', 'O'), ('pH', 'O'), ('-', 'O'), ('dependent', 'O'), ('interactions', 'O'), ('.', 'O'))"
Identification of three novel mutations and a high frequency of the Arg778Leu mutation in Korean patients with Wilson disease .,"(('Identification', 'O'), ('of', 'O'), ('three', 'O'), ('novel', 'O'), ('mutations', 'O'), ('and', 'O'), ('a', 'O'), ('high', 'O'), ('frequency', 'O'), ('of', 'O'), ('the', 'O'), ('Arg778Leu', 'O'), ('mutation', 'O'), ('in', 'O'), ('Korean', 'O'), ('patients', 'O'), ('with', 'O'), ('Wilson', 'B'), ('disease', 'I'), ('.', 'O'))"
"Four mutations - - R778L , A874V , L1083F , and 2304delC - - in the copper - transporting enzyme , P - type ATPase ( ATP7B ) , were identified in Korean Patients with Wilson disease .","(('Four', 'O'), ('mutations', 'O'), ('-', 'O'), ('-', 'O'), ('R778L', 'O'), (',', 'O'), ('A874V', 'O'), (',', 'O'), ('L1083F', 'O'), (',', 'O'), ('and', 'O'), ('2304delC', 'O'), ('-', 'O'), ('-', 'O'), ('in', 'O'), ('the', 'O'), ('copper', 'O'), ('-', 'O'), ('transporting', 'O'), ('enzyme', 'O'), (',', 'O'), ('P', 'O'), ('-', 'O'), ('type', 'O'), ('ATPase', 'O'), ('(', 'O'), ('ATP7B', 'O'), (')', 'O'), (',', 'O'), ('were', 'O'), ('identified', 'O'), ('in', 'O'), ('Korean', 'O'), ('Patients', 'O'), ('with', 'O'), ('Wilson', 'B'), ('disease', 'I'), ('.', 'O'))"
"Since a mutation at cDNA nucleotide 2302 ( 2302insC ) had been previously described , this region of the ATP7B gene may be susceptible to gene rearrangements causing Wilson disease .","(('Since', 'O'), ('a', 'O'), ('mutation', 'O'), ('at', 'O'), ('cDNA', 'O'), ('nucleotide', 'O'), ('2302', 'O'), ('(', 'O'), ('2302insC', 'O'), (')', 'O'), ('had', 'O'), ('been', 'O'), ('previously', 'O'), ('described', 'O'), (',', 'O'), ('this', 'O'), ('region', 'O'), ('of', 'O'), ('the', 'O'), ('ATP7B', 'O'), ('gene', 'O'), ('may', 'O'), ('be', 'O'), ('susceptible', 'O'), ('to', 'O'), ('gene', 'O'), ('rearrangements', 'O'), ('causing', 'O'), ('Wilson', 'B'), ('disease', 'I'), ('.', 'O'))"
Disruption of splicing regulated by a CUG - binding protein in myotonic dystrophy .,"(('Disruption', 'O'), ('of', 'O'), ('splicing', 'O'), ('regulated', 'O'), ('by', 'O'), ('a', 'O'), ('CUG', 'O'), ('-', 'O'), ('binding', 'O'), ('protein', 'O'), ('in', 'O'), ('myotonic', 'B'), ('dystrophy', 'I'), ('.', 'O'))"
Myotonic dystrophy ( DM ) is caused by a CTG expansion in the 3 untranslated region of the DM gene .,"(('Myotonic', 'B'), ('dystrophy', 'I'), ('(', 'O'), ('DM', 'B'), (')', 'O'), ('is', 'O'), ('caused', 'O'), ('by', 'O'), ('a', 'O'), ('CTG', 'O'), ('expansion', 'O'), ('in', 'O'), ('the', 'O'), ('3', 'O'), ('untranslated', 'O'), ('region', 'O'), ('of', 'O'), ('the', 'O'), ('DM', 'B'), ('gene', 'O'), ('.', 'O'))"
One model of DM pathogenesis suggests that RNAs from the expanded allele create a gain - of - function mutation by the inappropriate binding of proteins to the CUG repeats .,"(('One', 'O'), ('model', 'O'), ('of', 'O'), ('DM', 'B'), ('pathogenesis', 'O'), ('suggests', 'O'), ('that', 'O'), ('RNAs', 'O'), ('from', 'O'), ('the', 'O'), ('expanded', 'O'), ('allele', 'O'), ('create', 'O'), ('a', 'O'), ('gain', 'O'), ('-', 'O'), ('of', 'O'), ('-', 'O'), ('function', 'O'), ('mutation', 'O'), ('by', 'O'), ('the', 'O'), ('inappropriate', 'O'), ('binding', 'O'), ('of', 'O'), ('proteins', 'O'), ('to', 'O'), ('the', 'O'), ('CUG', 'O'), ('repeats', 'O'), ('.', 'O'))"
Splicing of cTNT was disrupted in DM striated muscle and in normal cells expressing transcripts that contain CUG repeats .,"(('Splicing', 'O'), ('of', 'O'), ('cTNT', 'O'), ('was', 'O'), ('disrupted', 'O'), ('in', 'O'), ('DM', 'B'), ('striated', 'O'), ('muscle', 'O'), ('and', 'O'), ('in', 'O'), ('normal', 'O'), ('cells', 'O'), ('expressing', 'O'), ('transcripts', 'O'), ('that', 'O'), ('contain', 'O'), ('CUG', 'O'), ('repeats', 'O'), ('.', 'O'))"
Altered expression of genes regulated posttranscriptionally by CUG - BP therefore may contribute to DM pathogenesis . .,"(('Altered', 'O'), ('expression', 'O'), ('of', 'O'), ('genes', 'O'), ('regulated', 'O'), ('posttranscriptionally', 'O'), ('by', 'O'), ('CUG', 'O'), ('-', 'O'), ('BP', 'O'), ('therefore', 'O'), ('may', 'O'), ('contribute', 'O'), ('to', 'O'), ('DM', 'B'), ('pathogenesis', 'O'), ('.', 'O'), ('.', 'O'))"
Identification of a novel nonsense mutation and a missense substitution in the vasopressin - neurophysin II gene in two Spanish kindreds with familial neurohypophyseal diabetes insipidus .,"(('Identification', 'O'), ('of', 'O'), ('a', 'O'), ('novel', 'O'), ('nonsense', 'O'), ('mutation', 'O'), ('and', 'O'), ('a', 'O'), ('missense', 'O'), ('substitution', 'O'), ('in', 'O'), ('the', 'O'), ('vasopressin', 'O'), ('-', 'O'), ('neurophysin', 'O'), ('II', 'O'), ('gene', 'O'), ('in', 'O'), ('two', 'O'), ('Spanish', 'O'), ('kindreds', 'O'), ('with', 'O'), ('familial', 'B'), ('neurohypophyseal', 'I'), ('diabetes', 'I'), ('insipidus', 'I'), ('.', 'O'))"
Familial neurohypophyseal diabetes insipidus ( FNDI ) is an autosomal dominant disease caused by deficiency in the antidiuretic hormone arginine vasopressin ( AVP ) encoded by the AVP - neurophysin II ( AVP - NPII ) gene on chromosome 20p13 .,"(('Familial', 'B'), ('neurohypophyseal', 'I'), ('diabetes', 'I'), ('insipidus', 'I'), ('(', 'O'), ('FNDI', 'B'), (')', 'O'), ('is', 'O'), ('an', 'O'), ('autosomal', 'B'), ('dominant', 'I'), ('disease', 'I'), ('caused', 'O'), ('by', 'O'), ('deficiency', 'O'), ('in', 'O'), ('the', 'O'), ('antidiuretic', 'O'), ('hormone', 'O'), ('arginine', 'O'), ('vasopressin', 'O'), ('(', 'O'), ('AVP', 'O'), (')', 'O'), ('encoded', 'O'), ('by', 'O'), ('the', 'O'), ('AVP', 'O'), ('-', 'O'), ('neurophysin', 'O'), ('II', 'O'), ('(', 'O'), ('AVP', 'O'), ('-', 'O'), ('NPII', 'O'), (')', 'O'), ('gene', 'O'), ('on', 'O'), ('chromosome', 'O'), ('20p13', 'O'), ('.', 'O'))"
"In this study , we analyzed two families with FNDI using direct automated fluorescent , solid phase , single - stranded DNA sequencing of PCR - amplified AVP - NPII DNA .","(('In', 'O'), ('this', 'O'), ('study', 'O'), (',', 'O'), ('we', 'O'), ('analyzed', 'O'), ('two', 'O'), ('families', 'O'), ('with', 'O'), ('FNDI', 'B'), ('using', 'O'), ('direct', 'O'), ('automated', 'O'), ('fluorescent', 'O'), (',', 'O'), ('solid', 'O'), ('phase', 'O'), (',', 'O'), ('single', 'O'), ('-', 'O'), ('stranded', 'O'), ('DNA', 'O'), ('sequencing', 'O'), ('of', 'O'), ('PCR', 'O'), ('-', 'O'), ('amplified', 'O'), ('AVP', 'O'), ('-', 'O'), ('NPII', 'O'), ('DNA', 'O'), ('.', 'O'))"
"This missense mutation , which replaces Ala with Thr , is frequent among FNDI patients and is thought to reduce the efficiency of cleavage by signal peptidases . .","(('This', 'O'), ('missense', 'O'), ('mutation', 'O'), (',', 'O'), ('which', 'O'), ('replaces', 'O'), ('Ala', 'O'), ('with', 'O'), ('Thr', 'O'), (',', 'O'), ('is', 'O'), ('frequent', 'O'), ('among', 'O'), ('FNDI', 'B'), ('patients', 'O'), ('and', 'O'), ('is', 'O'), ('thought', 'O'), ('to', 'O'), ('reduce', 'O'), ('the', 'O'), ('efficiency', 'O'), ('of', 'O'), ('cleavage', 'O'), ('by', 'O'), ('signal', 'O'), ('peptidases', 'O'), ('.', 'O'), ('.', 'O'))"
"Genetic heterogeneity of Saethre - Chotzen syndrome , due to TWIST and FGFR mutations .","(('Genetic', 'O'), ('heterogeneity', 'O'), ('of', 'O'), ('Saethre', 'B'), ('-', 'I'), ('Chotzen', 'I'), ('syndrome', 'I'), (',', 'O'), ('due', 'O'), ('to', 'O'), ('TWIST', 'O'), ('and', 'O'), ('FGFR', 'O'), ('mutations', 'O'), ('.', 'O'))"
"Thirty - two unrelated patients with features of Saethre - Chotzen syndrome , a common autosomal dominant condition of craniosynostosis and limb anomalies , were screened for mutations in TWIST , FGFR2 , and FGFR3 .","(('Thirty', 'O'), ('-', 'O'), ('two', 'O'), ('unrelated', 'O'), ('patients', 'O'), ('with', 'O'), ('features', 'O'), ('of', 'O'), ('Saethre', 'B'), ('-', 'I'), ('Chotzen', 'I'), ('syndrome', 'I'), (',', 'O'), ('a', 'O'), ('common', 'O'), ('autosomal', 'B'), ('dominant', 'I'), ('condition', 'I'), ('of', 'O'), ('craniosynostosis', 'B'), ('and', 'O'), ('limb', 'B'), ('anomalies', 'I'), (',', 'O'), ('were', 'O'), ('screened', 'O'), ('for', 'O'), ('mutations', 'O'), ('in', 'O'), ('TWIST', 'O'), (',', 'O'), ('FGFR2', 'O'), (',', 'O'), ('and', 'O'), ('FGFR3', 'O'), ('.', 'O'))"
"To date , our detection rate for TWIST or FGFR mutations is 68 % in our Saethre - Chotzen syndrome patients , including our five patients elsewhere reported with TWIST mutations .","(('To', 'O'), ('date', 'O'), (',', 'O'), ('our', 'O'), ('detection', 'O'), ('rate', 'O'), ('for', 'O'), ('TWIST', 'O'), ('or', 'O'), ('FGFR', 'O'), ('mutations', 'O'), ('is', 'O'), ('68', 'O'), ('%', 'O'), ('in', 'O'), ('our', 'O'), ('Saethre', 'B'), ('-', 'I'), ('Chotzen', 'I'), ('syndrome', 'I'), ('patients', 'O'), (',', 'O'), ('including', 'O'), ('our', 'O'), ('five', 'O'), ('patients', 'O'), ('elsewhere', 'O'), ('reported', 'O'), ('with', 'O'), ('TWIST', 'O'), ('mutations', 'O'), ('.', 'O'))"
"The most common phenotypic features , present in more than a third of our patients with TWIST mutations , are coronal synostosis , brachycephaly , low frontal hairline , facial asymmetry , ptosis , hypertelorism , broad great toes , and clinodactyly .","(('The', 'O'), ('most', 'O'), ('common', 'O'), ('phenotypic', 'O'), ('features', 'O'), (',', 'O'), ('present', 'O'), ('in', 'O'), ('more', 'O'), ('than', 'O'), ('a', 'O'), ('third', 'O'), ('of', 'O'), ('our', 'O'), ('patients', 'O'), ('with', 'O'), ('TWIST', 'O'), ('mutations', 'O'), (',', 'O'), ('are', 'O'), ('coronal', 'B'), ('synostosis', 'I'), (',', 'O'), ('brachycephaly', 'B'), (',', 'O'), ('low', 'B'), ('frontal', 'I'), ('hairline', 'I'), (',', 'O'), ('facial', 'B'), ('asymmetry', 'I'), (',', 'O'), ('ptosis', 'B'), (',', 'O'), ('hypertelorism', 'B'), (',', 'O'), ('broad', 'B'), ('great', 'I'), ('toes', 'I'), (',', 'O'), ('and', 'O'), ('clinodactyly', 'B'), ('.', 'O'))"
"The overlap in clinical features and the presence , in the same genes , of mutations for more than one craniosynostotic condition - such as Saethre - Chotzen , Crouzon , and Pfeiffer syndromes - support the hypothesis that TWIST and FGFRs are components of the same molecular pathway involved in the modulation of craniofacial and limb development in humans . .","(('The', 'O'), ('overlap', 'O'), ('in', 'O'), ('clinical', 'O'), ('features', 'O'), ('and', 'O'), ('the', 'O'), ('presence', 'O'), (',', 'O'), ('in', 'O'), ('the', 'O'), ('same', 'O'), ('genes', 'O'), (',', 'O'), ('of', 'O'), ('mutations', 'O'), ('for', 'O'), ('more', 'O'), ('than', 'O'), ('one', 'O'), ('craniosynostotic', 'B'), ('condition', 'I'), ('-', 'O'), ('such', 'O'), ('as', 'O'), ('Saethre', 'B'), ('-', 'I'), ('Chotzen', 'I'), (',', 'I'), ('Crouzon', 'I'), (',', 'I'), ('and', 'I'), ('Pfeiffer', 'I'), ('syndromes', 'I'), ('-', 'O'), ('support', 'O'), ('the', 'O'), ('hypothesis', 'O'), ('that', 'O'), ('TWIST', 'O'), ('and', 'O'), ('FGFRs', 'O'), ('are', 'O'), ('components', 'O'), ('of', 'O'), ('the', 'O'), ('same', 'O'), ('molecular', 'O'), ('pathway', 'O'), ('involved', 'O'), ('in', 'O'), ('the', 'O'), ('modulation', 'O'), ('of', 'O'), ('craniofacial', 'O'), ('and', 'O'), ('limb', 'O'), ('development', 'O'), ('in', 'O'), ('humans', 'O'), ('.', 'O'), ('.', 'O'))"
Mutation analysis of UBE3A in Angelman syndrome patients .,"(('Mutation', 'O'), ('analysis', 'O'), ('of', 'O'), ('UBE3A', 'O'), ('in', 'O'), ('Angelman', 'B'), ('syndrome', 'I'), ('patients', 'O'), ('.', 'O'))"
"Angelman syndrome ( AS ) is caused by chromosome 15q11 - q13 deletions of maternal origin , by paternal uniparental disomy ( UPD ) 15 , by imprinting defects , and by mutations in the UBE3A gene .","(('Angelman', 'B'), ('syndrome', 'I'), ('(', 'O'), ('AS', 'B'), (')', 'O'), ('is', 'O'), ('caused', 'O'), ('by', 'O'), ('chromosome', 'O'), ('15q11', 'O'), ('-', 'O'), ('q13', 'O'), ('deletions', 'O'), ('of', 'O'), ('maternal', 'O'), ('origin', 'O'), (',', 'O'), ('by', 'O'), ('paternal', 'O'), ('uniparental', 'B'), ('disomy', 'I'), ('(', 'O'), ('UPD', 'B'), (')', 'O'), ('15', 'O'), (',', 'O'), ('by', 'O'), ('imprinting', 'O'), ('defects', 'O'), (',', 'O'), ('and', 'O'), ('by', 'O'), ('mutations', 'O'), ('in', 'O'), ('the', 'O'), ('UBE3A', 'O'), ('gene', 'O'), ('.', 'O'))"
Here we describe UBE3A coding - region mutations detected by SSCP analysis in 13 AS individuals or families .,"(('Here', 'O'), ('we', 'O'), ('describe', 'O'), ('UBE3A', 'O'), ('coding', 'O'), ('-', 'O'), ('region', 'O'), ('mutations', 'O'), ('detected', 'O'), ('by', 'O'), ('SSCP', 'O'), ('analysis', 'O'), ('in', 'O'), ('13', 'O'), ('AS', 'B'), ('individuals', 'O'), ('or', 'O'), ('families', 'O'), ('.', 'O'))"
"In two familial cases and one sporadic case , mosaicism for UBE3A mutations was detected in the mother of three AS sons , in the maternal grandfather of two AS first cousins , and in the mother of an AS daughter .","(('In', 'O'), ('two', 'O'), ('familial', 'O'), ('cases', 'O'), ('and', 'O'), ('one', 'O'), ('sporadic', 'O'), ('case', 'O'), (',', 'O'), ('mosaicism', 'O'), ('for', 'O'), ('UBE3A', 'O'), ('mutations', 'O'), ('was', 'O'), ('detected', 'O'), ('in', 'O'), ('the', 'O'), ('mother', 'O'), ('of', 'O'), ('three', 'O'), ('AS', 'B'), ('sons', 'O'), (',', 'O'), ('in', 'O'), ('the', 'O'), ('maternal', 'O'), ('grandfather', 'O'), ('of', 'O'), ('two', 'O'), ('AS', 'B'), ('first', 'O'), ('cousins', 'O'), (',', 'O'), ('and', 'O'), ('in', 'O'), ('the', 'O'), ('mother', 'O'), ('of', 'O'), ('an', 'O'), ('AS', 'B'), ('daughter', 'O'), ('.', 'O'))"
The hemochromatosis 845 G - - > A and 187 C - - > G mutations : prevalence in non - Caucasian populations .,"(('The', 'O'), ('hemochromatosis', 'B'), ('845', 'O'), ('G', 'O'), ('-', 'O'), ('-', 'O'), ('>', 'O'), ('A', 'O'), ('and', 'O'), ('187', 'O'), ('C', 'O'), ('-', 'O'), ('-', 'O'), ('>', 'O'), ('G', 'O'), ('mutations', 'O'), (':', 'O'), ('prevalence', 'O'), ('in', 'O'), ('non', 'O'), ('-', 'O'), ('Caucasian', 'O'), ('populations', 'O'), ('.', 'O'))"
"Hemochromatosis , the inherited disorder of iron metabolism , leads , if untreated , to progressive iron overload and premature death .","(('Hemochromatosis', 'B'), (',', 'O'), ('the', 'O'), ('inherited', 'B'), ('disorder', 'I'), ('of', 'I'), ('iron', 'I'), ('metabolism', 'I'), (',', 'O'), ('leads', 'O'), (',', 'O'), ('if', 'O'), ('untreated', 'O'), (',', 'O'), ('to', 'O'), ('progressive', 'O'), ('iron', 'B'), ('overload', 'I'), ('and', 'O'), ('premature', 'B'), ('death', 'I'), ('.', 'O'))"
"The hemochromatosis gene , HFE , recently has been identified , and characterization of this gene has shown that it contains two mutations that result in amino acid substitutions - cDNA nucleotides 845 G - - > A ( C282Y ) and 187 C - - > G ( H63D ) .","(('The', 'O'), ('hemochromatosis', 'B'), ('gene', 'O'), (',', 'O'), ('HFE', 'O'), (',', 'O'), ('recently', 'O'), ('has', 'O'), ('been', 'O'), ('identified', 'O'), (',', 'O'), ('and', 'O'), ('characterization', 'O'), ('of', 'O'), ('this', 'O'), ('gene', 'O'), ('has', 'O'), ('shown', 'O'), ('that', 'O'), ('it', 'O'), ('contains', 'O'), ('two', 'O'), ('mutations', 'O'), ('that', 'O'), ('result', 'O'), ('in', 'O'), ('amino', 'O'), ('acid', 'O'), ('substitutions', 'O'), ('-', 'O'), ('cDNA', 'O'), ('nucleotides', 'O'), ('845', 'O'), ('G', 'O'), ('-', 'O'), ('-', 'O'), ('>', 'O'), ('A', 'O'), ('(', 'O'), ('C282Y', 'O'), (')', 'O'), ('and', 'O'), ('187', 'O'), ('C', 'O'), ('-', 'O'), ('-', 'O'), ('>', 'O'), ('G', 'O'), ('(', 'O'), ('H63D', 'O'), (')', 'O'), ('.', 'O'))"
"Although hemochromatosis is common in Caucasians , affecting > = 1 / 300 individuals of northern European origin , it has not been recognized in other populations .","(('Although', 'O'), ('hemochromatosis', 'B'), ('is', 'O'), ('common', 'O'), ('in', 'O'), ('Caucasians', 'O'), (',', 'O'), ('affecting', 'O'), ('>', 'O'), ('=', 'O'), ('1', 'O'), ('/', 'O'), ('300', 'O'), ('individuals', 'O'), ('of', 'O'), ('northern', 'O'), ('European', 'O'), ('origin', 'O'), (',', 'O'), ('it', 'O'), ('has', 'O'), ('not', 'O'), ('been', 'O'), ('recognized', 'O'), ('in', 'O'), ('other', 'O'), ('populations', 'O'), ('.', 'O'))"
Genotype - phenotype correlations in attenuated adenomatous polyposis coli .,"(('Genotype', 'O'), ('-', 'O'), ('phenotype', 'O'), ('correlations', 'O'), ('in', 'O'), ('attenuated', 'B'), ('adenomatous', 'I'), ('polyposis', 'I'), ('coli', 'I'), ('.', 'O'))"
"Germ - line mutations of the tumor suppressor APC are implicated in attenuated adenomatous polyposis coli ( AAPC ) , a variant of familial adenomatous polyposis ( FAP ) .","(('Germ', 'O'), ('-', 'O'), ('line', 'O'), ('mutations', 'O'), ('of', 'O'), ('the', 'O'), ('tumor', 'B'), ('suppressor', 'O'), ('APC', 'O'), ('are', 'O'), ('implicated', 'O'), ('in', 'O'), ('attenuated', 'B'), ('adenomatous', 'I'), ('polyposis', 'I'), ('coli', 'I'), ('(', 'O'), ('AAPC', 'B'), (')', 'O'), (',', 'O'), ('a', 'O'), ('variant', 'O'), ('of', 'O'), ('familial', 'B'), ('adenomatous', 'I'), ('polyposis', 'I'), ('(', 'O'), ('FAP', 'B'), (')', 'O'), ('.', 'O'))"
AAPC is recognized by the occurrence of < 100 colonic adenomas and a later onset of colorectal cancer ( age > 40 years ) .,"(('AAPC', 'B'), ('is', 'O'), ('recognized', 'O'), ('by', 'O'), ('the', 'O'), ('occurrence', 'O'), ('of', 'O'), ('<', 'O'), ('100', 'O'), ('colonic', 'B'), ('adenomas', 'I'), ('and', 'O'), ('a', 'O'), ('later', 'O'), ('onset', 'O'), ('of', 'O'), ('colorectal', 'B'), ('cancer', 'I'), ('(', 'O'), ('age', 'O'), ('>', 'O'), ('40', 'O'), ('years', 'O'), (')', 'O'), ('.', 'O'))"
The aim of this study was to assess genotype - phenotype correlations in AAPC families .,"(('The', 'O'), ('aim', 'O'), ('of', 'O'), ('this', 'O'), ('study', 'O'), ('was', 'O'), ('to', 'O'), ('assess', 'O'), ('genotype', 'O'), ('-', 'O'), ('phenotype', 'O'), ('correlations', 'O'), ('in', 'O'), ('AAPC', 'B'), ('families', 'O'), ('.', 'O'))"
"By protein - truncation test ( PTT ) assay , the entire coding region of the APC gene was screened in affected individuals from 11 AAPC kindreds , and their phenotypic differences were examined .","(('By', 'O'), ('protein', 'O'), ('-', 'O'), ('truncation', 'O'), ('test', 'O'), ('(', 'O'), ('PTT', 'O'), (')', 'O'), ('assay', 'O'), (',', 'O'), ('the', 'O'), ('entire', 'O'), ('coding', 'O'), ('region', 'O'), ('of', 'O'), ('the', 'O'), ('APC', 'B'), ('gene', 'O'), ('was', 'O'), ('screened', 'O'), ('in', 'O'), ('affected', 'O'), ('individuals', 'O'), ('from', 'O'), ('11', 'O'), ('AAPC', 'B'), ('kindreds', 'O'), (',', 'O'), ('and', 'O'), ('their', 'O'), ('phenotypic', 'O'), ('differences', 'O'), ('were', 'O'), ('examined', 'O'), ('.', 'O'))"
Five novel germ - line APC mutations were identified in seven kindreds .,"(('Five', 'O'), ('novel', 'O'), ('germ', 'O'), ('-', 'O'), ('line', 'O'), ('APC', 'B'), ('mutations', 'O'), ('were', 'O'), ('identified', 'O'), ('in', 'O'), ('seven', 'O'), ('kindreds', 'O'), ('.', 'O'))"
"Mutations were located in three different regions of the APC gene ( 1 ) at the 5 end spanning exons 4 and 5 , ( 2 ) within exon 9 , and ( 3 ) at the 3 distal end of the gene .","(('Mutations', 'O'), ('were', 'O'), ('located', 'O'), ('in', 'O'), ('three', 'O'), ('different', 'O'), ('regions', 'O'), ('of', 'O'), ('the', 'O'), ('APC', 'B'), ('gene', 'O'), ('(', 'O'), ('1', 'O'), (')', 'O'), ('at', 'O'), ('the', 'O'), ('5', 'O'), ('end', 'O'), ('spanning', 'O'), ('exons', 'O'), ('4', 'O'), ('and', 'O'), ('5', 'O'), (',', 'O'), ('(', 'O'), ('2', 'O'), (')', 'O'), ('within', 'O'), ('exon', 'O'), ('9', 'O'), (',', 'O'), ('and', 'O'), ('(', 'O'), ('3', 'O'), (')', 'O'), ('at', 'O'), ('the', 'O'), ('3', 'O'), ('distal', 'O'), ('end', 'O'), ('of', 'O'), ('the', 'O'), ('gene', 'O'), ('.', 'O'))"
"Variability in the number of colorectal adenomas was most apparent in individuals with mutations in region 1 , and upper - gastrointestinal manifestations were more severe in them .","(('Variability', 'O'), ('in', 'O'), ('the', 'O'), ('number', 'O'), ('of', 'O'), ('colorectal', 'B'), ('adenomas', 'I'), ('was', 'O'), ('most', 'O'), ('apparent', 'O'), ('in', 'O'), ('individuals', 'O'), ('with', 'O'), ('mutations', 'O'), ('in', 'O'), ('region', 'O'), ('1', 'O'), (',', 'O'), ('and', 'O'), ('upper', 'O'), ('-', 'O'), ('gastrointestinal', 'O'), ('manifestations', 'O'), ('were', 'O'), ('more', 'O'), ('severe', 'O'), ('in', 'O'), ('them', 'O'), ('.', 'O'))"
"In individuals with mutations in either region 2 or region 3 , the average number of adenomas tended to be lower than those in individuals with mutations in region 1 , although age at diagnosis was similar .","(('In', 'O'), ('individuals', 'O'), ('with', 'O'), ('mutations', 'O'), ('in', 'O'), ('either', 'O'), ('region', 'O'), ('2', 'O'), ('or', 'O'), ('region', 'O'), ('3', 'O'), (',', 'O'), ('the', 'O'), ('average', 'O'), ('number', 'O'), ('of', 'O'), ('adenomas', 'B'), ('tended', 'O'), ('to', 'O'), ('be', 'O'), ('lower', 'O'), ('than', 'O'), ('those', 'O'), ('in', 'O'), ('individuals', 'O'), ('with', 'O'), ('mutations', 'O'), ('in', 'O'), ('region', 'O'), ('1', 'O'), (',', 'O'), ('although', 'O'), ('age', 'O'), ('at', 'O'), ('diagnosis', 'O'), ('was', 'O'), ('similar', 'O'), ('.', 'O'))"
"In all AAPC kindreds , a predominance of right - sided colorectal adenomas and rectal polyp sparing was observed .","(('In', 'O'), ('all', 'O'), ('AAPC', 'B'), ('kindreds', 'O'), (',', 'O'), ('a', 'O'), ('predominance', 'O'), ('of', 'O'), ('right', 'O'), ('-', 'O'), ('sided', 'O'), ('colorectal', 'B'), ('adenomas', 'I'), ('and', 'O'), ('rectal', 'B'), ('polyp', 'I'), ('sparing', 'O'), ('was', 'O'), ('observed', 'O'), ('.', 'O'))"
No desmoid tumors were found in these kindreds .,"(('No', 'O'), ('desmoid', 'B'), ('tumors', 'I'), ('were', 'O'), ('found', 'O'), ('in', 'O'), ('these', 'O'), ('kindreds', 'O'), ('.', 'O'))"
"Our data suggest that , in AAPC families , the location of the APC mutation may partially predict specific phenotypic expression .","(('Our', 'O'), ('data', 'O'), ('suggest', 'O'), ('that', 'O'), (',', 'O'), ('in', 'O'), ('AAPC', 'B'), ('families', 'O'), (',', 'O'), ('the', 'O'), ('location', 'O'), ('of', 'O'), ('the', 'O'), ('APC', 'B'), ('mutation', 'O'), ('may', 'O'), ('partially', 'O'), ('predict', 'O'), ('specific', 'O'), ('phenotypic', 'O'), ('expression', 'O'), ('.', 'O'))"
This should help in the design of tailored clinical - management protocols in this subset of FAP patients . .,"(('This', 'O'), ('should', 'O'), ('help', 'O'), ('in', 'O'), ('the', 'O'), ('design', 'O'), ('of', 'O'), ('tailored', 'O'), ('clinical', 'O'), ('-', 'O'), ('management', 'O'), ('protocols', 'O'), ('in', 'O'), ('this', 'O'), ('subset', 'O'), ('of', 'O'), ('FAP', 'B'), ('patients', 'O'), ('.', 'O'), ('.', 'O'))"
Wilms ' tumor 1 and Dax - 1 modulate the orphan nuclear receptor SF - 1 in sex - specific gene expression .,"(('Wilms', 'B'), (""'"", 'I'), ('tumor', 'I'), ('1', 'O'), ('and', 'O'), ('Dax', 'O'), ('-', 'O'), ('1', 'O'), ('modulate', 'O'), ('the', 'O'), ('orphan', 'O'), ('nuclear', 'O'), ('receptor', 'O'), ('SF', 'O'), ('-', 'O'), ('1', 'O'), ('in', 'O'), ('sex', 'O'), ('-', 'O'), ('specific', 'O'), ('gene', 'O'), ('expression', 'O'), ('.', 'O'))"
Products of steroidogenic factor 1 ( SF - 1 ) and Wilms tumor 1 ( WT1 ) genes are essential for mammalian gonadogenesis prior to sexual differentiation .,"(('Products', 'O'), ('of', 'O'), ('steroidogenic', 'O'), ('factor', 'O'), ('1', 'O'), ('(', 'O'), ('SF', 'O'), ('-', 'O'), ('1', 'O'), (')', 'O'), ('and', 'O'), ('Wilms', 'B'), ('tumor', 'I'), ('1', 'O'), ('(', 'O'), ('WT1', 'O'), (')', 'O'), ('genes', 'O'), ('are', 'O'), ('essential', 'O'), ('for', 'O'), ('mammalian', 'O'), ('gonadogenesis', 'O'), ('prior', 'O'), ('to', 'O'), ('sexual', 'O'), ('differentiation', 'O'), ('.', 'O'))"
"In contrast , WT1 missense mutations , associated with male pseudohermaphroditism in Denys - Drash syndrome , fail to synergize with SF - 1 .","(('In', 'O'), ('contrast', 'O'), (',', 'O'), ('WT1', 'O'), ('missense', 'O'), ('mutations', 'O'), (',', 'O'), ('associated', 'O'), ('with', 'O'), ('male', 'B'), ('pseudohermaphroditism', 'I'), ('in', 'O'), ('Denys', 'B'), ('-', 'I'), ('Drash', 'I'), ('syndrome', 'I'), (',', 'O'), ('fail', 'O'), ('to', 'O'), ('synergize', 'O'), ('with', 'O'), ('SF', 'O'), ('-', 'O'), ('1', 'O'), ('.', 'O'))"
A mouse model for Prader - Willi syndrome imprinting - centre mutations .,"(('A', 'O'), ('mouse', 'O'), ('model', 'O'), ('for', 'O'), ('Prader', 'B'), ('-', 'I'), ('Willi', 'I'), ('syndrome', 'I'), ('imprinting', 'O'), ('-', 'O'), ('centre', 'O'), ('mutations', 'O'), ('.', 'O'))"
Deletion of this IC abolishes local paternally derived gene expression and results in Prader - Willi syndrome ( PWS ) .,"(('Deletion', 'O'), ('of', 'O'), ('this', 'O'), ('IC', 'O'), ('abolishes', 'O'), ('local', 'O'), ('paternally', 'O'), ('derived', 'O'), ('gene', 'O'), ('expression', 'O'), ('and', 'O'), ('results', 'O'), ('in', 'O'), ('Prader', 'B'), ('-', 'I'), ('Willi', 'I'), ('syndrome', 'I'), ('(', 'O'), ('PWS', 'B'), (')', 'O'), ('.', 'O'))"
We have created two deletion mutations in mice to understand PWS and the mechanism of this IC .,"(('We', 'O'), ('have', 'O'), ('created', 'O'), ('two', 'O'), ('deletion', 'O'), ('mutations', 'O'), ('in', 'O'), ('mice', 'O'), ('to', 'O'), ('understand', 'O'), ('PWS', 'B'), ('and', 'O'), ('the', 'O'), ('mechanism', 'O'), ('of', 'O'), ('this', 'O'), ('IC', 'O'), ('.', 'O'))"
"Mice harbouring an intragenic deletion in Snrpn are phenotypically normal , suggesting that mutations of SNRPN are not sufficient to induce PWS .","(('Mice', 'O'), ('harbouring', 'O'), ('an', 'O'), ('intragenic', 'O'), ('deletion', 'O'), ('in', 'O'), ('Snrpn', 'O'), ('are', 'O'), ('phenotypically', 'O'), ('normal', 'O'), (',', 'O'), ('suggesting', 'O'), ('that', 'O'), ('mutations', 'O'), ('of', 'O'), ('SNRPN', 'O'), ('are', 'O'), ('not', 'O'), ('sufficient', 'O'), ('to', 'O'), ('induce', 'O'), ('PWS', 'B'), ('.', 'O'))"
"Mice with a larger deletion involving both Snrpn and the putative PWS - IC lack expression of the imprinted genes Zfp127 ( mouse homologue of ZNF127 ) , Ndn and Ipw , and manifest several phenotypes common to PWS infants .","(('Mice', 'O'), ('with', 'O'), ('a', 'O'), ('larger', 'O'), ('deletion', 'O'), ('involving', 'O'), ('both', 'O'), ('Snrpn', 'O'), ('and', 'O'), ('the', 'O'), ('putative', 'O'), ('PWS', 'O'), ('-', 'O'), ('IC', 'O'), ('lack', 'O'), ('expression', 'O'), ('of', 'O'), ('the', 'O'), ('imprinted', 'O'), ('genes', 'O'), ('Zfp127', 'O'), ('(', 'O'), ('mouse', 'O'), ('homologue', 'O'), ('of', 'O'), ('ZNF127', 'O'), (')', 'O'), (',', 'O'), ('Ndn', 'O'), ('and', 'O'), ('Ipw', 'O'), (',', 'O'), ('and', 'O'), ('manifest', 'O'), ('several', 'O'), ('phenotypes', 'O'), ('common', 'O'), ('to', 'O'), ('PWS', 'B'), ('infants', 'O'), ('.', 'O'))"
Mutations of the ATM gene detected in Japanese ataxia - telangiectasia patients : possible preponderance of the two founder mutations 4612del165 and 7883del5 .,"(('Mutations', 'O'), ('of', 'O'), ('the', 'O'), ('ATM', 'O'), ('gene', 'O'), ('detected', 'O'), ('in', 'O'), ('Japanese', 'O'), ('ataxia', 'B'), ('-', 'I'), ('telangiectasia', 'I'), ('patients', 'O'), (':', 'O'), ('possible', 'O'), ('preponderance', 'O'), ('of', 'O'), ('the', 'O'), ('two', 'O'), ('founder', 'O'), ('mutations', 'O'), ('4612del165', 'O'), ('and', 'O'), ('7883del5', 'O'), ('.', 'O'))"
3 has recently been identified as the gene responsible for the human recessive disease ataxia - telangiectasia ( A - T ) .,"(('3', 'O'), ('has', 'O'), ('recently', 'O'), ('been', 'O'), ('identified', 'O'), ('as', 'O'), ('the', 'O'), ('gene', 'O'), ('responsible', 'O'), ('for', 'O'), ('the', 'O'), ('human', 'O'), ('recessive', 'B'), ('disease', 'I'), ('ataxia', 'B'), ('-', 'I'), ('telangiectasia', 'I'), ('(', 'O'), ('A', 'B'), ('-', 'I'), ('T', 'I'), (')', 'O'), ('.', 'O'))"
"In order to define the types of disease - causing ATM mutations in Japanese A - T patients as well as to look for possible mutational hotspots , reverse - transcribed RNA derived from ten patients belonging to eight unrelated Japanese A - T families was analyzed for mutations by the restriction endonuclease fingerprinting method .","(('In', 'O'), ('order', 'O'), ('to', 'O'), ('define', 'O'), ('the', 'O'), ('types', 'O'), ('of', 'O'), ('disease', 'O'), ('-', 'O'), ('causing', 'O'), ('ATM', 'O'), ('mutations', 'O'), ('in', 'O'), ('Japanese', 'O'), ('A', 'B'), ('-', 'I'), ('T', 'I'), ('patients', 'O'), ('as', 'O'), ('well', 'O'), ('as', 'O'), ('to', 'O'), ('look', 'O'), ('for', 'O'), ('possible', 'O'), ('mutational', 'O'), ('hotspots', 'O'), (',', 'O'), ('reverse', 'O'), ('-', 'O'), ('transcribed', 'O'), ('RNA', 'O'), ('derived', 'O'), ('from', 'O'), ('ten', 'O'), ('patients', 'O'), ('belonging', 'O'), ('to', 'O'), ('eight', 'O'), ('unrelated', 'O'), ('Japanese', 'O'), ('A', 'B'), ('-', 'I'), ('T', 'I'), ('families', 'O'), ('was', 'O'), ('analyzed', 'O'), ('for', 'O'), ('mutations', 'O'), ('by', 'O'), ('the', 'O'), ('restriction', 'O'), ('endonuclease', 'O'), ('fingerprinting', 'O'), ('method', 'O'), ('.', 'O'))"
W474C amino acid substitution affects early processing of the alpha - subunit of beta - hexosaminidase A and is associated with subacute G ( M2 ) gangliosidosis .,"(('W474C', 'O'), ('amino', 'O'), ('acid', 'O'), ('substitution', 'O'), ('affects', 'O'), ('early', 'O'), ('processing', 'O'), ('of', 'O'), ('the', 'O'), ('alpha', 'O'), ('-', 'O'), ('subunit', 'O'), ('of', 'O'), ('beta', 'O'), ('-', 'O'), ('hexosaminidase', 'O'), ('A', 'O'), ('and', 'O'), ('is', 'O'), ('associated', 'O'), ('with', 'O'), ('subacute', 'O'), ('G', 'B'), ('(', 'I'), ('M2', 'I'), (')', 'I'), ('gangliosidosis', 'I'), ('.', 'O'))"
"Mutations in the HEXA gene , encoding the alpha - subunit of beta - hexosaminidase A ( Hex A ) , that abolish Hex A enzyme activity cause Tay - Sachs disease ( TSD ) , the fatal infantile form of G ( M2 ) gangliosidosis , Type 1 .","(('Mutations', 'O'), ('in', 'O'), ('the', 'O'), ('HEXA', 'O'), ('gene', 'O'), (',', 'O'), ('encoding', 'O'), ('the', 'O'), ('alpha', 'O'), ('-', 'O'), ('subunit', 'O'), ('of', 'O'), ('beta', 'O'), ('-', 'O'), ('hexosaminidase', 'O'), ('A', 'O'), ('(', 'O'), ('Hex', 'O'), ('A', 'O'), (')', 'O'), (',', 'O'), ('that', 'O'), ('abolish', 'O'), ('Hex', 'O'), ('A', 'O'), ('enzyme', 'O'), ('activity', 'O'), ('cause', 'O'), ('Tay', 'B'), ('-', 'I'), ('Sachs', 'I'), ('disease', 'I'), ('(', 'O'), ('TSD', 'B'), (')', 'O'), (',', 'O'), ('the', 'O'), ('fatal', 'O'), ('infantile', 'B'), ('form', 'I'), ('of', 'I'), ('G', 'I'), ('(', 'I'), ('M2', 'I'), (')', 'I'), ('gangliosidosis', 'I'), (',', 'I'), ('Type', 'I'), ('1', 'I'), ('.', 'O'))"
We identified a 1422 G - - > C ( amino acid W474C ) substitution in the first position of exon 13 of HEXA of a non - Jewish proband who manifested a subacute variant of G ( M2 ) gangliosidosis .,"(('We', 'O'), ('identified', 'O'), ('a', 'O'), ('1422', 'O'), ('G', 'O'), ('-', 'O'), ('-', 'O'), ('>', 'O'), ('C', 'O'), ('(', 'O'), ('amino', 'O'), ('acid', 'O'), ('W474C', 'O'), (')', 'O'), ('substitution', 'O'), ('in', 'O'), ('the', 'O'), ('first', 'O'), ('position', 'O'), ('of', 'O'), ('exon', 'O'), ('13', 'O'), ('of', 'O'), ('HEXA', 'O'), ('of', 'O'), ('a', 'O'), ('non', 'O'), ('-', 'O'), ('Jewish', 'O'), ('proband', 'O'), ('who', 'O'), ('manifested', 'O'), ('a', 'O'), ('subacute', 'O'), ('variant', 'O'), ('of', 'O'), ('G', 'B'), ('(', 'I'), ('M2', 'I'), (')', 'I'), ('gangliosidosis', 'I'), ('.', 'O'))"
"When the W474C - containing alpha - subunit was transiently co - expressed with the beta - subunit to produce Hex A ( alphabeta ) in COS - 7 cells , the mature alpha - subunit was present , but its level was much lower than that from normal alpha - subunit transfections , although higher than in those cells transfected with an alpha - subunit associated with infantile TSD .","(('When', 'O'), ('the', 'O'), ('W474C', 'O'), ('-', 'O'), ('containing', 'O'), ('alpha', 'O'), ('-', 'O'), ('subunit', 'O'), ('was', 'O'), ('transiently', 'O'), ('co', 'O'), ('-', 'O'), ('expressed', 'O'), ('with', 'O'), ('the', 'O'), ('beta', 'O'), ('-', 'O'), ('subunit', 'O'), ('to', 'O'), ('produce', 'O'), ('Hex', 'O'), ('A', 'O'), ('(', 'O'), ('alphabeta', 'O'), (')', 'O'), ('in', 'O'), ('COS', 'O'), ('-', 'O'), ('7', 'O'), ('cells', 'O'), (',', 'O'), ('the', 'O'), ('mature', 'O'), ('alpha', 'O'), ('-', 'O'), ('subunit', 'O'), ('was', 'O'), ('present', 'O'), (',', 'O'), ('but', 'O'), ('its', 'O'), ('level', 'O'), ('was', 'O'), ('much', 'O'), ('lower', 'O'), ('than', 'O'), ('that', 'O'), ('from', 'O'), ('normal', 'O'), ('alpha', 'O'), ('-', 'O'), ('subunit', 'O'), ('transfections', 'O'), (',', 'O'), ('although', 'O'), ('higher', 'O'), ('than', 'O'), ('in', 'O'), ('those', 'O'), ('cells', 'O'), ('transfected', 'O'), ('with', 'O'), ('an', 'O'), ('alpha', 'O'), ('-', 'O'), ('subunit', 'O'), ('associated', 'O'), ('with', 'O'), ('infantile', 'O'), ('TSD', 'B'), ('.', 'O'))"
We conclude that the 1422 G - - > C mutation is the cause of Hex A enzyme deficiency in the proband .,"(('We', 'O'), ('conclude', 'O'), ('that', 'O'), ('the', 'O'), ('1422', 'O'), ('G', 'O'), ('-', 'O'), ('-', 'O'), ('>', 'O'), ('C', 'O'), ('mutation', 'O'), ('is', 'O'), ('the', 'O'), ('cause', 'O'), ('of', 'O'), ('Hex', 'B'), ('A', 'I'), ('enzyme', 'I'), ('deficiency', 'I'), ('in', 'O'), ('the', 'O'), ('proband', 'O'), ('.', 'O'))"
"The resulting W474C substitution clearly interferes with alpha - subunit processing , but because the base substitution falls at the first position of exon 13 , aberrant splicing may also contribute to Hex A deficiency in this proband . .","(('The', 'O'), ('resulting', 'O'), ('W474C', 'O'), ('substitution', 'O'), ('clearly', 'O'), ('interferes', 'O'), ('with', 'O'), ('alpha', 'O'), ('-', 'O'), ('subunit', 'O'), ('processing', 'O'), (',', 'O'), ('but', 'O'), ('because', 'O'), ('the', 'O'), ('base', 'O'), ('substitution', 'O'), ('falls', 'O'), ('at', 'O'), ('the', 'O'), ('first', 'O'), ('position', 'O'), ('of', 'O'), ('exon', 'O'), ('13', 'O'), (',', 'O'), ('aberrant', 'O'), ('splicing', 'O'), ('may', 'O'), ('also', 'O'), ('contribute', 'O'), ('to', 'O'), ('Hex', 'B'), ('A', 'I'), ('deficiency', 'I'), ('in', 'O'), ('this', 'O'), ('proband', 'O'), ('.', 'O'), ('.', 'O'))"
Two frequent missense mutations in Pendred syndrome .,"(('Two', 'O'), ('frequent', 'O'), ('missense', 'O'), ('mutations', 'O'), ('in', 'O'), ('Pendred', 'B'), ('syndrome', 'I'), ('.', 'O'))"
Pendred syndrome is an autosomal recessive disorder characterized by early childhood deafness and goiter .,"(('Pendred', 'B'), ('syndrome', 'I'), ('is', 'O'), ('an', 'O'), ('autosomal', 'B'), ('recessive', 'I'), ('disorder', 'I'), ('characterized', 'O'), ('by', 'O'), ('early', 'O'), ('childhood', 'O'), ('deafness', 'B'), ('and', 'O'), ('goiter', 'B'), ('.', 'O'))"
We performed mutation analysis of the PDS gene in patients from 14 Pendred families originating from seven countries and identified all mutations .,"(('We', 'O'), ('performed', 'O'), ('mutation', 'O'), ('analysis', 'O'), ('of', 'O'), ('the', 'O'), ('PDS', 'B'), ('gene', 'O'), ('in', 'O'), ('patients', 'O'), ('from', 'O'), ('14', 'O'), ('Pendred', 'B'), ('families', 'O'), ('originating', 'O'), ('from', 'O'), ('seven', 'O'), ('countries', 'O'), ('and', 'O'), ('identified', 'O'), ('all', 'O'), ('mutations', 'O'), ('.', 'O'))"
Pendred patients in three non - consanguineous families were shown to be compound heterozygotes for L236P and T416P .,"(('Pendred', 'B'), ('patients', 'O'), ('in', 'O'), ('three', 'O'), ('non', 'O'), ('-', 'O'), ('consanguineous', 'O'), ('families', 'O'), ('were', 'O'), ('shown', 'O'), ('to', 'O'), ('be', 'O'), ('compound', 'O'), ('heterozygotes', 'O'), ('for', 'O'), ('L236P', 'O'), ('and', 'O'), ('T416P', 'O'), ('.', 'O'))"
The identification of two frequent PDS mutations will facilitate the molecular diagnosis of Pendred syndrome .,"(('The', 'O'), ('identification', 'O'), ('of', 'O'), ('two', 'O'), ('frequent', 'O'), ('PDS', 'B'), ('mutations', 'O'), ('will', 'O'), ('facilitate', 'O'), ('the', 'O'), ('molecular', 'O'), ('diagnosis', 'O'), ('of', 'O'), ('Pendred', 'B'), ('syndrome', 'I'), ('.', 'O'))"
"Insertional mutation by transposable element , L1 , in the DMD gene results in X - linked dilated cardiomyopathy .","(('Insertional', 'O'), ('mutation', 'O'), ('by', 'O'), ('transposable', 'O'), ('element', 'O'), (',', 'O'), ('L1', 'O'), (',', 'O'), ('in', 'O'), ('the', 'O'), ('DMD', 'B'), ('gene', 'O'), ('results', 'O'), ('in', 'O'), ('X', 'B'), ('-', 'I'), ('linked', 'I'), ('dilated', 'I'), ('cardiomyopathy', 'I'), ('.', 'O'))"
X - linked dilated cardiomyopathy ( XLDCM ) is a clinical phenotype of dystrophinopathy which is characterized by preferential myocardial involvement without any overt clinical signs of skeletal myopathy .,"(('X', 'B'), ('-', 'I'), ('linked', 'I'), ('dilated', 'I'), ('cardiomyopathy', 'I'), ('(', 'O'), ('XLDCM', 'B'), (')', 'O'), ('is', 'O'), ('a', 'O'), ('clinical', 'O'), ('phenotype', 'O'), ('of', 'O'), ('dystrophinopathy', 'B'), ('which', 'O'), ('is', 'O'), ('characterized', 'O'), ('by', 'O'), ('preferential', 'O'), ('myocardial', 'B'), ('involvement', 'I'), ('without', 'O'), ('any', 'O'), ('overt', 'O'), ('clinical', 'O'), ('signs', 'O'), ('of', 'O'), ('skeletal', 'B'), ('myopathy', 'I'), ('.', 'O'))"
"To date , several mutations in the Duchenne muscular dystrophy gene , DMD , have been identified in patients with XLDCM , but a pathogenic correlation of these cardiospecific mutations in DMD with the XLDCM phenotype has remained to be elucidated .","(('To', 'O'), ('date', 'O'), (',', 'O'), ('several', 'O'), ('mutations', 'O'), ('in', 'O'), ('the', 'O'), ('Duchenne', 'B'), ('muscular', 'I'), ('dystrophy', 'I'), ('gene', 'O'), (',', 'O'), ('DMD', 'O'), (',', 'O'), ('have', 'O'), ('been', 'O'), ('identified', 'O'), ('in', 'O'), ('patients', 'O'), ('with', 'O'), ('XLDCM', 'B'), (',', 'O'), ('but', 'O'), ('a', 'O'), ('pathogenic', 'O'), ('correlation', 'O'), ('of', 'O'), ('these', 'O'), ('cardiospecific', 'O'), ('mutations', 'O'), ('in', 'O'), ('DMD', 'O'), ('with', 'O'), ('the', 'O'), ('XLDCM', 'B'), ('phenotype', 'O'), ('has', 'O'), ('remained', 'O'), ('to', 'O'), ('be', 'O'), ('elucidated', 'O'), ('.', 'O'))"
"Severe early - onset obesity , adrenal insufficiency and red hair pigmentation caused by POMC mutations in humans .","(('Severe', 'O'), ('early', 'O'), ('-', 'O'), ('onset', 'O'), ('obesity', 'B'), (',', 'O'), ('adrenal', 'B'), ('insufficiency', 'I'), ('and', 'O'), ('red', 'O'), ('hair', 'O'), ('pigmentation', 'O'), ('caused', 'O'), ('by', 'O'), ('POMC', 'O'), ('mutations', 'O'), ('in', 'O'), ('humans', 'O'), ('.', 'O'))"
"While a few cases of isolated ACTH deficiency have been reported ( OMIM 201400 ) , an inherited POMC defect has not been described so far .","(('While', 'O'), ('a', 'O'), ('few', 'O'), ('cases', 'O'), ('of', 'O'), ('isolated', 'O'), ('ACTH', 'B'), ('deficiency', 'I'), ('have', 'O'), ('been', 'O'), ('reported', 'O'), ('(', 'O'), ('OMIM', 'O'), ('201400', 'O'), (')', 'O'), (',', 'O'), ('an', 'O'), ('inherited', 'O'), ('POMC', 'O'), ('defect', 'O'), ('has', 'O'), ('not', 'O'), ('been', 'O'), ('described', 'O'), ('so', 'O'), ('far', 'O'), ('.', 'O'))"
"Recent studies in animal models elucidated a central role of alpha - MSH in the regulation of food intake by activation of the brain melanocortin - 4 - receptor ( MC4 - R ; refs 3 - 5 ) and the linkage of human obesity to chromosome 2 in close proximity to the POMC locus , led to the proposal of an association of POMC with human obesity .","(('Recent', 'O'), ('studies', 'O'), ('in', 'O'), ('animal', 'O'), ('models', 'O'), ('elucidated', 'O'), ('a', 'O'), ('central', 'O'), ('role', 'O'), ('of', 'O'), ('alpha', 'O'), ('-', 'O'), ('MSH', 'O'), ('in', 'O'), ('the', 'O'), ('regulation', 'O'), ('of', 'O'), ('food', 'O'), ('intake', 'O'), ('by', 'O'), ('activation', 'O'), ('of', 'O'), ('the', 'O'), ('brain', 'O'), ('melanocortin', 'O'), ('-', 'O'), ('4', 'O'), ('-', 'O'), ('receptor', 'O'), ('(', 'O'), ('MC4', 'O'), ('-', 'O'), ('R', 'O'), (';', 'O'), ('refs', 'O'), ('3', 'O'), ('-', 'O'), ('5', 'O'), (')', 'O'), ('and', 'O'), ('the', 'O'), ('linkage', 'O'), ('of', 'O'), ('human', 'O'), ('obesity', 'B'), ('to', 'O'), ('chromosome', 'O'), ('2', 'O'), ('in', 'O'), ('close', 'O'), ('proximity', 'O'), ('to', 'O'), ('the', 'O'), ('POMC', 'O'), ('locus', 'O'), (',', 'O'), ('led', 'O'), ('to', 'O'), ('the', 'O'), ('proposal', 'O'), ('of', 'O'), ('an', 'O'), ('association', 'O'), ('of', 'O'), ('POMC', 'O'), ('with', 'O'), ('human', 'O'), ('obesity', 'B'), ('.', 'O'))"
"The dual role of alpha - MSH in regulating food intake and influencing hair pigmentation predicts that the phenotype associated with a defect in POMC function would include obesity , alteration in pigmentation and ACTH deficiency .","(('The', 'O'), ('dual', 'O'), ('role', 'O'), ('of', 'O'), ('alpha', 'O'), ('-', 'O'), ('MSH', 'O'), ('in', 'O'), ('regulating', 'O'), ('food', 'O'), ('intake', 'O'), ('and', 'O'), ('influencing', 'O'), ('hair', 'O'), ('pigmentation', 'O'), ('predicts', 'O'), ('that', 'O'), ('the', 'O'), ('phenotype', 'O'), ('associated', 'O'), ('with', 'O'), ('a', 'O'), ('defect', 'O'), ('in', 'O'), ('POMC', 'O'), ('function', 'O'), ('would', 'O'), ('include', 'O'), ('obesity', 'B'), (',', 'O'), ('alteration', 'O'), ('in', 'O'), ('pigmentation', 'O'), ('and', 'O'), ('ACTH', 'B'), ('deficiency', 'I'), ('.', 'O'))"
"These findings represent the first examples of a genetic defect within the POMC gene and define a new monogenic endocrine disorder resulting in early - onset obesity , adrenal insufficiency and red hair pigmentation . .","(('These', 'O'), ('findings', 'O'), ('represent', 'O'), ('the', 'O'), ('first', 'O'), ('examples', 'O'), ('of', 'O'), ('a', 'O'), ('genetic', 'B'), ('defect', 'I'), ('within', 'O'), ('the', 'O'), ('POMC', 'O'), ('gene', 'O'), ('and', 'O'), ('define', 'O'), ('a', 'O'), ('new', 'O'), ('monogenic', 'B'), ('endocrine', 'I'), ('disorder', 'I'), ('resulting', 'O'), ('in', 'O'), ('early', 'O'), ('-', 'O'), ('onset', 'O'), ('obesity', 'B'), (',', 'O'), ('adrenal', 'B'), ('insufficiency', 'I'), ('and', 'O'), ('red', 'O'), ('hair', 'O'), ('pigmentation', 'O'), ('.', 'O'), ('.', 'O'))"
A European multicenter study of phenylalanine hydroxylase deficiency : classification of 105 mutations and a general system for genotype - based prediction of metabolic phenotype .,"(('A', 'O'), ('European', 'O'), ('multicenter', 'O'), ('study', 'O'), ('of', 'O'), ('phenylalanine', 'B'), ('hydroxylase', 'I'), ('deficiency', 'I'), (':', 'O'), ('classification', 'O'), ('of', 'O'), ('105', 'O'), ('mutations', 'O'), ('and', 'O'), ('a', 'O'), ('general', 'O'), ('system', 'O'), ('for', 'O'), ('genotype', 'O'), ('-', 'O'), ('based', 'O'), ('prediction', 'O'), ('of', 'O'), ('metabolic', 'O'), ('phenotype', 'O'), ('.', 'O'))"
Phenylketonuria ( PKU ) and mild hyperphenylalaninemia ( MHP ) are allelic disorders caused by mutations in the gene encoding phenylalanine hydroxylase ( PAH ) .,"(('Phenylketonuria', 'B'), ('(', 'O'), ('PKU', 'B'), (')', 'O'), ('and', 'O'), ('mild', 'B'), ('hyperphenylalaninemia', 'I'), ('(', 'O'), ('MHP', 'B'), (')', 'O'), ('are', 'O'), ('allelic', 'B'), ('disorders', 'I'), ('caused', 'O'), ('by', 'O'), ('mutations', 'O'), ('in', 'O'), ('the', 'O'), ('gene', 'O'), ('encoding', 'O'), ('phenylalanine', 'O'), ('hydroxylase', 'O'), ('(', 'O'), ('PAH', 'O'), (')', 'O'), ('.', 'O'))"
Previous studies have suggested that the highly variable metabolic phenotypes of PAH deficiency correlate with PAH genotypes .,"(('Previous', 'O'), ('studies', 'O'), ('have', 'O'), ('suggested', 'O'), ('that', 'O'), ('the', 'O'), ('highly', 'O'), ('variable', 'O'), ('metabolic', 'O'), ('phenotypes', 'O'), ('of', 'O'), ('PAH', 'B'), ('deficiency', 'I'), ('correlate', 'O'), ('with', 'O'), ('PAH', 'O'), ('genotypes', 'O'), ('.', 'O'))"
Our data indicate that the PAH - mutation genotype is the main determinant of metabolic phenotype in most patients with PAH deficiency .,"(('Our', 'O'), ('data', 'O'), ('indicate', 'O'), ('that', 'O'), ('the', 'O'), ('PAH', 'O'), ('-', 'O'), ('mutation', 'O'), ('genotype', 'O'), ('is', 'O'), ('the', 'O'), ('main', 'O'), ('determinant', 'O'), ('of', 'O'), ('metabolic', 'O'), ('phenotype', 'O'), ('in', 'O'), ('most', 'O'), ('patients', 'O'), ('with', 'O'), ('PAH', 'B'), ('deficiency', 'I'), ('.', 'O'))"
"In the present study , the classification of 105 PAH mutations may allow the prediction of the biochemical phenotype in > 10 , 000 genotypes , which may be useful for the management of hyperphenylalaninemia in newborns .","(('In', 'O'), ('the', 'O'), ('present', 'O'), ('study', 'O'), (',', 'O'), ('the', 'O'), ('classification', 'O'), ('of', 'O'), ('105', 'O'), ('PAH', 'O'), ('mutations', 'O'), ('may', 'O'), ('allow', 'O'), ('the', 'O'), ('prediction', 'O'), ('of', 'O'), ('the', 'O'), ('biochemical', 'O'), ('phenotype', 'O'), ('in', 'O'), ('>', 'O'), ('10', 'O'), (',', 'O'), ('000', 'O'), ('genotypes', 'O'), (',', 'O'), ('which', 'O'), ('may', 'O'), ('be', 'O'), ('useful', 'O'), ('for', 'O'), ('the', 'O'), ('management', 'O'), ('of', 'O'), ('hyperphenylalaninemia', 'B'), ('in', 'O'), ('newborns', 'O'), ('.', 'O'))"
Somatic instability of the CTG repeat in mice transgenic for the myotonic dystrophy region is age dependent but not correlated to the relative intertissue transcription levels and proliferative capacities .,"(('Somatic', 'O'), ('instability', 'O'), ('of', 'O'), ('the', 'O'), ('CTG', 'O'), ('repeat', 'O'), ('in', 'O'), ('mice', 'O'), ('transgenic', 'O'), ('for', 'O'), ('the', 'O'), ('myotonic', 'B'), ('dystrophy', 'I'), ('region', 'O'), ('is', 'O'), ('age', 'O'), ('dependent', 'O'), ('but', 'O'), ('not', 'O'), ('correlated', 'O'), ('to', 'O'), ('the', 'O'), ('relative', 'O'), ('intertissue', 'O'), ('transcription', 'O'), ('levels', 'O'), ('and', 'O'), ('proliferative', 'O'), ('capacities', 'O'), ('.', 'O'))"
A ( CTG ) nexpansion in the 3 - untranslated region ( UTR ) of the DM protein kinase gene ( DMPK ) is responsible for causing myotonic dystrophy ( DM ) .,"(('A', 'O'), ('(', 'O'), ('CTG', 'O'), (')', 'O'), ('nexpansion', 'O'), ('in', 'O'), ('the', 'O'), ('3', 'O'), ('-', 'O'), ('untranslated', 'O'), ('region', 'O'), ('(', 'O'), ('UTR', 'O'), (')', 'O'), ('of', 'O'), ('the', 'O'), ('DM', 'O'), ('protein', 'O'), ('kinase', 'O'), ('gene', 'O'), ('(', 'O'), ('DMPK', 'O'), (')', 'O'), ('is', 'O'), ('responsible', 'O'), ('for', 'O'), ('causing', 'O'), ('myotonic', 'B'), ('dystrophy', 'I'), ('(', 'O'), ('DM', 'B'), (')', 'O'), ('.', 'O'))"
The trinucleotide repeat instability mechanisms involved in DM and other human genetic diseases are unknown .,"(('The', 'O'), ('trinucleotide', 'O'), ('repeat', 'O'), ('instability', 'O'), ('mechanisms', 'O'), ('involved', 'O'), ('in', 'O'), ('DM', 'B'), ('and', 'O'), ('other', 'O'), ('human', 'O'), ('genetic', 'B'), ('diseases', 'I'), ('are', 'O'), ('unknown', 'O'), ('.', 'O'))"
"We studied somatic instability by measuring the CTG repeat length at several ages in various tissues of transgenic mice carrying a ( CTG ) 55expansion surrounded by 45 kb of the human DM region , using small - pool PCR .","(('We', 'O'), ('studied', 'O'), ('somatic', 'O'), ('instability', 'O'), ('by', 'O'), ('measuring', 'O'), ('the', 'O'), ('CTG', 'O'), ('repeat', 'O'), ('length', 'O'), ('at', 'O'), ('several', 'O'), ('ages', 'O'), ('in', 'O'), ('various', 'O'), ('tissues', 'O'), ('of', 'O'), ('transgenic', 'O'), ('mice', 'O'), ('carrying', 'O'), ('a', 'O'), ('(', 'O'), ('CTG', 'O'), (')', 'O'), ('55expansion', 'O'), ('surrounded', 'O'), ('by', 'O'), ('45', 'O'), ('kb', 'O'), ('of', 'O'), ('the', 'O'), ('human', 'O'), ('DM', 'B'), ('region', 'O'), (',', 'O'), ('using', 'O'), ('small', 'O'), ('-', 'O'), ('pool', 'O'), ('PCR', 'O'), ('.', 'O'))"
"As observed in some of the tissues of DM patients , there is a tendency for repeat length and somatic mosaicism to increase with the age of the mouse .","(('As', 'O'), ('observed', 'O'), ('in', 'O'), ('some', 'O'), ('of', 'O'), ('the', 'O'), ('tissues', 'O'), ('of', 'O'), ('DM', 'B'), ('patients', 'O'), (',', 'O'), ('there', 'O'), ('is', 'O'), ('a', 'O'), ('tendency', 'O'), ('for', 'O'), ('repeat', 'O'), ('length', 'O'), ('and', 'O'), ('somatic', 'O'), ('mosaicism', 'O'), ('to', 'O'), ('increase', 'O'), ('with', 'O'), ('the', 'O'), ('age', 'O'), ('of', 'O'), ('the', 'O'), ('mouse', 'O'), ('.', 'O'))"
A novel missense mutation in patients from a retinoblastoma pedigree showing only mild expression of the tumor phenotype .,"(('A', 'O'), ('novel', 'O'), ('missense', 'O'), ('mutation', 'O'), ('in', 'O'), ('patients', 'O'), ('from', 'O'), ('a', 'O'), ('retinoblastoma', 'B'), ('pedigree', 'O'), ('showing', 'O'), ('only', 'O'), ('mild', 'O'), ('expression', 'O'), ('of', 'O'), ('the', 'O'), ('tumor', 'B'), ('phenotype', 'O'), ('.', 'O'))"
We have used single strand conformation polymorphism analysis to study the 27 exons of the RB1 gene in individuals from a family showing mild expression of the retinoblastoma phenotype .,"(('We', 'O'), ('have', 'O'), ('used', 'O'), ('single', 'O'), ('strand', 'O'), ('conformation', 'O'), ('polymorphism', 'O'), ('analysis', 'O'), ('to', 'O'), ('study', 'O'), ('the', 'O'), ('27', 'O'), ('exons', 'O'), ('of', 'O'), ('the', 'O'), ('RB1', 'O'), ('gene', 'O'), ('in', 'O'), ('individuals', 'O'), ('from', 'O'), ('a', 'O'), ('family', 'O'), ('showing', 'O'), ('mild', 'O'), ('expression', 'O'), ('of', 'O'), ('the', 'O'), ('retinoblastoma', 'B'), ('phenotype', 'O'), ('.', 'O'))"
"In this family affected individuals developed unilateral tumors and , as a result of linkage analysis , unaffected mutation carriers were also identified within the pedigree .","(('In', 'O'), ('this', 'O'), ('family', 'O'), ('affected', 'O'), ('individuals', 'O'), ('developed', 'O'), ('unilateral', 'B'), ('tumors', 'I'), ('and', 'O'), (',', 'O'), ('as', 'O'), ('a', 'O'), ('result', 'O'), ('of', 'O'), ('linkage', 'O'), ('analysis', 'O'), (',', 'O'), ('unaffected', 'O'), ('mutation', 'O'), ('carriers', 'O'), ('were', 'O'), ('also', 'O'), ('identified', 'O'), ('within', 'O'), ('the', 'O'), ('pedigree', 'O'), ('.', 'O'))"
"Analysis of all family members demonstrated that the missense mutation co - segregated with patients with tumors or who , as a result of linkage analysis had been predicted to carry the predisposing mutation .","(('Analysis', 'O'), ('of', 'O'), ('all', 'O'), ('family', 'O'), ('members', 'O'), ('demonstrated', 'O'), ('that', 'O'), ('the', 'O'), ('missense', 'O'), ('mutation', 'O'), ('co', 'O'), ('-', 'O'), ('segregated', 'O'), ('with', 'O'), ('patients', 'O'), ('with', 'O'), ('tumors', 'B'), ('or', 'O'), ('who', 'O'), (',', 'O'), ('as', 'O'), ('a', 'O'), ('result', 'O'), ('of', 'O'), ('linkage', 'O'), ('analysis', 'O'), ('had', 'O'), ('been', 'O'), ('predicted', 'O'), ('to', 'O'), ('carry', 'O'), ('the', 'O'), ('predisposing', 'O'), ('mutation', 'O'), ('.', 'O'))"
Maternal disomy and Prader - Willi syndrome consistent with gamete complementation in a case of familial translocation ( 3 ; 15 ) ( p25 ; q11 . 2 ) .,"(('Maternal', 'B'), ('disomy', 'I'), ('and', 'O'), ('Prader', 'B'), ('-', 'I'), ('Willi', 'I'), ('syndrome', 'I'), ('consistent', 'O'), ('with', 'O'), ('gamete', 'O'), ('complementation', 'O'), ('in', 'O'), ('a', 'O'), ('case', 'O'), ('of', 'O'), ('familial', 'O'), ('translocation', 'O'), ('(', 'O'), ('3', 'O'), (';', 'O'), ('15', 'O'), (')', 'O'), ('(', 'O'), ('p25', 'O'), (';', 'O'), ('q11', 'O'), ('.', 'O'), ('2', 'O'), (')', 'O'), ('.', 'O'))"
Maternal uniparental disomy ( UPD ) for chromosome 15 is responsible for an estimated 30 % of cases of Prader - Willi syndrome ( PWS ) .,"(('Maternal', 'B'), ('uniparental', 'I'), ('disomy', 'I'), ('(', 'I'), ('UPD', 'I'), (')', 'I'), ('for', 'I'), ('chromosome', 'I'), ('15', 'I'), ('is', 'O'), ('responsible', 'O'), ('for', 'O'), ('an', 'O'), ('estimated', 'O'), ('30', 'O'), ('%', 'O'), ('of', 'O'), ('cases', 'O'), ('of', 'O'), ('Prader', 'B'), ('-', 'I'), ('Willi', 'I'), ('syndrome', 'I'), ('(', 'O'), ('PWS', 'B'), (')', 'O'), ('.', 'O'))"
We report on an unusual case of maternal disomy 15 in PWS that is most consistent with adjacent - 1 segregation of a paternal t ( 3 ; 15 ) ( p25 ; q11 . 2 ) with simultaneous maternal meiotic nondisjunction for chromosome 15 .,"(('We', 'O'), ('report', 'O'), ('on', 'O'), ('an', 'O'), ('unusual', 'O'), ('case', 'O'), ('of', 'O'), ('maternal', 'B'), ('disomy', 'I'), ('15', 'I'), ('in', 'O'), ('PWS', 'B'), ('that', 'O'), ('is', 'O'), ('most', 'O'), ('consistent', 'O'), ('with', 'O'), ('adjacent', 'O'), ('-', 'O'), ('1', 'O'), ('segregation', 'O'), ('of', 'O'), ('a', 'O'), ('paternal', 'O'), ('t', 'O'), ('(', 'O'), ('3', 'O'), (';', 'O'), ('15', 'O'), (')', 'O'), ('(', 'O'), ('p25', 'O'), (';', 'O'), ('q11', 'O'), ('.', 'O'), ('2', 'O'), (')', 'O'), ('with', 'O'), ('simultaneous', 'O'), ('maternal', 'O'), ('meiotic', 'O'), ('nondisjunction', 'O'), ('for', 'O'), ('chromosome', 'O'), ('15', 'O'), ('.', 'O'))"
"The patient ( J . B . ) , a 17 - year - old white male with PWS , was found to have 47 chromosomes with a supernumerary , paternal der ( 15 ) consisting of the short arm and the proximal long arm of chromosome 15 , and distal chromosome arm 3p .","(('The', 'O'), ('patient', 'O'), ('(', 'O'), ('J', 'O'), ('.', 'O'), ('B', 'O'), ('.', 'O'), (')', 'O'), (',', 'O'), ('a', 'O'), ('17', 'O'), ('-', 'O'), ('year', 'O'), ('-', 'O'), ('old', 'O'), ('white', 'O'), ('male', 'O'), ('with', 'O'), ('PWS', 'B'), (',', 'O'), ('was', 'O'), ('found', 'O'), ('to', 'O'), ('have', 'O'), ('47', 'O'), ('chromosomes', 'O'), ('with', 'O'), ('a', 'O'), ('supernumerary', 'O'), (',', 'O'), ('paternal', 'O'), ('der', 'O'), ('(', 'O'), ('15', 'O'), (')', 'O'), ('consisting', 'O'), ('of', 'O'), ('the', 'O'), ('short', 'O'), ('arm', 'O'), ('and', 'O'), ('the', 'O'), ('proximal', 'O'), ('long', 'O'), ('arm', 'O'), ('of', 'O'), ('chromosome', 'O'), ('15', 'O'), (',', 'O'), ('and', 'O'), ('distal', 'O'), ('chromosome', 'O'), ('arm', 'O'), ('3p', 'O'), ('.', 'O'))"
Fluorescent in situ hybridization analysis demonstrated that the PWS critical region resided on the derivative chromosome 3 and that there was no deletion of the PWS region on the normal pair of 15s present in J .,"(('Fluorescent', 'O'), ('in', 'O'), ('situ', 'O'), ('hybridization', 'O'), ('analysis', 'O'), ('demonstrated', 'O'), ('that', 'O'), ('the', 'O'), ('PWS', 'B'), ('critical', 'O'), ('region', 'O'), ('resided', 'O'), ('on', 'O'), ('the', 'O'), ('derivative', 'O'), ('chromosome', 'O'), ('3', 'O'), ('and', 'O'), ('that', 'O'), ('there', 'O'), ('was', 'O'), ('no', 'O'), ('deletion', 'O'), ('of', 'O'), ('the', 'O'), ('PWS', 'B'), ('region', 'O'), ('on', 'O'), ('the', 'O'), ('normal', 'O'), ('pair', 'O'), ('of', 'O'), ('15s', 'O'), ('present', 'O'), ('in', 'O'), ('J', 'O'), ('.', 'O'))"
Maternal disomy was confirmed by polymerase chain reaction analysis of microsatellite repeats at the gamma - aminobutyric acid receptor beta3 subunit ( GABRB3 ) locus .,"(('Maternal', 'B'), ('disomy', 'I'), ('was', 'O'), ('confirmed', 'O'), ('by', 'O'), ('polymerase', 'O'), ('chain', 'O'), ('reaction', 'O'), ('analysis', 'O'), ('of', 'O'), ('microsatellite', 'O'), ('repeats', 'O'), ('at', 'O'), ('the', 'O'), ('gamma', 'O'), ('-', 'O'), ('aminobutyric', 'O'), ('acid', 'O'), ('receptor', 'O'), ('beta3', 'O'), ('subunit', 'O'), ('(', 'O'), ('GABRB3', 'O'), (')', 'O'), ('locus', 'O'), ('.', 'O'))"
"Uniparental disomy associated with unbalanced segregation of non - Robertsonian translocations has been reported previously but has not , to our knowledge , been observed in a case of PWS .","(('Uniparental', 'B'), ('disomy', 'I'), ('associated', 'O'), ('with', 'O'), ('unbalanced', 'O'), ('segregation', 'O'), ('of', 'O'), ('non', 'O'), ('-', 'O'), ('Robertsonian', 'O'), ('translocations', 'O'), ('has', 'O'), ('been', 'O'), ('reported', 'O'), ('previously', 'O'), ('but', 'O'), ('has', 'O'), ('not', 'O'), (',', 'O'), ('to', 'O'), ('our', 'O'), ('knowledge', 'O'), (',', 'O'), ('been', 'O'), ('observed', 'O'), ('in', 'O'), ('a', 'O'), ('case', 'O'), ('of', 'O'), ('PWS', 'B'), ('.', 'O'))"
"Furthermore , our findings are best interpreted as true gamete complementation resulting in maternal UPD 15 and PWS","(('Furthermore', 'O'), (',', 'O'), ('our', 'O'), ('findings', 'O'), ('are', 'O'), ('best', 'O'), ('interpreted', 'O'), ('as', 'O'), ('true', 'O'), ('gamete', 'O'), ('complementation', 'O'), ('resulting', 'O'), ('in', 'O'), ('maternal', 'B'), ('UPD', 'I'), ('15', 'I'), ('and', 'O'), ('PWS', 'B'))"
"Schwartz - Jampel syndrome type 2 and Stuve - Wiedemann syndrome : a case for "" lumping "" .","(('Schwartz', 'B'), ('-', 'I'), ('Jampel', 'I'), ('syndrome', 'I'), ('type', 'I'), ('2', 'I'), ('and', 'O'), ('Stuve', 'B'), ('-', 'I'), ('Wiedemann', 'I'), ('syndrome', 'I'), (':', 'O'), ('a', 'O'), ('case', 'O'), ('for', 'O'), ('""', 'O'), ('lumping', 'O'), ('""', 'O'), ('.', 'O'))"
"Recent studies demonstrated the existence of a genetically distinct , usually lethal form of the Schwartz - Jampel syndrome ( SJS ) of myotonia and skeletal dysplasia , which we called SJS type 2 .","(('Recent', 'O'), ('studies', 'O'), ('demonstrated', 'O'), ('the', 'O'), ('existence', 'O'), ('of', 'O'), ('a', 'O'), ('genetically', 'O'), ('distinct', 'O'), (',', 'O'), ('usually', 'O'), ('lethal', 'O'), ('form', 'O'), ('of', 'O'), ('the', 'O'), ('Schwartz', 'B'), ('-', 'I'), ('Jampel', 'I'), ('syndrome', 'I'), ('(', 'O'), ('SJS', 'B'), (')', 'O'), ('of', 'O'), ('myotonia', 'B'), ('and', 'O'), ('skeletal', 'B'), ('dysplasia', 'I'), (',', 'O'), ('which', 'O'), ('we', 'O'), ('called', 'O'), ('SJS', 'B'), ('type', 'I'), ('2', 'I'), ('.', 'O'))"
"This disorder is reminiscent of another rare condition , the Stuve - Wiedemann syndrome ( SWS ) , which comprises campomelia at birth with skeletal dysplasia , contractures , and early death .","(('This', 'O'), ('disorder', 'O'), ('is', 'O'), ('reminiscent', 'O'), ('of', 'O'), ('another', 'O'), ('rare', 'O'), ('condition', 'O'), (',', 'O'), ('the', 'O'), ('Stuve', 'B'), ('-', 'I'), ('Wiedemann', 'I'), ('syndrome', 'I'), ('(', 'O'), ('SWS', 'B'), (')', 'O'), (',', 'O'), ('which', 'O'), ('comprises', 'O'), ('campomelia', 'B'), ('at', 'O'), ('birth', 'O'), ('with', 'O'), ('skeletal', 'B'), ('dysplasia', 'I'), (',', 'O'), ('contractures', 'B'), (',', 'O'), ('and', 'O'), ('early', 'B'), ('death', 'I'), ('.', 'O'))"
"To test for possible nosologic identity between these disorders , we reviewed the literature and obtained a follow - up of the only two surviving patients , one with SJS type 2 at age 10 years and another with SWS at age 7 years .","(('To', 'O'), ('test', 'O'), ('for', 'O'), ('possible', 'O'), ('nosologic', 'O'), ('identity', 'O'), ('between', 'O'), ('these', 'O'), ('disorders', 'O'), (',', 'O'), ('we', 'O'), ('reviewed', 'O'), ('the', 'O'), ('literature', 'O'), ('and', 'O'), ('obtained', 'O'), ('a', 'O'), ('follow', 'O'), ('-', 'O'), ('up', 'O'), ('of', 'O'), ('the', 'O'), ('only', 'O'), ('two', 'O'), ('surviving', 'O'), ('patients', 'O'), (',', 'O'), ('one', 'O'), ('with', 'O'), ('SJS', 'B'), ('type', 'I'), ('2', 'I'), ('at', 'O'), ('age', 'O'), ('10', 'O'), ('years', 'O'), ('and', 'O'), ('another', 'O'), ('with', 'O'), ('SWS', 'B'), ('at', 'O'), ('age', 'O'), ('7', 'O'), ('years', 'O'), ('.', 'O'))"
"Patients reported as having either neonatal SJS or SWS presented a combination of a severe , prenatal - onset neuromuscular disorder ( with congenital joint contractures , respiratory and feeding difficulties , tendency to hyperthermia , and frequent death in infancy ) with a distinct campomelic - metaphyseal skeletal dysplasia .","(('Patients', 'O'), ('reported', 'O'), ('as', 'O'), ('having', 'O'), ('either', 'O'), ('neonatal', 'O'), ('SJS', 'B'), ('or', 'O'), ('SWS', 'B'), ('presented', 'O'), ('a', 'O'), ('combination', 'O'), ('of', 'O'), ('a', 'O'), ('severe', 'O'), (',', 'O'), ('prenatal', 'O'), ('-', 'O'), ('onset', 'O'), ('neuromuscular', 'B'), ('disorder', 'I'), ('(', 'O'), ('with', 'O'), ('congenital', 'B'), ('joint', 'I'), ('contractures', 'I'), (',', 'O'), ('respiratory', 'O'), ('and', 'O'), ('feeding', 'O'), ('difficulties', 'O'), (',', 'O'), ('tendency', 'O'), ('to', 'O'), ('hyperthermia', 'B'), (',', 'O'), ('and', 'O'), ('frequent', 'O'), ('death', 'O'), ('in', 'O'), ('infancy', 'O'), (')', 'O'), ('with', 'O'), ('a', 'O'), ('distinct', 'O'), ('campomelic', 'B'), ('-', 'I'), ('metaphyseal', 'I'), ('skeletal', 'I'), ('dysplasia', 'I'), ('.', 'O'))"
"The follow - up observation of an identical and unique pattern of progressive bone dysplasia in the two patients ( one with SJS type 2 , one with SWS ) surviving beyond infancy adds to the evidence in favor of identity .","(('The', 'O'), ('follow', 'O'), ('-', 'O'), ('up', 'O'), ('observation', 'O'), ('of', 'O'), ('an', 'O'), ('identical', 'O'), ('and', 'O'), ('unique', 'O'), ('pattern', 'O'), ('of', 'O'), ('progressive', 'O'), ('bone', 'B'), ('dysplasia', 'I'), ('in', 'O'), ('the', 'O'), ('two', 'O'), ('patients', 'O'), ('(', 'O'), ('one', 'O'), ('with', 'O'), ('SJS', 'B'), ('type', 'I'), ('2', 'I'), (',', 'O'), ('one', 'O'), ('with', 'O'), ('SWS', 'B'), (')', 'O'), ('surviving', 'O'), ('beyond', 'O'), ('infancy', 'O'), ('adds', 'O'), ('to', 'O'), ('the', 'O'), ('evidence', 'O'), ('in', 'O'), ('favor', 'O'), ('of', 'O'), ('identity', 'O'), ('.', 'O'))"
The hypothesis that SWS and SJS type 2 are the same disorder should be testable by molecular methods . .,"(('The', 'O'), ('hypothesis', 'O'), ('that', 'O'), ('SWS', 'B'), ('and', 'O'), ('SJS', 'B'), ('type', 'I'), ('2', 'I'), ('are', 'O'), ('the', 'O'), ('same', 'O'), ('disorder', 'O'), ('should', 'O'), ('be', 'O'), ('testable', 'O'), ('by', 'O'), ('molecular', 'O'), ('methods', 'O'), ('.', 'O'), ('.', 'O'))"
A mouse model of severe von Willebrand disease : defects in hemostasis and thrombosis .,"(('A', 'O'), ('mouse', 'O'), ('model', 'O'), ('of', 'O'), ('severe', 'O'), ('von', 'B'), ('Willebrand', 'I'), ('disease', 'I'), (':', 'O'), ('defects', 'O'), ('in', 'O'), ('hemostasis', 'O'), ('and', 'O'), ('thrombosis', 'B'), ('.', 'O'))"
von Willebrand factor ( vWf ) deficiency causes severe von Willebrand disease in humans .,"(('von', 'B'), ('Willebrand', 'I'), ('factor', 'I'), ('(', 'I'), ('vWf', 'I'), (')', 'I'), ('deficiency', 'I'), ('causes', 'O'), ('severe', 'O'), ('von', 'B'), ('Willebrand', 'I'), ('disease', 'I'), ('in', 'O'), ('humans', 'O'), ('.', 'O'))"
vWf - deficient mice appeared normal at birth ; they were viable and fertile .,"(('vWf', 'B'), ('-', 'I'), ('deficient', 'I'), ('mice', 'O'), ('appeared', 'O'), ('normal', 'O'), ('at', 'O'), ('birth', 'O'), (';', 'O'), ('they', 'O'), ('were', 'O'), ('viable', 'O'), ('and', 'O'), ('fertile', 'O'), ('.', 'O'))"
"Neither vWf nor vWf propolypeptide ( von Willebrand antigen II ) were detectable in plasma , platelets , or endothelial cells of the homozygous mutant mice .","(('Neither', 'O'), ('vWf', 'O'), ('nor', 'O'), ('vWf', 'O'), ('propolypeptide', 'O'), ('(', 'O'), ('von', 'B'), ('Willebrand', 'I'), ('antigen', 'O'), ('II', 'O'), (')', 'O'), ('were', 'O'), ('detectable', 'O'), ('in', 'O'), ('plasma', 'O'), (',', 'O'), ('platelets', 'O'), (',', 'O'), ('or', 'O'), ('endothelial', 'O'), ('cells', 'O'), ('of', 'O'), ('the', 'O'), ('homozygous', 'O'), ('mutant', 'O'), ('mice', 'O'), ('.', 'O'))"
Defective thrombosis in mutant mice was also evident in an in vivo model of vascular injury .,"(('Defective', 'O'), ('thrombosis', 'B'), ('in', 'O'), ('mutant', 'O'), ('mice', 'O'), ('was', 'O'), ('also', 'O'), ('evident', 'O'), ('in', 'O'), ('an', 'O'), ('in', 'O'), ('vivo', 'O'), ('model', 'O'), ('of', 'O'), ('vascular', 'B'), ('injury', 'I'), ('.', 'O'))"
We conclude that these mice very closely mimic severe human von Willebrand disease and will be very useful for investigating the role of vWf in normal physiology and in disease models . .,"(('We', 'O'), ('conclude', 'O'), ('that', 'O'), ('these', 'O'), ('mice', 'O'), ('very', 'O'), ('closely', 'O'), ('mimic', 'O'), ('severe', 'O'), ('human', 'O'), ('von', 'B'), ('Willebrand', 'I'), ('disease', 'I'), ('and', 'O'), ('will', 'O'), ('be', 'O'), ('very', 'O'), ('useful', 'O'), ('for', 'O'), ('investigating', 'O'), ('the', 'O'), ('role', 'O'), ('of', 'O'), ('vWf', 'O'), ('in', 'O'), ('normal', 'O'), ('physiology', 'O'), ('and', 'O'), ('in', 'O'), ('disease', 'O'), ('models', 'O'), ('.', 'O'), ('.', 'O'))"
Oral contraceptives and the risk of hereditary ovarian cancer .,"(('Oral', 'O'), ('contraceptives', 'O'), ('and', 'O'), ('the', 'O'), ('risk', 'O'), ('of', 'O'), ('hereditary', 'B'), ('ovarian', 'I'), ('cancer', 'I'), ('.', 'O'))"
Hereditary Ovarian Cancer Clinical Study Group .,"(('Hereditary', 'B'), ('Ovarian', 'I'), ('Cancer', 'I'), ('Clinical', 'O'), ('Study', 'O'), ('Group', 'O'), ('.', 'O'))"
BACKGROUND Women with mutations in either the BRCA1 or the BRCA2 gene have a high lifetime risk of ovarian cancer .,"(('BACKGROUND', 'O'), ('Women', 'O'), ('with', 'O'), ('mutations', 'O'), ('in', 'O'), ('either', 'O'), ('the', 'O'), ('BRCA1', 'O'), ('or', 'O'), ('the', 'O'), ('BRCA2', 'O'), ('gene', 'O'), ('have', 'O'), ('a', 'O'), ('high', 'O'), ('lifetime', 'O'), ('risk', 'O'), ('of', 'O'), ('ovarian', 'B'), ('cancer', 'I'), ('.', 'O'))"
"Oral contraceptives protect against ovarian cancer in general , but it is not known whether they also protect against hereditary forms of ovarian cancer .","(('Oral', 'O'), ('contraceptives', 'O'), ('protect', 'O'), ('against', 'O'), ('ovarian', 'B'), ('cancer', 'I'), ('in', 'O'), ('general', 'O'), (',', 'O'), ('but', 'O'), ('it', 'O'), ('is', 'O'), ('not', 'O'), ('known', 'O'), ('whether', 'O'), ('they', 'O'), ('also', 'O'), ('protect', 'O'), ('against', 'O'), ('hereditary', 'B'), ('forms', 'I'), ('of', 'I'), ('ovarian', 'I'), ('cancer', 'I'), ('.', 'O'))"
METHODS We enrolled 207 women with hereditary ovarian cancer and 161 of their sisters as controls in a case - control study .,"(('METHODS', 'O'), ('We', 'O'), ('enrolled', 'O'), ('207', 'O'), ('women', 'O'), ('with', 'O'), ('hereditary', 'B'), ('ovarian', 'I'), ('cancer', 'I'), ('and', 'O'), ('161', 'O'), ('of', 'O'), ('their', 'O'), ('sisters', 'O'), ('as', 'O'), ('controls', 'O'), ('in', 'O'), ('a', 'O'), ('case', 'O'), ('-', 'O'), ('control', 'O'), ('study', 'O'), ('.', 'O'))"
RESULTS The adjusted odds ratio for ovarian cancer associated with any past use of oral contraceptives was 0 .,"(('RESULTS', 'O'), ('The', 'O'), ('adjusted', 'O'), ('odds', 'O'), ('ratio', 'O'), ('for', 'O'), ('ovarian', 'B'), ('cancer', 'I'), ('associated', 'O'), ('with', 'O'), ('any', 'O'), ('past', 'O'), ('use', 'O'), ('of', 'O'), ('oral', 'O'), ('contraceptives', 'O'), ('was', 'O'), ('0', 'O'), ('.', 'O'))"
"Oral - contraceptive use protected against ovarian cancer both for carriers of the BRCA1 mutation ( odds ratio , 0 . 5 ; 95 percent confidence interval , 0 . 3 to 0 . 9 ) and for carriers of the BRCA2 mutation ( odds ratio , 0 . 4 ; 95 percent confidence interval , 0 . 2 to 1 . 1 ) .","(('Oral', 'O'), ('-', 'O'), ('contraceptive', 'O'), ('use', 'O'), ('protected', 'O'), ('against', 'O'), ('ovarian', 'B'), ('cancer', 'I'), ('both', 'O'), ('for', 'O'), ('carriers', 'O'), ('of', 'O'), ('the', 'O'), ('BRCA1', 'O'), ('mutation', 'O'), ('(', 'O'), ('odds', 'O'), ('ratio', 'O'), (',', 'O'), ('0', 'O'), ('.', 'O'), ('5', 'O'), (';', 'O'), ('95', 'O'), ('percent', 'O'), ('confidence', 'O'), ('interval', 'O'), (',', 'O'), ('0', 'O'), ('.', 'O'), ('3', 'O'), ('to', 'O'), ('0', 'O'), ('.', 'O'), ('9', 'O'), (')', 'O'), ('and', 'O'), ('for', 'O'), ('carriers', 'O'), ('of', 'O'), ('the', 'O'), ('BRCA2', 'O'), ('mutation', 'O'), ('(', 'O'), ('odds', 'O'), ('ratio', 'O'), (',', 'O'), ('0', 'O'), ('.', 'O'), ('4', 'O'), (';', 'O'), ('95', 'O'), ('percent', 'O'), ('confidence', 'O'), ('interval', 'O'), (',', 'O'), ('0', 'O'), ('.', 'O'), ('2', 'O'), ('to', 'O'), ('1', 'O'), ('.', 'O'), ('1', 'O'), (')', 'O'), ('.', 'O'))"
CONCLUSIONS Oral - contraceptive use may reduce the risk of ovarian cancer in women with pathogenic mutations in the BRCA1 or BRCA2 gene,"(('CONCLUSIONS', 'O'), ('Oral', 'O'), ('-', 'O'), ('contraceptive', 'O'), ('use', 'O'), ('may', 'O'), ('reduce', 'O'), ('the', 'O'), ('risk', 'O'), ('of', 'O'), ('ovarian', 'B'), ('cancer', 'I'), ('in', 'O'), ('women', 'O'), ('with', 'O'), ('pathogenic', 'O'), ('mutations', 'O'), ('in', 'O'), ('the', 'O'), ('BRCA1', 'O'), ('or', 'O'), ('BRCA2', 'O'), ('gene', 'O'))"
"A Japanese family with adrenoleukodystrophy with a codon 291 deletion : a clinical , biochemical , pathological , and genetic report .","(('A', 'O'), ('Japanese', 'O'), ('family', 'O'), ('with', 'O'), ('adrenoleukodystrophy', 'B'), ('with', 'O'), ('a', 'O'), ('codon', 'O'), ('291', 'O'), ('deletion', 'O'), (':', 'O'), ('a', 'O'), ('clinical', 'O'), (',', 'O'), ('biochemical', 'O'), (',', 'O'), ('pathological', 'O'), (',', 'O'), ('and', 'O'), ('genetic', 'O'), ('report', 'O'), ('.', 'O'))"
We report a Japanese family with adrenoleukodystrophy ( ALD ) with a three base pair deletion ( delGAG 291 ) in the ALD gene .,"(('We', 'O'), ('report', 'O'), ('a', 'O'), ('Japanese', 'O'), ('family', 'O'), ('with', 'O'), ('adrenoleukodystrophy', 'B'), ('(', 'O'), ('ALD', 'B'), (')', 'O'), ('with', 'O'), ('a', 'O'), ('three', 'O'), ('base', 'O'), ('pair', 'O'), ('deletion', 'O'), ('(', 'O'), ('delGAG', 'O'), ('291', 'O'), (')', 'O'), ('in', 'O'), ('the', 'O'), ('ALD', 'B'), ('gene', 'O'), ('.', 'O'))"
"While the proband ( patient 1 ) was classified as having a rare intermediate type of adult cerebral and cerebello - brain stem forms , his younger brother ( patient 2 ) and nephew ( patient 3 ) had a childhood ALD type .","(('While', 'O'), ('the', 'O'), ('proband', 'O'), ('(', 'O'), ('patient', 'O'), ('1', 'O'), (')', 'O'), ('was', 'O'), ('classified', 'O'), ('as', 'O'), ('having', 'O'), ('a', 'O'), ('rare', 'O'), ('intermediate', 'O'), ('type', 'O'), ('of', 'O'), ('adult', 'O'), ('cerebral', 'O'), ('and', 'O'), ('cerebello', 'O'), ('-', 'O'), ('brain', 'O'), ('stem', 'O'), ('forms', 'O'), (',', 'O'), ('his', 'O'), ('younger', 'O'), ('brother', 'O'), ('(', 'O'), ('patient', 'O'), ('2', 'O'), (')', 'O'), ('and', 'O'), ('nephew', 'O'), ('(', 'O'), ('patient', 'O'), ('3', 'O'), (')', 'O'), ('had', 'O'), ('a', 'O'), ('childhood', 'O'), ('ALD', 'B'), ('type', 'O'), ('.', 'O'))"
The tau level in the cerebrospinal fluid ( CSF ) in patient 1 was as high as that of patients with Alzheimers disease ( AD ) .,"(('The', 'O'), ('tau', 'O'), ('level', 'O'), ('in', 'O'), ('the', 'O'), ('cerebrospinal', 'O'), ('fluid', 'O'), ('(', 'O'), ('CSF', 'O'), (')', 'O'), ('in', 'O'), ('patient', 'O'), ('1', 'O'), ('was', 'O'), ('as', 'O'), ('high', 'O'), ('as', 'O'), ('that', 'O'), ('of', 'O'), ('patients', 'O'), ('with', 'O'), ('Alzheimers', 'B'), ('disease', 'I'), ('(', 'O'), ('AD', 'B'), (')', 'O'), ('.', 'O'))"
"His brain magnetic resonance image ( MRI ) showed abnormalities in the bilateral cerebellar hemispheres and brain stem , but not in the cerebral white matter , where marked reductions of the cerebral blood flow and oxygen metabolism were clearly demonstrated by positron emission tomography ( PET ) .","(('His', 'O'), ('brain', 'O'), ('magnetic', 'O'), ('resonance', 'O'), ('image', 'O'), ('(', 'O'), ('MRI', 'O'), (')', 'O'), ('showed', 'O'), ('abnormalities', 'B'), ('in', 'I'), ('the', 'I'), ('bilateral', 'I'), ('cerebellar', 'I'), ('hemispheres', 'I'), ('and', 'O'), ('brain', 'O'), ('stem', 'O'), (',', 'O'), ('but', 'O'), ('not', 'O'), ('in', 'O'), ('the', 'O'), ('cerebral', 'O'), ('white', 'O'), ('matter', 'O'), (',', 'O'), ('where', 'O'), ('marked', 'O'), ('reductions', 'O'), ('of', 'O'), ('the', 'O'), ('cerebral', 'O'), ('blood', 'O'), ('flow', 'O'), ('and', 'O'), ('oxygen', 'O'), ('metabolism', 'O'), ('were', 'O'), ('clearly', 'O'), ('demonstrated', 'O'), ('by', 'O'), ('positron', 'O'), ('emission', 'O'), ('tomography', 'O'), ('(', 'O'), ('PET', 'O'), (')', 'O'), ('.', 'O'))"
"In patients 2 and 3 , the autopsy findings showed massive demyelination of the cerebral white matter with sparing of the U - fibers , compatible with the findings of childhood ALD .","(('In', 'O'), ('patients', 'O'), ('2', 'O'), ('and', 'O'), ('3', 'O'), (',', 'O'), ('the', 'O'), ('autopsy', 'O'), ('findings', 'O'), ('showed', 'O'), ('massive', 'O'), ('demyelination', 'B'), ('of', 'I'), ('the', 'I'), ('cerebral', 'I'), ('white', 'I'), ('matter', 'I'), ('with', 'O'), ('sparing', 'O'), ('of', 'O'), ('the', 'O'), ('U', 'O'), ('-', 'O'), ('fibers', 'O'), (',', 'O'), ('compatible', 'O'), ('with', 'O'), ('the', 'O'), ('findings', 'O'), ('of', 'O'), ('childhood', 'O'), ('ALD', 'B'), ('.', 'O'))"
The findings in this family suggest that delGAG291 is part of the cause of Japanese ALD with phenotypic variations .,"(('The', 'O'), ('findings', 'O'), ('in', 'O'), ('this', 'O'), ('family', 'O'), ('suggest', 'O'), ('that', 'O'), ('delGAG291', 'O'), ('is', 'O'), ('part', 'O'), ('of', 'O'), ('the', 'O'), ('cause', 'O'), ('of', 'O'), ('Japanese', 'O'), ('ALD', 'B'), ('with', 'O'), ('phenotypic', 'O'), ('variations', 'O'), ('.', 'O'))"
"Moreover , although the scale of the study is limited , there is a possibility that PET can detect an insidious lesion which is undetectable by computed tomogram ( CT ) or MRI analysis , and that the higher level of tau reflects the process of neuronal degeneration in ALD .","(('Moreover', 'O'), (',', 'O'), ('although', 'O'), ('the', 'O'), ('scale', 'O'), ('of', 'O'), ('the', 'O'), ('study', 'O'), ('is', 'O'), ('limited', 'O'), (',', 'O'), ('there', 'O'), ('is', 'O'), ('a', 'O'), ('possibility', 'O'), ('that', 'O'), ('PET', 'O'), ('can', 'O'), ('detect', 'O'), ('an', 'O'), ('insidious', 'B'), ('lesion', 'I'), ('which', 'O'), ('is', 'O'), ('undetectable', 'O'), ('by', 'O'), ('computed', 'O'), ('tomogram', 'O'), ('(', 'O'), ('CT', 'O'), (')', 'O'), ('or', 'O'), ('MRI', 'O'), ('analysis', 'O'), (',', 'O'), ('and', 'O'), ('that', 'O'), ('the', 'O'), ('higher', 'O'), ('level', 'O'), ('of', 'O'), ('tau', 'O'), ('reflects', 'O'), ('the', 'O'), ('process', 'O'), ('of', 'O'), ('neuronal', 'B'), ('degeneration', 'I'), ('in', 'O'), ('ALD', 'B'), ('.', 'O'))"
Nonsense mutation in exon 4 of human complement C9 gene is the major cause of Japanese complement C9 deficiency .,"(('Nonsense', 'O'), ('mutation', 'O'), ('in', 'O'), ('exon', 'O'), ('4', 'O'), ('of', 'O'), ('human', 'O'), ('complement', 'O'), ('C9', 'O'), ('gene', 'O'), ('is', 'O'), ('the', 'O'), ('major', 'O'), ('cause', 'O'), ('of', 'O'), ('Japanese', 'O'), ('complement', 'B'), ('C9', 'I'), ('deficiency', 'I'), ('.', 'O'))"
Deficiency of the ninth component of human complement ( C9 ) is the most common complement deficiency in Japan but is rare in other countries .,"(('Deficiency', 'B'), ('of', 'I'), ('the', 'I'), ('ninth', 'I'), ('component', 'I'), ('of', 'I'), ('human', 'I'), ('complement', 'I'), ('(', 'O'), ('C9', 'O'), (')', 'O'), ('is', 'O'), ('the', 'O'), ('most', 'O'), ('common', 'O'), ('complement', 'B'), ('deficiency', 'I'), ('in', 'O'), ('Japan', 'O'), ('but', 'O'), ('is', 'O'), ('rare', 'O'), ('in', 'O'), ('other', 'O'), ('countries', 'O'), ('.', 'O'))"
We studied the molecular basis of C9 deficiency in four Japanese C9 - deficient patients who had suffered from meningococcal meningitis .,"(('We', 'O'), ('studied', 'O'), ('the', 'O'), ('molecular', 'O'), ('basis', 'O'), ('of', 'O'), ('C9', 'B'), ('deficiency', 'I'), ('in', 'O'), ('four', 'O'), ('Japanese', 'O'), ('C9', 'B'), ('-', 'I'), ('deficient', 'I'), ('patients', 'O'), ('who', 'O'), ('had', 'O'), ('suffered', 'O'), ('from', 'O'), ('meningococcal', 'B'), ('meningitis', 'I'), ('.', 'O'))"
Direct sequencing of amplified C9 cDNA and DNA revealed a nonsense substitution ( CGA - - > TGA ) at codon 95 in exon 4 in the four C9 - deficient individuals .,"(('Direct', 'O'), ('sequencing', 'O'), ('of', 'O'), ('amplified', 'O'), ('C9', 'O'), ('cDNA', 'O'), ('and', 'O'), ('DNA', 'O'), ('revealed', 'O'), ('a', 'O'), ('nonsense', 'O'), ('substitution', 'O'), ('(', 'O'), ('CGA', 'O'), ('-', 'O'), ('-', 'O'), ('>', 'O'), ('TGA', 'O'), (')', 'O'), ('at', 'O'), ('codon', 'O'), ('95', 'O'), ('in', 'O'), ('exon', 'O'), ('4', 'O'), ('in', 'O'), ('the', 'O'), ('four', 'O'), ('C9', 'B'), ('-', 'I'), ('deficient', 'I'), ('individuals', 'O'), ('.', 'O'))"
The common mutation at codon 95 in exon 4 might be responsible for most Japanese C9 deficiency . .,"(('The', 'O'), ('common', 'O'), ('mutation', 'O'), ('at', 'O'), ('codon', 'O'), ('95', 'O'), ('in', 'O'), ('exon', 'O'), ('4', 'O'), ('might', 'O'), ('be', 'O'), ('responsible', 'O'), ('for', 'O'), ('most', 'O'), ('Japanese', 'O'), ('C9', 'B'), ('deficiency', 'I'), ('.', 'O'), ('.', 'O'))"
The breast and ovarian cancer susceptibility gene BRCA1 encodes a zinc finger protein of unknown function .,"(('The', 'O'), ('breast', 'B'), ('and', 'I'), ('ovarian', 'I'), ('cancer', 'I'), ('susceptibility', 'O'), ('gene', 'O'), ('BRCA1', 'O'), ('encodes', 'O'), ('a', 'O'), ('zinc', 'O'), ('finger', 'O'), ('protein', 'O'), ('of', 'O'), ('unknown', 'O'), ('function', 'O'), ('.', 'O'))"
"Here , it is shown that mouse embryonic stem cells deficient in BRCA1 are defective in the ability to carry out transcription - coupled repair of oxidative DNA damage , and are hypersensitive to ionizing radiation and hydrogen peroxide .","(('Here', 'O'), (',', 'O'), ('it', 'O'), ('is', 'O'), ('shown', 'O'), ('that', 'O'), ('mouse', 'O'), ('embryonic', 'O'), ('stem', 'O'), ('cells', 'O'), ('deficient', 'B'), ('in', 'I'), ('BRCA1', 'I'), ('are', 'O'), ('defective', 'O'), ('in', 'O'), ('the', 'O'), ('ability', 'O'), ('to', 'O'), ('carry', 'O'), ('out', 'O'), ('transcription', 'O'), ('-', 'O'), ('coupled', 'O'), ('repair', 'O'), ('of', 'O'), ('oxidative', 'O'), ('DNA', 'O'), ('damage', 'O'), (',', 'O'), ('and', 'O'), ('are', 'O'), ('hypersensitive', 'O'), ('to', 'O'), ('ionizing', 'O'), ('radiation', 'O'), ('and', 'O'), ('hydrogen', 'O'), ('peroxide', 'O'), ('.', 'O'))"
"Heterozygous mutations in the human PAX6 gene result in various phenotypes , including aniridia , Peters anomaly , autosomal dominant keratitis , and familial foveal dysplasia .","(('Heterozygous', 'O'), ('mutations', 'O'), ('in', 'O'), ('the', 'O'), ('human', 'O'), ('PAX6', 'O'), ('gene', 'O'), ('result', 'O'), ('in', 'O'), ('various', 'O'), ('phenotypes', 'O'), (',', 'O'), ('including', 'O'), ('aniridia', 'B'), (',', 'O'), ('Peters', 'B'), ('anomaly', 'I'), (',', 'O'), ('autosomal', 'B'), ('dominant', 'I'), ('keratitis', 'I'), (',', 'O'), ('and', 'O'), ('familial', 'B'), ('foveal', 'I'), ('dysplasia', 'I'), ('.', 'O'))"
It is believed that the mutated allele of PAX6 produces an inactive protein and aniridia is caused due to genetic haploinsufficiency .,"(('It', 'O'), ('is', 'O'), ('believed', 'O'), ('that', 'O'), ('the', 'O'), ('mutated', 'O'), ('allele', 'O'), ('of', 'O'), ('PAX6', 'O'), ('produces', 'O'), ('an', 'O'), ('inactive', 'O'), ('protein', 'O'), ('and', 'O'), ('aniridia', 'B'), ('is', 'O'), ('caused', 'O'), ('due', 'O'), ('to', 'O'), ('genetic', 'O'), ('haploinsufficiency', 'O'), ('.', 'O'))"
"However , several truncation mutations have been found to occur in the C - terminal half of PAX6 in patients with Aniridia resulting in mutant proteins that retain the DNA - binding domains but have lost most of the transactivation domain .","(('However', 'O'), (',', 'O'), ('several', 'O'), ('truncation', 'O'), ('mutations', 'O'), ('have', 'O'), ('been', 'O'), ('found', 'O'), ('to', 'O'), ('occur', 'O'), ('in', 'O'), ('the', 'O'), ('C', 'O'), ('-', 'O'), ('terminal', 'O'), ('half', 'O'), ('of', 'O'), ('PAX6', 'O'), ('in', 'O'), ('patients', 'O'), ('with', 'O'), ('Aniridia', 'B'), ('resulting', 'O'), ('in', 'O'), ('mutant', 'O'), ('proteins', 'O'), ('that', 'O'), ('retain', 'O'), ('the', 'O'), ('DNA', 'O'), ('-', 'O'), ('binding', 'O'), ('domains', 'O'), ('but', 'O'), ('have', 'O'), ('lost', 'O'), ('most', 'O'), ('of', 'O'), ('the', 'O'), ('transactivation', 'O'), ('domain', 'O'), ('.', 'O'))"
These results provide a new insight into the role of mutant PAX6 in causing aniridia . .,"(('These', 'O'), ('results', 'O'), ('provide', 'O'), ('a', 'O'), ('new', 'O'), ('insight', 'O'), ('into', 'O'), ('the', 'O'), ('role', 'O'), ('of', 'O'), ('mutant', 'O'), ('PAX6', 'O'), ('in', 'O'), ('causing', 'O'), ('aniridia', 'B'), ('.', 'O'), ('.', 'O'))"
Reversal of severe hypertrophic cardiomyopathy and excellent neuropsychologic outcome in very - long - chain acyl - coenzyme A dehydrogenase deficiency .,"(('Reversal', 'O'), ('of', 'O'), ('severe', 'O'), ('hypertrophic', 'B'), ('cardiomyopathy', 'I'), ('and', 'O'), ('excellent', 'O'), ('neuropsychologic', 'O'), ('outcome', 'O'), ('in', 'O'), ('very', 'B'), ('-', 'I'), ('long', 'I'), ('-', 'I'), ('chain', 'I'), ('acyl', 'I'), ('-', 'I'), ('coenzyme', 'I'), ('A', 'I'), ('dehydrogenase', 'I'), ('deficiency', 'I'), ('.', 'O'))"
Very - long - chain acyl - coenzyme A dehydrogenase ( VLCAD ) deficiency is a disorder of fatty acid beta oxidation that reportedly has high rates of morbidity and mortality .,"(('Very', 'B'), ('-', 'I'), ('long', 'I'), ('-', 'I'), ('chain', 'I'), ('acyl', 'I'), ('-', 'I'), ('coenzyme', 'I'), ('A', 'I'), ('dehydrogenase', 'I'), ('(', 'I'), ('VLCAD', 'I'), (')', 'I'), ('deficiency', 'I'), ('is', 'O'), ('a', 'O'), ('disorder', 'O'), ('of', 'O'), ('fatty', 'O'), ('acid', 'O'), ('beta', 'O'), ('oxidation', 'O'), ('that', 'O'), ('reportedly', 'O'), ('has', 'O'), ('high', 'O'), ('rates', 'O'), ('of', 'O'), ('morbidity', 'O'), ('and', 'O'), ('mortality', 'O'), ('.', 'O'))"
"We describe the outcome of a 5 - year - old girl with VLCAD deficiency who was first seen at 5 months of age with severe hypertrophic cardiomyopathy , hepatomegaly , encephalopathy , and hypotonia .","(('We', 'O'), ('describe', 'O'), ('the', 'O'), ('outcome', 'O'), ('of', 'O'), ('a', 'O'), ('5', 'O'), ('-', 'O'), ('year', 'O'), ('-', 'O'), ('old', 'O'), ('girl', 'O'), ('with', 'O'), ('VLCAD', 'B'), ('deficiency', 'I'), ('who', 'O'), ('was', 'O'), ('first', 'O'), ('seen', 'O'), ('at', 'O'), ('5', 'O'), ('months', 'O'), ('of', 'O'), ('age', 'O'), ('with', 'O'), ('severe', 'O'), ('hypertrophic', 'B'), ('cardiomyopathy', 'I'), (',', 'O'), ('hepatomegaly', 'B'), (',', 'O'), ('encephalopathy', 'B'), (',', 'O'), ('and', 'O'), ('hypotonia', 'B'), ('.', 'O'))"
Biochemical studies indicated VLCAD deficiency caused by a stable yet inactive enzyme .,"(('Biochemical', 'O'), ('studies', 'O'), ('indicated', 'O'), ('VLCAD', 'B'), ('deficiency', 'I'), ('caused', 'O'), ('by', 'O'), ('a', 'O'), ('stable', 'O'), ('yet', 'O'), ('inactive', 'O'), ('enzyme', 'O'), ('.', 'O'))"
Clinical recognition of VLCAD deficiency is important because it is one of the few directly treatable causes of cardiomyopathy in children . .,"(('Clinical', 'O'), ('recognition', 'O'), ('of', 'O'), ('VLCAD', 'B'), ('deficiency', 'I'), ('is', 'O'), ('important', 'O'), ('because', 'O'), ('it', 'O'), ('is', 'O'), ('one', 'O'), ('of', 'O'), ('the', 'O'), ('few', 'O'), ('directly', 'O'), ('treatable', 'O'), ('causes', 'O'), ('of', 'O'), ('cardiomyopathy', 'B'), ('in', 'O'), ('children', 'O'), ('.', 'O'), ('.', 'O'))"
A gene encoding a novel transmembrane protein was identified by DNA sequence analysis within the insulin - dependent diabetes mellitus ( IDDM ) locus IDDM4 on chromosome 11q13 .,"(('A', 'O'), ('gene', 'O'), ('encoding', 'O'), ('a', 'O'), ('novel', 'O'), ('transmembrane', 'O'), ('protein', 'O'), ('was', 'O'), ('identified', 'O'), ('by', 'O'), ('DNA', 'O'), ('sequence', 'O'), ('analysis', 'O'), ('within', 'O'), ('the', 'O'), ('insulin', 'B'), ('-', 'I'), ('dependent', 'I'), ('diabetes', 'I'), ('mellitus', 'I'), ('(', 'O'), ('IDDM', 'B'), (')', 'O'), ('locus', 'O'), ('IDDM4', 'O'), ('on', 'O'), ('chromosome', 'O'), ('11q13', 'O'), ('.', 'O'))"
"Based on its chromosomal position , this gene is a candidate for conferring susceptibility to diabetes .","(('Based', 'O'), ('on', 'O'), ('its', 'O'), ('chromosomal', 'O'), ('position', 'O'), (',', 'O'), ('this', 'O'), ('gene', 'O'), ('is', 'O'), ('a', 'O'), ('candidate', 'O'), ('for', 'O'), ('conferring', 'O'), ('susceptibility', 'O'), ('to', 'O'), ('diabetes', 'B'), ('.', 'O'))"
"The APC variants I1307K and E1317Q are associated with colorectal tumors , but not always with a family history .","(('The', 'O'), ('APC', 'B'), ('variants', 'O'), ('I1307K', 'O'), ('and', 'O'), ('E1317Q', 'O'), ('are', 'O'), ('associated', 'O'), ('with', 'O'), ('colorectal', 'B'), ('tumors', 'I'), (',', 'O'), ('but', 'O'), ('not', 'O'), ('always', 'O'), ('with', 'O'), ('a', 'O'), ('family', 'O'), ('history', 'O'), ('.', 'O'))"
Classical familial adenomatous polyposis ( FAP ) is a high - penetrance autosomal dominant disease that predisposes to hundreds or thousands of colorectal adenomas and carcinoma and that results from truncating mutations in the APC gene .,"(('Classical', 'O'), ('familial', 'B'), ('adenomatous', 'I'), ('polyposis', 'I'), ('(', 'O'), ('FAP', 'B'), (')', 'O'), ('is', 'O'), ('a', 'O'), ('high', 'O'), ('-', 'O'), ('penetrance', 'O'), ('autosomal', 'B'), ('dominant', 'I'), ('disease', 'I'), ('that', 'O'), ('predisposes', 'O'), ('to', 'O'), ('hundreds', 'O'), ('or', 'O'), ('thousands', 'O'), ('of', 'O'), ('colorectal', 'B'), ('adenomas', 'I'), ('and', 'I'), ('carcinoma', 'I'), ('and', 'O'), ('that', 'O'), ('results', 'O'), ('from', 'O'), ('truncating', 'O'), ('mutations', 'O'), ('in', 'O'), ('the', 'O'), ('APC', 'B'), ('gene', 'O'), ('.', 'O'))"
"A variant of FAP is attenuated adenomatous polyposis coli , which results from germ - line mutations in the 5 and 3 regions of the APC gene .","(('A', 'O'), ('variant', 'O'), ('of', 'O'), ('FAP', 'B'), ('is', 'O'), ('attenuated', 'B'), ('adenomatous', 'I'), ('polyposis', 'I'), ('coli', 'I'), (',', 'O'), ('which', 'O'), ('results', 'O'), ('from', 'O'), ('germ', 'O'), ('-', 'O'), ('line', 'O'), ('mutations', 'O'), ('in', 'O'), ('the', 'O'), ('5', 'O'), ('and', 'O'), ('3', 'O'), ('regions', 'O'), ('of', 'O'), ('the', 'O'), ('APC', 'B'), ('gene', 'O'), ('.', 'O'))"
"Attenuated adenomatous polyposis coli patients have "" multiple "" colorectal adenomas ( typically fewer than 100 ) without the florid phenotype of classical FAP .","(('Attenuated', 'B'), ('adenomatous', 'I'), ('polyposis', 'I'), ('coli', 'I'), ('patients', 'O'), ('have', 'O'), ('""', 'O'), ('multiple', 'O'), ('""', 'O'), ('colorectal', 'B'), ('adenomas', 'I'), ('(', 'O'), ('typically', 'O'), ('fewer', 'O'), ('than', 'O'), ('100', 'O'), (')', 'O'), ('without', 'O'), ('the', 'O'), ('florid', 'O'), ('phenotype', 'O'), ('of', 'O'), ('classical', 'O'), ('FAP', 'B'), ('.', 'O'))"
"Another group of patients with multiple adenomas has no mutations in the APC gene , and their phenotype probably results from variation at a locus , or loci , elsewhere in the genome .","(('Another', 'O'), ('group', 'O'), ('of', 'O'), ('patients', 'O'), ('with', 'O'), ('multiple', 'O'), ('adenomas', 'B'), ('has', 'O'), ('no', 'O'), ('mutations', 'O'), ('in', 'O'), ('the', 'O'), ('APC', 'B'), ('gene', 'O'), (',', 'O'), ('and', 'O'), ('their', 'O'), ('phenotype', 'O'), ('probably', 'O'), ('results', 'O'), ('from', 'O'), ('variation', 'O'), ('at', 'O'), ('a', 'O'), ('locus', 'O'), (',', 'O'), ('or', 'O'), ('loci', 'O'), (',', 'O'), ('elsewhere', 'O'), ('in', 'O'), ('the', 'O'), ('genome', 'O'), ('.', 'O'))"
"Recently , however , a missense variant of APC ( I1307K ) was described that confers an increased risk of colorectal tumors , including multiple adenomas , in Ashkenazim .","(('Recently', 'O'), (',', 'O'), ('however', 'O'), (',', 'O'), ('a', 'O'), ('missense', 'O'), ('variant', 'O'), ('of', 'O'), ('APC', 'B'), ('(', 'O'), ('I1307K', 'O'), (')', 'O'), ('was', 'O'), ('described', 'O'), ('that', 'O'), ('confers', 'O'), ('an', 'O'), ('increased', 'O'), ('risk', 'O'), ('of', 'O'), ('colorectal', 'B'), ('tumors', 'I'), (',', 'O'), ('including', 'O'), ('multiple', 'O'), ('adenomas', 'B'), (',', 'O'), ('in', 'O'), ('Ashkenazim', 'O'), ('.', 'O'))"
We have studied a set of 164 patients with multiple colorectal adenomas and / or carcinoma and analyzed codons 1263 - 1377 ( exon 15G ) of the APC gene for germ - line variants .,"(('We', 'O'), ('have', 'O'), ('studied', 'O'), ('a', 'O'), ('set', 'O'), ('of', 'O'), ('164', 'O'), ('patients', 'O'), ('with', 'O'), ('multiple', 'O'), ('colorectal', 'B'), ('adenomas', 'I'), ('and', 'I'), ('/', 'I'), ('or', 'I'), ('carcinoma', 'I'), ('and', 'O'), ('analyzed', 'O'), ('codons', 'O'), ('1263', 'O'), ('-', 'O'), ('1377', 'O'), ('(', 'O'), ('exon', 'O'), ('15G', 'O'), (')', 'O'), ('of', 'O'), ('the', 'O'), ('APC', 'B'), ('gene', 'O'), ('for', 'O'), ('germ', 'O'), ('-', 'O'), ('line', 'O'), ('variants', 'O'), ('.', 'O'))"
Four patients had a germ - line E1317Q missense variant of APC that was not present in controls ; one of these individuals had an unusually large number of metaplastic polyps of the colorectum .,"(('Four', 'O'), ('patients', 'O'), ('had', 'O'), ('a', 'O'), ('germ', 'O'), ('-', 'O'), ('line', 'O'), ('E1317Q', 'O'), ('missense', 'O'), ('variant', 'O'), ('of', 'O'), ('APC', 'O'), ('that', 'O'), ('was', 'O'), ('not', 'O'), ('present', 'O'), ('in', 'O'), ('controls', 'O'), (';', 'O'), ('one', 'O'), ('of', 'O'), ('these', 'O'), ('individuals', 'O'), ('had', 'O'), ('an', 'O'), ('unusually', 'O'), ('large', 'O'), ('number', 'O'), ('of', 'O'), ('metaplastic', 'B'), ('polyps', 'I'), ('of', 'I'), ('the', 'I'), ('colorectum', 'I'), ('.', 'O'))"
"There is increasing evidence that there exist germ - line variants of the APC gene that predispose to the development of multiple colorectal adenomas and carcinoma , but without the florid phenotype of classical FAP , and possibly with importance for colorectal cancer risk in the general population . .","(('There', 'O'), ('is', 'O'), ('increasing', 'O'), ('evidence', 'O'), ('that', 'O'), ('there', 'O'), ('exist', 'O'), ('germ', 'O'), ('-', 'O'), ('line', 'O'), ('variants', 'O'), ('of', 'O'), ('the', 'O'), ('APC', 'B'), ('gene', 'O'), ('that', 'O'), ('predispose', 'O'), ('to', 'O'), ('the', 'O'), ('development', 'O'), ('of', 'O'), ('multiple', 'O'), ('colorectal', 'B'), ('adenomas', 'I'), ('and', 'I'), ('carcinoma', 'I'), (',', 'O'), ('but', 'O'), ('without', 'O'), ('the', 'O'), ('florid', 'O'), ('phenotype', 'O'), ('of', 'O'), ('classical', 'O'), ('FAP', 'B'), (',', 'O'), ('and', 'O'), ('possibly', 'O'), ('with', 'O'), ('importance', 'O'), ('for', 'O'), ('colorectal', 'B'), ('cancer', 'I'), ('risk', 'O'), ('in', 'O'), ('the', 'O'), ('general', 'O'), ('population', 'O'), ('.', 'O'), ('.', 'O'))"
Genomic structure of the human congenital chloride diarrhea ( CLD ) gene .,"(('Genomic', 'O'), ('structure', 'O'), ('of', 'O'), ('the', 'O'), ('human', 'O'), ('congenital', 'B'), ('chloride', 'I'), ('diarrhea', 'I'), ('(', 'O'), ('CLD', 'B'), (')', 'O'), ('gene', 'O'), ('.', 'O'))"
Congenital chloride diarrhea ( CLD ) is caused by mutations in a gene which encodes an intestinal anion transporter .,"(('Congenital', 'B'), ('chloride', 'I'), ('diarrhea', 'I'), ('(', 'O'), ('CLD', 'B'), (')', 'O'), ('is', 'O'), ('caused', 'O'), ('by', 'O'), ('mutations', 'O'), ('in', 'O'), ('a', 'O'), ('gene', 'O'), ('which', 'O'), ('encodes', 'O'), ('an', 'O'), ('intestinal', 'O'), ('anion', 'O'), ('transporter', 'O'), ('.', 'O'))"
"Genomic sequencing of a BAC clone H _ RG364P16 revealed the presence of another , highly homologous gene 3 of the CLD gene , with a similar genomic structure , recently identified as the Pendred syndrome gene ( PDS ) . .","(('Genomic', 'O'), ('sequencing', 'O'), ('of', 'O'), ('a', 'O'), ('BAC', 'O'), ('clone', 'O'), ('H', 'O'), ('_', 'O'), ('RG364P16', 'O'), ('revealed', 'O'), ('the', 'O'), ('presence', 'O'), ('of', 'O'), ('another', 'O'), (',', 'O'), ('highly', 'O'), ('homologous', 'O'), ('gene', 'O'), ('3', 'O'), ('of', 'O'), ('the', 'O'), ('CLD', 'B'), ('gene', 'O'), (',', 'O'), ('with', 'O'), ('a', 'O'), ('similar', 'O'), ('genomic', 'O'), ('structure', 'O'), (',', 'O'), ('recently', 'O'), ('identified', 'O'), ('as', 'O'), ('the', 'O'), ('Pendred', 'B'), ('syndrome', 'I'), ('gene', 'O'), ('(', 'O'), ('PDS', 'B'), (')', 'O'), ('.', 'O'), ('.', 'O'))"
The APCI1307K allele and cancer risk in a community - based study of Ashkenazi Jews .,"(('The', 'O'), ('APCI1307K', 'O'), ('allele', 'O'), ('and', 'O'), ('cancer', 'B'), ('risk', 'O'), ('in', 'O'), ('a', 'O'), ('community', 'O'), ('-', 'O'), ('based', 'O'), ('study', 'O'), ('of', 'O'), ('Ashkenazi', 'O'), ('Jews', 'O'), ('.', 'O'))"
"Mutations in APC are classically associated with familial adenomatous polyposis ( FAP ) , a highly penetrant autosomal dominant disorder characterized by multiple intestinal polyps and , without surgical intervention , the development of colorectal cancer ( CRC ) .","(('Mutations', 'O'), ('in', 'O'), ('APC', 'O'), ('are', 'O'), ('classically', 'O'), ('associated', 'O'), ('with', 'O'), ('familial', 'B'), ('adenomatous', 'I'), ('polyposis', 'I'), ('(', 'O'), ('FAP', 'B'), (')', 'O'), (',', 'O'), ('a', 'O'), ('highly', 'O'), ('penetrant', 'O'), ('autosomal', 'B'), ('dominant', 'I'), ('disorder', 'I'), ('characterized', 'O'), ('by', 'O'), ('multiple', 'O'), ('intestinal', 'O'), ('polyps', 'B'), ('and', 'O'), (',', 'O'), ('without', 'O'), ('surgical', 'O'), ('intervention', 'O'), (',', 'O'), ('the', 'O'), ('development', 'O'), ('of', 'O'), ('colorectal', 'B'), ('cancer', 'I'), ('(', 'O'), ('CRC', 'B'), (')', 'O'), ('.', 'O'))"
"APC is a tumour - suppressor gene , and somatic loss occurs in tumours .","(('APC', 'B'), ('is', 'O'), ('a', 'O'), ('tumour', 'O'), ('-', 'O'), ('suppressor', 'O'), ('gene', 'O'), (',', 'O'), ('and', 'O'), ('somatic', 'O'), ('loss', 'O'), ('occurs', 'O'), ('in', 'O'), ('tumours', 'B'), ('.', 'O'))"
"To evaluate the role of I1307K in cancer , we genotyped 5 , 081 Ashkenazi volunteers in a community survey .","(('To', 'O'), ('evaluate', 'O'), ('the', 'O'), ('role', 'O'), ('of', 'O'), ('I1307K', 'O'), ('in', 'O'), ('cancer', 'B'), (',', 'O'), ('we', 'O'), ('genotyped', 'O'), ('5', 'O'), (',', 'O'), ('081', 'O'), ('Ashkenazi', 'O'), ('volunteers', 'O'), ('in', 'O'), ('a', 'O'), ('community', 'O'), ('survey', 'O'), ('.', 'O'))"
"Risk of developing colorectal , breast and other cancers were compared between genotyped I1307K carriers and non - carriers and their first - degree relatives .","(('Risk', 'O'), ('of', 'O'), ('developing', 'O'), ('colorectal', 'B'), (',', 'I'), ('breast', 'I'), ('and', 'I'), ('other', 'I'), ('cancers', 'I'), ('were', 'O'), ('compared', 'O'), ('between', 'O'), ('genotyped', 'O'), ('I1307K', 'O'), ('carriers', 'O'), ('and', 'O'), ('non', 'O'), ('-', 'O'), ('carriers', 'O'), ('and', 'O'), ('their', 'O'), ('first', 'O'), ('-', 'O'), ('degree', 'O'), ('relatives', 'O'), ('.', 'O'))"
Sperm DNA analysis in a Friedreich ataxia premutation carrier suggests both meiotic and mitotic expansion in the FRDA gene .,"(('Sperm', 'O'), ('DNA', 'O'), ('analysis', 'O'), ('in', 'O'), ('a', 'O'), ('Friedreich', 'B'), ('ataxia', 'I'), ('premutation', 'O'), ('carrier', 'O'), ('suggests', 'O'), ('both', 'O'), ('meiotic', 'O'), ('and', 'O'), ('mitotic', 'O'), ('expansion', 'O'), ('in', 'O'), ('the', 'O'), ('FRDA', 'B'), ('gene', 'O'), ('.', 'O'))"
Friedreich ataxia is usually caused by an expansion of a GAA trinucleotide repeat in intron 1 of the FRDA gene .,"(('Friedreich', 'B'), ('ataxia', 'I'), ('is', 'O'), ('usually', 'O'), ('caused', 'O'), ('by', 'O'), ('an', 'O'), ('expansion', 'O'), ('of', 'O'), ('a', 'O'), ('GAA', 'O'), ('trinucleotide', 'O'), ('repeat', 'O'), ('in', 'O'), ('intron', 'O'), ('1', 'O'), ('of', 'O'), ('the', 'O'), ('FRDA', 'B'), ('gene', 'O'), ('.', 'O'))"
The R496H mutation of arylsulfatase A does not cause metachromatic leukodystrophy .,"(('The', 'O'), ('R496H', 'O'), ('mutation', 'O'), ('of', 'O'), ('arylsulfatase', 'O'), ('A', 'O'), ('does', 'O'), ('not', 'O'), ('cause', 'O'), ('metachromatic', 'B'), ('leukodystrophy', 'I'), ('.', 'O'))"
Deficiency of arylsulfatase A ( ARSA ) enzyme activity causes metachromatic leukodystrophy ( MLD ) .,"(('Deficiency', 'B'), ('of', 'I'), ('arylsulfatase', 'I'), ('A', 'I'), ('(', 'O'), ('ARSA', 'O'), (')', 'O'), ('enzyme', 'O'), ('activity', 'O'), ('causes', 'O'), ('metachromatic', 'B'), ('leukodystrophy', 'I'), ('(', 'O'), ('MLD', 'B'), (')', 'O'), ('.', 'O'))"
A number of ARSA gene mutations responsible for MLD have been identified .,"(('A', 'O'), ('number', 'O'), ('of', 'O'), ('ARSA', 'O'), ('gene', 'O'), ('mutations', 'O'), ('responsible', 'O'), ('for', 'O'), ('MLD', 'B'), ('have', 'O'), ('been', 'O'), ('identified', 'O'), ('.', 'O'))"
"Recently , the R496H mutation of ARSA was proposed to be a cause of MLD ( Draghia et al . , 1997 ) .","(('Recently', 'O'), (',', 'O'), ('the', 'O'), ('R496H', 'O'), ('mutation', 'O'), ('of', 'O'), ('ARSA', 'O'), ('was', 'O'), ('proposed', 'O'), ('to', 'O'), ('be', 'O'), ('a', 'O'), ('cause', 'O'), ('of', 'O'), ('MLD', 'B'), ('(', 'O'), ('Draghia', 'O'), ('et', 'O'), ('al', 'O'), ('.', 'O'), (',', 'O'), ('1997', 'O'), (')', 'O'), ('.', 'O'))"
It is therefore concluded that the R496H mutation of ARSA does not negatively influence the activity of ARSA and is not a cause of MLD,"(('It', 'O'), ('is', 'O'), ('therefore', 'O'), ('concluded', 'O'), ('that', 'O'), ('the', 'O'), ('R496H', 'O'), ('mutation', 'O'), ('of', 'O'), ('ARSA', 'O'), ('does', 'O'), ('not', 'O'), ('negatively', 'O'), ('influence', 'O'), ('the', 'O'), ('activity', 'O'), ('of', 'O'), ('ARSA', 'O'), ('and', 'O'), ('is', 'O'), ('not', 'O'), ('a', 'O'), ('cause', 'O'), ('of', 'O'), ('MLD', 'B'))"
Down - regulation of transmembrane carbonic anhydrases in renal cell carcinoma cell lines by wild - type von Hippel - Lindau transgenes .,"(('Down', 'O'), ('-', 'O'), ('regulation', 'O'), ('of', 'O'), ('transmembrane', 'O'), ('carbonic', 'O'), ('anhydrases', 'O'), ('in', 'O'), ('renal', 'B'), ('cell', 'I'), ('carcinoma', 'I'), ('cell', 'O'), ('lines', 'O'), ('by', 'O'), ('wild', 'O'), ('-', 'O'), ('type', 'O'), ('von', 'B'), ('Hippel', 'I'), ('-', 'I'), ('Lindau', 'I'), ('transgenes', 'O'), ('.', 'O'))"
"To discover genes involved in von Hippel - Lindau ( VHL ) - mediated carcinogenesis , we used renal cell carcinoma cell lines stably transfected with wild - type VHL - expressing transgenes .","(('To', 'O'), ('discover', 'O'), ('genes', 'O'), ('involved', 'O'), ('in', 'O'), ('von', 'B'), ('Hippel', 'I'), ('-', 'I'), ('Lindau', 'I'), ('(', 'O'), ('VHL', 'B'), (')', 'O'), ('-', 'O'), ('mediated', 'O'), ('carcinogenesis', 'O'), (',', 'O'), ('we', 'O'), ('used', 'O'), ('renal', 'B'), ('cell', 'I'), ('carcinoma', 'I'), ('cell', 'O'), ('lines', 'O'), ('stably', 'O'), ('transfected', 'O'), ('with', 'O'), ('wild', 'O'), ('-', 'O'), ('type', 'O'), ('VHL', 'O'), ('-', 'O'), ('expressing', 'O'), ('transgenes', 'O'), ('.', 'O'))"
Reintroduced wild - type VHL strongly inhibited the overexpression of the CA12 gene in the parental renal cell carcinoma cell lines .,"(('Reintroduced', 'O'), ('wild', 'O'), ('-', 'O'), ('type', 'O'), ('VHL', 'B'), ('strongly', 'O'), ('inhibited', 'O'), ('the', 'O'), ('overexpression', 'O'), ('of', 'O'), ('the', 'O'), ('CA12', 'O'), ('gene', 'O'), ('in', 'O'), ('the', 'O'), ('parental', 'O'), ('renal', 'B'), ('cell', 'I'), ('carcinoma', 'I'), ('cell', 'O'), ('lines', 'O'), ('.', 'O'))"
"Although both domains of the VHL protein contribute to regulation of CA12 expression , the elongin binding domain alone could effectively regulate CA9 expression .","(('Although', 'O'), ('both', 'O'), ('domains', 'O'), ('of', 'O'), ('the', 'O'), ('VHL', 'B'), ('protein', 'O'), ('contribute', 'O'), ('to', 'O'), ('regulation', 'O'), ('of', 'O'), ('CA12', 'O'), ('expression', 'O'), (',', 'O'), ('the', 'O'), ('elongin', 'O'), ('binding', 'O'), ('domain', 'O'), ('alone', 'O'), ('could', 'O'), ('effectively', 'O'), ('regulate', 'O'), ('CA9', 'O'), ('expression', 'O'), ('.', 'O'))"
"2 respectively , regions prone to amplification in some human cancers .","(('2', 'O'), ('respectively', 'O'), (',', 'O'), ('regions', 'O'), ('prone', 'O'), ('to', 'O'), ('amplification', 'O'), ('in', 'O'), ('some', 'O'), ('human', 'O'), ('cancers', 'B'), ('.', 'O'))"
Additional experiments are needed to define the role of CA IX and CA XII enzymes in the regulation of pH in the extracellular microenvironment and its potential impact on cancer cell growth .,"(('Additional', 'O'), ('experiments', 'O'), ('are', 'O'), ('needed', 'O'), ('to', 'O'), ('define', 'O'), ('the', 'O'), ('role', 'O'), ('of', 'O'), ('CA', 'O'), ('IX', 'O'), ('and', 'O'), ('CA', 'O'), ('XII', 'O'), ('enzymes', 'O'), ('in', 'O'), ('the', 'O'), ('regulation', 'O'), ('of', 'O'), ('pH', 'O'), ('in', 'O'), ('the', 'O'), ('extracellular', 'O'), ('microenvironment', 'O'), ('and', 'O'), ('its', 'O'), ('potential', 'O'), ('impact', 'O'), ('on', 'O'), ('cancer', 'B'), ('cell', 'O'), ('growth', 'O'), ('.', 'O'))"
A gene encoding a transmembrane protein is mutated in patients with diabetes mellitus and optic atrophy ( Wolfram syndrome ) .,"(('A', 'O'), ('gene', 'O'), ('encoding', 'O'), ('a', 'O'), ('transmembrane', 'O'), ('protein', 'O'), ('is', 'O'), ('mutated', 'O'), ('in', 'O'), ('patients', 'O'), ('with', 'O'), ('diabetes', 'B'), ('mellitus', 'I'), ('and', 'O'), ('optic', 'B'), ('atrophy', 'I'), ('(', 'O'), ('Wolfram', 'B'), ('syndrome', 'I'), (')', 'O'), ('.', 'O'))"
Wolfram syndrome ( WFS ; OMIM 222300 ) is an autosomal recessive neurodegenerative disorder defined by young - onset non - immune insulin - dependent diabetes mellitus and progressive optic atrophy .,"(('Wolfram', 'B'), ('syndrome', 'I'), ('(', 'O'), ('WFS', 'B'), (';', 'O'), ('OMIM', 'O'), ('222300', 'O'), (')', 'O'), ('is', 'O'), ('an', 'O'), ('autosomal', 'B'), ('recessive', 'I'), ('neurodegenerative', 'I'), ('disorder', 'I'), ('defined', 'O'), ('by', 'O'), ('young', 'O'), ('-', 'O'), ('onset', 'O'), ('non', 'O'), ('-', 'O'), ('immune', 'O'), ('insulin', 'B'), ('-', 'I'), ('dependent', 'I'), ('diabetes', 'I'), ('mellitus', 'I'), ('and', 'O'), ('progressive', 'O'), ('optic', 'B'), ('atrophy', 'I'), ('.', 'O'))"
Stable interaction between the products of the BRCA1 and BRCA2 tumor suppressor genes in mitotic and meiotic cells .,"(('Stable', 'O'), ('interaction', 'O'), ('between', 'O'), ('the', 'O'), ('products', 'O'), ('of', 'O'), ('the', 'O'), ('BRCA1', 'O'), ('and', 'O'), ('BRCA2', 'O'), ('tumor', 'B'), ('suppressor', 'O'), ('genes', 'O'), ('in', 'O'), ('mitotic', 'O'), ('and', 'O'), ('meiotic', 'O'), ('cells', 'O'), ('.', 'O'))"
"BRCA1 and BRCA2 account for most cases of familial , early onset breast and / or ovarian cancer and encode products that each interact with hRAD51 .","(('BRCA1', 'O'), ('and', 'O'), ('BRCA2', 'O'), ('account', 'O'), ('for', 'O'), ('most', 'O'), ('cases', 'O'), ('of', 'O'), ('familial', 'O'), (',', 'O'), ('early', 'O'), ('onset', 'O'), ('breast', 'B'), ('and', 'I'), ('/', 'I'), ('or', 'I'), ('ovarian', 'I'), ('cancer', 'I'), ('and', 'O'), ('encode', 'O'), ('products', 'O'), ('that', 'O'), ('each', 'O'), ('interact', 'O'), ('with', 'O'), ('hRAD51', 'O'), ('.', 'O'))"
Dysfunction of this pathway may be a general phenomenon in the majority of cases of hereditary breast and / or ovarian cancer . .,"(('Dysfunction', 'O'), ('of', 'O'), ('this', 'O'), ('pathway', 'O'), ('may', 'O'), ('be', 'O'), ('a', 'O'), ('general', 'O'), ('phenomenon', 'O'), ('in', 'O'), ('the', 'O'), ('majority', 'O'), ('of', 'O'), ('cases', 'O'), ('of', 'O'), ('hereditary', 'B'), ('breast', 'I'), ('and', 'I'), ('/', 'I'), ('or', 'I'), ('ovarian', 'I'), ('cancer', 'I'), ('.', 'O'), ('.', 'O'))"
A novel C to A mutation in the sterol 27 - hydroxylase gene ( CYP27 ) was identified by sequencing amplified CYP27 gene products from a patient with cerebrotendinous xanthomatosis ( CTX ) .,"(('A', 'O'), ('novel', 'O'), ('C', 'O'), ('to', 'O'), ('A', 'O'), ('mutation', 'O'), ('in', 'O'), ('the', 'O'), ('sterol', 'O'), ('27', 'O'), ('-', 'O'), ('hydroxylase', 'O'), ('gene', 'O'), ('(', 'O'), ('CYP27', 'O'), (')', 'O'), ('was', 'O'), ('identified', 'O'), ('by', 'O'), ('sequencing', 'O'), ('amplified', 'O'), ('CYP27', 'O'), ('gene', 'O'), ('products', 'O'), ('from', 'O'), ('a', 'O'), ('patient', 'O'), ('with', 'O'), ('cerebrotendinous', 'B'), ('xanthomatosis', 'I'), ('(', 'O'), ('CTX', 'B'), (')', 'O'), ('.', 'O'))"
"Our data suggest that the C to A mutation at the penultimate nucleotide of exon 6 of the CYP27 gene not only causes the deficiency in the sterol 27 - hydroxylase activity , but also partially leads to alternative pre - mRNA splicing of the gene .","(('Our', 'O'), ('data', 'O'), ('suggest', 'O'), ('that', 'O'), ('the', 'O'), ('C', 'O'), ('to', 'O'), ('A', 'O'), ('mutation', 'O'), ('at', 'O'), ('the', 'O'), ('penultimate', 'O'), ('nucleotide', 'O'), ('of', 'O'), ('exon', 'O'), ('6', 'O'), ('of', 'O'), ('the', 'O'), ('CYP27', 'O'), ('gene', 'O'), ('not', 'O'), ('only', 'O'), ('causes', 'O'), ('the', 'O'), ('deficiency', 'B'), ('in', 'I'), ('the', 'I'), ('sterol', 'I'), ('27', 'I'), ('-', 'I'), ('hydroxylase', 'I'), ('activity', 'I'), (',', 'O'), ('but', 'O'), ('also', 'O'), ('partially', 'O'), ('leads', 'O'), ('to', 'O'), ('alternative', 'O'), ('pre', 'O'), ('-', 'O'), ('mRNA', 'O'), ('splicing', 'O'), ('of', 'O'), ('the', 'O'), ('gene', 'O'), ('.', 'O'))"
ATM germline mutations in classical ataxia - telangiectasia patients in the Dutch population .,"(('ATM', 'O'), ('germline', 'O'), ('mutations', 'O'), ('in', 'O'), ('classical', 'O'), ('ataxia', 'B'), ('-', 'I'), ('telangiectasia', 'I'), ('patients', 'O'), ('in', 'O'), ('the', 'O'), ('Dutch', 'O'), ('population', 'O'), ('.', 'O'))"
Germline mutations in the ATM gene are responsible for the autosomal recessive disorder ataxia - telangiectasia ( A - T ) .,"(('Germline', 'O'), ('mutations', 'O'), ('in', 'O'), ('the', 'O'), ('ATM', 'O'), ('gene', 'O'), ('are', 'O'), ('responsible', 'O'), ('for', 'O'), ('the', 'O'), ('autosomal', 'B'), ('recessive', 'I'), ('disorder', 'I'), ('ataxia', 'B'), ('-', 'I'), ('telangiectasia', 'I'), ('(', 'O'), ('A', 'B'), ('-', 'I'), ('T', 'I'), (')', 'O'), ('.', 'O'))"
"In our study , we have determined the ATM mutation spectrum in 19 classical A - T patients , including some immigrant populations , as well as 12 of Dutch ethnic origin .","(('In', 'O'), ('our', 'O'), ('study', 'O'), (',', 'O'), ('we', 'O'), ('have', 'O'), ('determined', 'O'), ('the', 'O'), ('ATM', 'O'), ('mutation', 'O'), ('spectrum', 'O'), ('in', 'O'), ('19', 'O'), ('classical', 'O'), ('A', 'B'), ('-', 'I'), ('T', 'I'), ('patients', 'O'), (',', 'O'), ('including', 'O'), ('some', 'O'), ('immigrant', 'O'), ('populations', 'O'), (',', 'O'), ('as', 'O'), ('well', 'O'), ('as', 'O'), ('12', 'O'), ('of', 'O'), ('Dutch', 'O'), ('ethnic', 'O'), ('origin', 'O'), ('.', 'O'))"
"The most frequently found mutation , identified in three unrelated Turkish A - T individuals , was previously described to be a Turkish A - T founder mutation .","(('The', 'O'), ('most', 'O'), ('frequently', 'O'), ('found', 'O'), ('mutation', 'O'), (',', 'O'), ('identified', 'O'), ('in', 'O'), ('three', 'O'), ('unrelated', 'O'), ('Turkish', 'O'), ('A', 'B'), ('-', 'I'), ('T', 'I'), ('individuals', 'O'), (',', 'O'), ('was', 'O'), ('previously', 'O'), ('described', 'O'), ('to', 'O'), ('be', 'O'), ('a', 'O'), ('Turkish', 'O'), ('A', 'B'), ('-', 'I'), ('T', 'I'), ('founder', 'O'), ('mutation', 'O'), ('.', 'O'))"
All patients manifested classical A - T and increased cellular radioresistant DNA synthesis .,"(('All', 'O'), ('patients', 'O'), ('manifested', 'O'), ('classical', 'O'), ('A', 'B'), ('-', 'I'), ('T', 'I'), ('and', 'O'), ('increased', 'O'), ('cellular', 'O'), ('radioresistant', 'O'), ('DNA', 'O'), ('synthesis', 'O'), ('.', 'O'))"
Determination of the genomic structure of the COL4A4 gene and of novel mutations causing autosomal recessive Alport syndrome .,"(('Determination', 'O'), ('of', 'O'), ('the', 'O'), ('genomic', 'O'), ('structure', 'O'), ('of', 'O'), ('the', 'O'), ('COL4A4', 'O'), ('gene', 'O'), ('and', 'O'), ('of', 'O'), ('novel', 'O'), ('mutations', 'O'), ('causing', 'O'), ('autosomal', 'B'), ('recessive', 'I'), ('Alport', 'I'), ('syndrome', 'I'), ('.', 'O'))"
"Autosomal recessive Alport syndrome is a progressive hematuric glomerulonephritis characterized by glomerular basement membrane abnormalities and associated with mutations in either the COL4A3 or the COL4A4 gene , which encode the alpha3 and alpha4 type IV collagen chains , respectively .","(('Autosomal', 'B'), ('recessive', 'I'), ('Alport', 'I'), ('syndrome', 'I'), ('is', 'O'), ('a', 'O'), ('progressive', 'O'), ('hematuric', 'B'), ('glomerulonephritis', 'I'), ('characterized', 'O'), ('by', 'O'), ('glomerular', 'B'), ('basement', 'I'), ('membrane', 'I'), ('abnormalities', 'I'), ('and', 'O'), ('associated', 'O'), ('with', 'O'), ('mutations', 'O'), ('in', 'O'), ('either', 'O'), ('the', 'O'), ('COL4A3', 'O'), ('or', 'O'), ('the', 'O'), ('COL4A4', 'O'), ('gene', 'O'), (',', 'O'), ('which', 'O'), ('encode', 'O'), ('the', 'O'), ('alpha3', 'O'), ('and', 'O'), ('alpha4', 'O'), ('type', 'O'), ('IV', 'O'), ('collagen', 'O'), ('chains', 'O'), (',', 'O'), ('respectively', 'O'), ('.', 'O'))"
"We report here the complete characterization of the 48 exons of the COL4A4 gene , a comprehensive gene screen , and the subsequent detection of 10 novel mutations in eight patients diagnosed with autosomal recessive Alport syndrome .","(('We', 'O'), ('report', 'O'), ('here', 'O'), ('the', 'O'), ('complete', 'O'), ('characterization', 'O'), ('of', 'O'), ('the', 'O'), ('48', 'O'), ('exons', 'O'), ('of', 'O'), ('the', 'O'), ('COL4A4', 'O'), ('gene', 'O'), (',', 'O'), ('a', 'O'), ('comprehensive', 'O'), ('gene', 'O'), ('screen', 'O'), (',', 'O'), ('and', 'O'), ('the', 'O'), ('subsequent', 'O'), ('detection', 'O'), ('of', 'O'), ('10', 'O'), ('novel', 'O'), ('mutations', 'O'), ('in', 'O'), ('eight', 'O'), ('patients', 'O'), ('diagnosed', 'O'), ('with', 'O'), ('autosomal', 'B'), ('recessive', 'I'), ('Alport', 'I'), ('syndrome', 'I'), ('.', 'O'))"
Founder BRCA1 and BRCA2 mutations in French Canadian breast and ovarian cancer families .,"(('Founder', 'O'), ('BRCA1', 'O'), ('and', 'O'), ('BRCA2', 'O'), ('mutations', 'O'), ('in', 'O'), ('French', 'O'), ('Canadian', 'O'), ('breast', 'B'), ('and', 'I'), ('ovarian', 'I'), ('cancer', 'I'), ('families', 'O'), ('.', 'O'))"
"We have identified four mutations in each of the breast cancer - susceptibility genes , BRCA1 and BRCA2 , in French Canadian breast cancer and breast / ovarian cancer families from Quebec .","(('We', 'O'), ('have', 'O'), ('identified', 'O'), ('four', 'O'), ('mutations', 'O'), ('in', 'O'), ('each', 'O'), ('of', 'O'), ('the', 'O'), ('breast', 'B'), ('cancer', 'I'), ('-', 'O'), ('susceptibility', 'O'), ('genes', 'O'), (',', 'O'), ('BRCA1', 'O'), ('and', 'O'), ('BRCA2', 'O'), (',', 'O'), ('in', 'O'), ('French', 'O'), ('Canadian', 'O'), ('breast', 'B'), ('cancer', 'I'), ('and', 'O'), ('breast', 'B'), ('/', 'I'), ('ovarian', 'I'), ('cancer', 'I'), ('families', 'O'), ('from', 'O'), ('Quebec', 'O'), ('.', 'O'))"
"To identify founder effects , we examined independently ascertained French Canadian cancer families for the distribution of these eight mutations .","(('To', 'O'), ('identify', 'O'), ('founder', 'O'), ('effects', 'O'), (',', 'O'), ('we', 'O'), ('examined', 'O'), ('independently', 'O'), ('ascertained', 'O'), ('French', 'O'), ('Canadian', 'O'), ('cancer', 'B'), ('families', 'O'), ('for', 'O'), ('the', 'O'), ('distribution', 'O'), ('of', 'O'), ('these', 'O'), ('eight', 'O'), ('mutations', 'O'), ('.', 'O'))"
7x greater if one or more cases of ovarian cancer were also present in the family .,"(('7x', 'O'), ('greater', 'O'), ('if', 'O'), ('one', 'O'), ('or', 'O'), ('more', 'O'), ('cases', 'O'), ('of', 'O'), ('ovarian', 'B'), ('cancer', 'I'), ('were', 'O'), ('also', 'O'), ('present', 'O'), ('in', 'O'), ('the', 'O'), ('family', 'O'), ('.', 'O'))"
3x greater if there were at least five cases of breast cancer in the family .,"(('3x', 'O'), ('greater', 'O'), ('if', 'O'), ('there', 'O'), ('were', 'O'), ('at', 'O'), ('least', 'O'), ('five', 'O'), ('cases', 'O'), ('of', 'O'), ('breast', 'B'), ('cancer', 'I'), ('in', 'O'), ('the', 'O'), ('family', 'O'), ('.', 'O'))"
"Interestingly , the presence of a breast cancer case < 36 years of age was strongly predictive of the presence of any of the eight mutations screened .","(('Interestingly', 'O'), (',', 'O'), ('the', 'O'), ('presence', 'O'), ('of', 'O'), ('a', 'O'), ('breast', 'B'), ('cancer', 'I'), ('case', 'O'), ('<', 'O'), ('36', 'O'), ('years', 'O'), ('of', 'O'), ('age', 'O'), ('was', 'O'), ('strongly', 'O'), ('predictive', 'O'), ('of', 'O'), ('the', 'O'), ('presence', 'O'), ('of', 'O'), ('any', 'O'), ('of', 'O'), ('the', 'O'), ('eight', 'O'), ('mutations', 'O'), ('screened', 'O'), ('.', 'O'))"
The identification of common BRCA1 and BRCA2 mutations will facilitate carrier detection in French Canadian breast cancer and breast / ovarian cancer families .,"(('The', 'O'), ('identification', 'O'), ('of', 'O'), ('common', 'O'), ('BRCA1', 'O'), ('and', 'O'), ('BRCA2', 'O'), ('mutations', 'O'), ('will', 'O'), ('facilitate', 'O'), ('carrier', 'O'), ('detection', 'O'), ('in', 'O'), ('French', 'O'), ('Canadian', 'O'), ('breast', 'B'), ('cancer', 'I'), ('and', 'O'), ('breast', 'B'), ('/', 'I'), ('ovarian', 'I'), ('cancer', 'I'), ('families', 'O'), ('.', 'O'))"
Are Dp71 and Dp140 brain dystrophin isoforms related to cognitive impairment in Duchenne muscular dystrophy ?,"(('Are', 'O'), ('Dp71', 'O'), ('and', 'O'), ('Dp140', 'O'), ('brain', 'O'), ('dystrophin', 'O'), ('isoforms', 'O'), ('related', 'O'), ('to', 'O'), ('cognitive', 'B'), ('impairment', 'I'), ('in', 'O'), ('Duchenne', 'B'), ('muscular', 'I'), ('dystrophy', 'I'), ('?', 'O'))"
Molecular study and neuropsychological analysis were performed concurrently on 49 patients with Duchenne muscular dystrophy ( DMD ) in order to find a molecular explanation for the cognitive impairment observed in most DMD patients .,"(('Molecular', 'O'), ('study', 'O'), ('and', 'O'), ('neuropsychological', 'O'), ('analysis', 'O'), ('were', 'O'), ('performed', 'O'), ('concurrently', 'O'), ('on', 'O'), ('49', 'O'), ('patients', 'O'), ('with', 'O'), ('Duchenne', 'B'), ('muscular', 'I'), ('dystrophy', 'I'), ('(', 'O'), ('DMD', 'B'), (')', 'O'), ('in', 'O'), ('order', 'O'), ('to', 'O'), ('find', 'O'), ('a', 'O'), ('molecular', 'O'), ('explanation', 'O'), ('for', 'O'), ('the', 'O'), ('cognitive', 'B'), ('impairment', 'I'), ('observed', 'O'), ('in', 'O'), ('most', 'O'), ('DMD', 'B'), ('patients', 'O'), ('.', 'O'))"
Complete analysis of the dystrophin gene was performed to define the localization of deletions and duplications in relation to the different DMD promoters .,"(('Complete', 'O'), ('analysis', 'O'), ('of', 'O'), ('the', 'O'), ('dystrophin', 'O'), ('gene', 'O'), ('was', 'O'), ('performed', 'O'), ('to', 'O'), ('define', 'O'), ('the', 'O'), ('localization', 'O'), ('of', 'O'), ('deletions', 'O'), ('and', 'O'), ('duplications', 'O'), ('in', 'O'), ('relation', 'O'), ('to', 'O'), ('the', 'O'), ('different', 'O'), ('DMD', 'B'), ('promoters', 'O'), ('.', 'O'))"
Comparison of molecular and psychometric findings demonstrated that deletions and duplications that were localized in the distal part of the gene seemed to be preferentially associated with cognitive impairment .,"(('Comparison', 'O'), ('of', 'O'), ('molecular', 'O'), ('and', 'O'), ('psychometric', 'O'), ('findings', 'O'), ('demonstrated', 'O'), ('that', 'O'), ('deletions', 'O'), ('and', 'O'), ('duplications', 'O'), ('that', 'O'), ('were', 'O'), ('localized', 'O'), ('in', 'O'), ('the', 'O'), ('distal', 'O'), ('part', 'O'), ('of', 'O'), ('the', 'O'), ('gene', 'O'), ('seemed', 'O'), ('to', 'O'), ('be', 'O'), ('preferentially', 'O'), ('associated', 'O'), ('with', 'O'), ('cognitive', 'B'), ('impairment', 'I'), ('.', 'O'))"
Two altered Dp71 transcripts and two deleted Dp140 DNA sequences were found in four patients with severe cerebral dysfunction .,"(('Two', 'O'), ('altered', 'O'), ('Dp71', 'O'), ('transcripts', 'O'), ('and', 'O'), ('two', 'O'), ('deleted', 'O'), ('Dp140', 'O'), ('DNA', 'O'), ('sequences', 'O'), ('were', 'O'), ('found', 'O'), ('in', 'O'), ('four', 'O'), ('patients', 'O'), ('with', 'O'), ('severe', 'O'), ('cerebral', 'B'), ('dysfunction', 'I'), ('.', 'O'))"
"These findings suggest that some sequences located in the distal part of the gene and , in particular , some DMD isoforms expressed in the brain may be related to the cognitive impairment associated with DMD . .","(('These', 'O'), ('findings', 'O'), ('suggest', 'O'), ('that', 'O'), ('some', 'O'), ('sequences', 'O'), ('located', 'O'), ('in', 'O'), ('the', 'O'), ('distal', 'O'), ('part', 'O'), ('of', 'O'), ('the', 'O'), ('gene', 'O'), ('and', 'O'), (',', 'O'), ('in', 'O'), ('particular', 'O'), (',', 'O'), ('some', 'O'), ('DMD', 'B'), ('isoforms', 'O'), ('expressed', 'O'), ('in', 'O'), ('the', 'O'), ('brain', 'O'), ('may', 'O'), ('be', 'O'), ('related', 'O'), ('to', 'O'), ('the', 'O'), ('cognitive', 'B'), ('impairment', 'I'), ('associated', 'O'), ('with', 'O'), ('DMD', 'B'), ('.', 'O'), ('.', 'O'))"
I1307K APC and hMLH1 mutations in a non - Jewish family with hereditary non - polyposis colorectal cancer .,"(('I1307K', 'O'), ('APC', 'O'), ('and', 'O'), ('hMLH1', 'O'), ('mutations', 'O'), ('in', 'O'), ('a', 'O'), ('non', 'O'), ('-', 'O'), ('Jewish', 'O'), ('family', 'O'), ('with', 'O'), ('hereditary', 'B'), ('non', 'I'), ('-', 'I'), ('polyposis', 'I'), ('colorectal', 'I'), ('cancer', 'I'), ('.', 'O'))"
We describe a French Canadian hereditary non - polyposis colorectal cancer ( HNPCC ) kindred which carries a novel truncating mutation in hMLH1 .,"(('We', 'O'), ('describe', 'O'), ('a', 'O'), ('French', 'O'), ('Canadian', 'O'), ('hereditary', 'B'), ('non', 'I'), ('-', 'I'), ('polyposis', 'I'), ('colorectal', 'I'), ('cancer', 'I'), ('(', 'O'), ('HNPCC', 'B'), (')', 'O'), ('kindred', 'O'), ('which', 'O'), ('carries', 'O'), ('a', 'O'), ('novel', 'O'), ('truncating', 'O'), ('mutation', 'O'), ('in', 'O'), ('hMLH1', 'O'), ('.', 'O'))"
"Interestingly , the I1307K APC polymorphism , associated with an increased risk of colorectal cancer , is also present in this family .","(('Interestingly', 'O'), (',', 'O'), ('the', 'O'), ('I1307K', 'O'), ('APC', 'O'), ('polymorphism', 'O'), (',', 'O'), ('associated', 'O'), ('with', 'O'), ('an', 'O'), ('increased', 'O'), ('risk', 'O'), ('of', 'O'), ('colorectal', 'B'), ('cancer', 'I'), (',', 'O'), ('is', 'O'), ('also', 'O'), ('present', 'O'), ('in', 'O'), ('this', 'O'), ('family', 'O'), ('.', 'O'))"
"In addition , in this family , there appears to be no relationship between the I1307K polymorphism and the presence or absence of cancer . .","(('In', 'O'), ('addition', 'O'), (',', 'O'), ('in', 'O'), ('this', 'O'), ('family', 'O'), (',', 'O'), ('there', 'O'), ('appears', 'O'), ('to', 'O'), ('be', 'O'), ('no', 'O'), ('relationship', 'O'), ('between', 'O'), ('the', 'O'), ('I1307K', 'O'), ('polymorphism', 'O'), ('and', 'O'), ('the', 'O'), ('presence', 'O'), ('or', 'O'), ('absence', 'O'), ('of', 'O'), ('cancer', 'B'), ('.', 'O'), ('.', 'O'))"
Identification of a novel mutation of the CPO gene in a Japanese hereditary coproporphyria family .,"(('Identification', 'O'), ('of', 'O'), ('a', 'O'), ('novel', 'O'), ('mutation', 'O'), ('of', 'O'), ('the', 'O'), ('CPO', 'O'), ('gene', 'O'), ('in', 'O'), ('a', 'O'), ('Japanese', 'O'), ('hereditary', 'B'), ('coproporphyria', 'I'), ('family', 'O'), ('.', 'O'))"
Hereditary coproporphyria ( HCP ) is an autosomal dominant disease characterized by a deficiency of coproporphyrinogen oxidase ( CPO ) caused by a mutation in the CPO gene .,"(('Hereditary', 'B'), ('coproporphyria', 'I'), ('(', 'O'), ('HCP', 'B'), (')', 'O'), ('is', 'O'), ('an', 'O'), ('autosomal', 'B'), ('dominant', 'I'), ('disease', 'I'), ('characterized', 'O'), ('by', 'O'), ('a', 'O'), ('deficiency', 'B'), ('of', 'I'), ('coproporphyrinogen', 'I'), ('oxidase', 'I'), ('(', 'O'), ('CPO', 'O'), (')', 'O'), ('caused', 'O'), ('by', 'O'), ('a', 'O'), ('mutation', 'O'), ('in', 'O'), ('the', 'O'), ('CPO', 'O'), ('gene', 'O'), ('.', 'O'))"
Human complement factor H deficiency associated with hemolytic uremic syndrome .,"(('Human', 'B'), ('complement', 'I'), ('factor', 'I'), ('H', 'I'), ('deficiency', 'I'), ('associated', 'O'), ('with', 'O'), ('hemolytic', 'B'), ('uremic', 'I'), ('syndrome', 'I'), ('.', 'O'))"
This study reports on six cases of deficiency in the human complement regulatory protein Factor H ( FH ) in the context of an acute renal disease .,"(('This', 'O'), ('study', 'O'), ('reports', 'O'), ('on', 'O'), ('six', 'O'), ('cases', 'O'), ('of', 'O'), ('deficiency', 'B'), ('in', 'I'), ('the', 'I'), ('human', 'I'), ('complement', 'I'), ('regulatory', 'I'), ('protein', 'I'), ('Factor', 'I'), ('H', 'I'), ('(', 'O'), ('FH', 'O'), (')', 'O'), ('in', 'O'), ('the', 'O'), ('context', 'O'), ('of', 'O'), ('an', 'O'), ('acute', 'B'), ('renal', 'I'), ('disease', 'I'), ('.', 'O'))"
Five of the cases were observed in children presenting with idiopathic hemolytic uremic syndrome ( HUS ) .,"(('Five', 'O'), ('of', 'O'), ('the', 'O'), ('cases', 'O'), ('were', 'O'), ('observed', 'O'), ('in', 'O'), ('children', 'O'), ('presenting', 'O'), ('with', 'O'), ('idiopathic', 'O'), ('hemolytic', 'B'), ('uremic', 'I'), ('syndrome', 'I'), ('(', 'O'), ('HUS', 'B'), (')', 'O'), ('.', 'O'))"
Factor H deficiency is the only complement deficiency associated with HUS .,"(('Factor', 'B'), ('H', 'I'), ('deficiency', 'I'), ('is', 'O'), ('the', 'O'), ('only', 'O'), ('complement', 'B'), ('deficiency', 'I'), ('associated', 'O'), ('with', 'O'), ('HUS', 'B'), ('.', 'O'))"
Further evidence for a major ancient mutation underlying myotonic dystrophy from linkage disequilibrium studies in the Japanese population .,"(('Further', 'O'), ('evidence', 'O'), ('for', 'O'), ('a', 'O'), ('major', 'O'), ('ancient', 'O'), ('mutation', 'O'), ('underlying', 'O'), ('myotonic', 'B'), ('dystrophy', 'I'), ('from', 'O'), ('linkage', 'O'), ('disequilibrium', 'O'), ('studies', 'O'), ('in', 'O'), ('the', 'O'), ('Japanese', 'O'), ('population', 'O'), ('.', 'O'))"
"The myotonic dystrophy ( DM ) mutation is an unstable ( CTG ) n repeat , present at a copy number of 5 - 37 repeats on normal chromosomes but amplified to 50 - 3000 copies on DM chromosomes .","(('The', 'O'), ('myotonic', 'B'), ('dystrophy', 'I'), ('(', 'O'), ('DM', 'B'), (')', 'O'), ('mutation', 'O'), ('is', 'O'), ('an', 'O'), ('unstable', 'O'), ('(', 'O'), ('CTG', 'O'), (')', 'O'), ('n', 'O'), ('repeat', 'O'), (',', 'O'), ('present', 'O'), ('at', 'O'), ('a', 'O'), ('copy', 'O'), ('number', 'O'), ('of', 'O'), ('5', 'O'), ('-', 'O'), ('37', 'O'), ('repeats', 'O'), ('on', 'O'), ('normal', 'O'), ('chromosomes', 'O'), ('but', 'O'), ('amplified', 'O'), ('to', 'O'), ('50', 'O'), ('-', 'O'), ('3000', 'O'), ('copies', 'O'), ('on', 'O'), ('DM', 'B'), ('chromosomes', 'O'), ('.', 'O'))"
Previous findings in Caucasian populations of a DM founder chromosome raise a question about the molecular events involved in the expansion mutation .,"(('Previous', 'O'), ('findings', 'O'), ('in', 'O'), ('Caucasian', 'O'), ('populations', 'O'), ('of', 'O'), ('a', 'O'), ('DM', 'B'), ('founder', 'O'), ('chromosome', 'O'), ('raise', 'O'), ('a', 'O'), ('question', 'O'), ('about', 'O'), ('the', 'O'), ('molecular', 'O'), ('events', 'O'), ('involved', 'O'), ('in', 'O'), ('the', 'O'), ('expansion', 'O'), ('mutation', 'O'), ('.', 'O'))"
"To investigate whether a founder chromosome for the DM mutation exists in the Japanese population , we genotyped families using polymorphic markers near the ( CTG ) n repeat region and constructed haplotypes .","(('To', 'O'), ('investigate', 'O'), ('whether', 'O'), ('a', 'O'), ('founder', 'O'), ('chromosome', 'O'), ('for', 'O'), ('the', 'O'), ('DM', 'B'), ('mutation', 'O'), ('exists', 'O'), ('in', 'O'), ('the', 'O'), ('Japanese', 'O'), ('population', 'O'), (',', 'O'), ('we', 'O'), ('genotyped', 'O'), ('families', 'O'), ('using', 'O'), ('polymorphic', 'O'), ('markers', 'O'), ('near', 'O'), ('the', 'O'), ('(', 'O'), ('CTG', 'O'), (')', 'O'), ('n', 'O'), ('repeat', 'O'), ('region', 'O'), ('and', 'O'), ('constructed', 'O'), ('haplotypes', 'O'), ('.', 'O'))"
Six different haplotypes were found and DM alleles were always haplotype A .,"(('Six', 'O'), ('different', 'O'), ('haplotypes', 'O'), ('were', 'O'), ('found', 'O'), ('and', 'O'), ('DM', 'B'), ('alleles', 'O'), ('were', 'O'), ('always', 'O'), ('haplotype', 'O'), ('A', 'O'), ('.', 'O'))"
To find an origin of the ( CTG ) n repeat mutation and to investigate the mechanism of the expansion mutation in the Japanese population we have studied 90 Japanese DM families comprising 190 affected and 130 unaffected members .,"(('To', 'O'), ('find', 'O'), ('an', 'O'), ('origin', 'O'), ('of', 'O'), ('the', 'O'), ('(', 'O'), ('CTG', 'O'), (')', 'O'), ('n', 'O'), ('repeat', 'O'), ('mutation', 'O'), ('and', 'O'), ('to', 'O'), ('investigate', 'O'), ('the', 'O'), ('mechanism', 'O'), ('of', 'O'), ('the', 'O'), ('expansion', 'O'), ('mutation', 'O'), ('in', 'O'), ('the', 'O'), ('Japanese', 'O'), ('population', 'O'), ('we', 'O'), ('have', 'O'), ('studied', 'O'), ('90', 'O'), ('Japanese', 'O'), ('DM', 'B'), ('families', 'O'), ('comprising', 'O'), ('190', 'O'), ('affected', 'O'), ('and', 'O'), ('130', 'O'), ('unaffected', 'O'), ('members', 'O'), ('.', 'O'))"
These data support multistep models of triplet repeat expansion that have been proposed for both DM and Friedreichs ataxia . .,"(('These', 'O'), ('data', 'O'), ('support', 'O'), ('multistep', 'O'), ('models', 'O'), ('of', 'O'), ('triplet', 'O'), ('repeat', 'O'), ('expansion', 'O'), ('that', 'O'), ('have', 'O'), ('been', 'O'), ('proposed', 'O'), ('for', 'O'), ('both', 'O'), ('DM', 'B'), ('and', 'O'), ('Friedreichs', 'B'), ('ataxia', 'I'), ('.', 'O'), ('.', 'O'))"
"The molecular basis of C6 deficiency in the western Cape , South Africa .","(('The', 'O'), ('molecular', 'O'), ('basis', 'O'), ('of', 'O'), ('C6', 'B'), ('deficiency', 'I'), ('in', 'O'), ('the', 'O'), ('western', 'O'), ('Cape', 'O'), (',', 'O'), ('South', 'O'), ('Africa', 'O'), ('.', 'O'))"
"Deficiency of the sixth component of human complement ( C6 ) has been reported in a number of families from the western Cape , South Africa .","(('Deficiency', 'B'), ('of', 'I'), ('the', 'I'), ('sixth', 'I'), ('component', 'I'), ('of', 'I'), ('human', 'I'), ('complement', 'I'), ('(', 'O'), ('C6', 'O'), (')', 'O'), ('has', 'O'), ('been', 'O'), ('reported', 'O'), ('in', 'O'), ('a', 'O'), ('number', 'O'), ('of', 'O'), ('families', 'O'), ('from', 'O'), ('the', 'O'), ('western', 'O'), ('Cape', 'O'), (',', 'O'), ('South', 'O'), ('Africa', 'O'), ('.', 'O'))"
Meningococcal disease is endemic in the Cape and almost all pedigrees of total C6 deficiency ( C6Q0 ) have been ascertained because of recurrent disease .,"(('Meningococcal', 'B'), ('disease', 'I'), ('is', 'O'), ('endemic', 'O'), ('in', 'O'), ('the', 'O'), ('Cape', 'O'), ('and', 'O'), ('almost', 'O'), ('all', 'O'), ('pedigrees', 'O'), ('of', 'O'), ('total', 'O'), ('C6', 'B'), ('deficiency', 'I'), ('(', 'O'), ('C6Q0', 'O'), (')', 'O'), ('have', 'O'), ('been', 'O'), ('ascertained', 'O'), ('because', 'O'), ('of', 'O'), ('recurrent', 'O'), ('disease', 'O'), ('.', 'O'))"
"We have also observed the 879delG defect in two Dutch C6 - deficient kindreds , but the 879delG defect in the Cape probably did not come from The Netherlands . .","(('We', 'O'), ('have', 'O'), ('also', 'O'), ('observed', 'O'), ('the', 'O'), ('879delG', 'O'), ('defect', 'O'), ('in', 'O'), ('two', 'O'), ('Dutch', 'O'), ('C6', 'B'), ('-', 'I'), ('deficient', 'I'), ('kindreds', 'O'), (',', 'O'), ('but', 'O'), ('the', 'O'), ('879delG', 'O'), ('defect', 'O'), ('in', 'O'), ('the', 'O'), ('Cape', 'O'), ('probably', 'O'), ('did', 'O'), ('not', 'O'), ('come', 'O'), ('from', 'O'), ('The', 'O'), ('Netherlands', 'O'), ('.', 'O'), ('.', 'O'))"
Complement C7 deficiency : seven further molecular defects and their associated marker haplotypes .,"(('Complement', 'B'), ('C7', 'I'), ('deficiency', 'I'), (':', 'O'), ('seven', 'O'), ('further', 'O'), ('molecular', 'O'), ('defects', 'O'), ('and', 'O'), ('their', 'O'), ('associated', 'O'), ('marker', 'O'), ('haplotypes', 'O'), ('.', 'O'))"
Seven further molecular bases of C7 deficiency are described .,"(('Seven', 'O'), ('further', 'O'), ('molecular', 'O'), ('bases', 'O'), ('of', 'O'), ('C7', 'B'), ('deficiency', 'I'), ('are', 'O'), ('described', 'O'), ('.', 'O'))"
The C6 / C7 marker haplotypes associated with most C7 defects are tabulated . .,"(('The', 'O'), ('C6', 'O'), ('/', 'O'), ('C7', 'O'), ('marker', 'O'), ('haplotypes', 'O'), ('associated', 'O'), ('with', 'O'), ('most', 'O'), ('C7', 'B'), ('defects', 'I'), ('are', 'O'), ('tabulated', 'O'), ('.', 'O'), ('.', 'O'))"
A genome - wide search for chromosomal loci linked to mental health wellness in relatives at high risk for bipolar affective disorder among the Old Order Amish .,"(('A', 'O'), ('genome', 'O'), ('-', 'O'), ('wide', 'O'), ('search', 'O'), ('for', 'O'), ('chromosomal', 'O'), ('loci', 'O'), ('linked', 'O'), ('to', 'O'), ('mental', 'O'), ('health', 'O'), ('wellness', 'O'), ('in', 'O'), ('relatives', 'O'), ('at', 'O'), ('high', 'O'), ('risk', 'O'), ('for', 'O'), ('bipolar', 'B'), ('affective', 'I'), ('disorder', 'I'), ('among', 'O'), ('the', 'O'), ('Old', 'O'), ('Order', 'O'), ('Amish', 'O'), ('.', 'O'))"
Bipolar affective disorder ( BPAD ; manic - depressive illness ) is characterized by episodes of mania and / or hypomania interspersed with periods of depression .,"(('Bipolar', 'B'), ('affective', 'I'), ('disorder', 'I'), ('(', 'O'), ('BPAD', 'B'), (';', 'O'), ('manic', 'B'), ('-', 'I'), ('depressive', 'I'), ('illness', 'I'), (')', 'O'), ('is', 'O'), ('characterized', 'O'), ('by', 'O'), ('episodes', 'O'), ('of', 'O'), ('mania', 'B'), ('and', 'O'), ('/', 'O'), ('or', 'O'), ('hypomania', 'B'), ('interspersed', 'O'), ('with', 'O'), ('periods', 'O'), ('of', 'O'), ('depression', 'B'), ('.', 'O'))"
Compelling evidence supports a significant genetic component in the susceptibility to develop BPAD .,"(('Compelling', 'O'), ('evidence', 'O'), ('supports', 'O'), ('a', 'O'), ('significant', 'O'), ('genetic', 'O'), ('component', 'O'), ('in', 'O'), ('the', 'O'), ('susceptibility', 'O'), ('to', 'O'), ('develop', 'O'), ('BPAD', 'B'), ('.', 'O'))"
"To date , however , linkage studies have attempted only to identify chromosomal loci that cause or increase the risk of developing BPAD .","(('To', 'O'), ('date', 'O'), (',', 'O'), ('however', 'O'), (',', 'O'), ('linkage', 'O'), ('studies', 'O'), ('have', 'O'), ('attempted', 'O'), ('only', 'O'), ('to', 'O'), ('identify', 'O'), ('chromosomal', 'O'), ('loci', 'O'), ('that', 'O'), ('cause', 'O'), ('or', 'O'), ('increase', 'O'), ('the', 'O'), ('risk', 'O'), ('of', 'O'), ('developing', 'O'), ('BPAD', 'B'), ('.', 'O'))"
"To determine whether there could be protective alleles that prevent or reduce the risk of developing BPAD , similar to what is observed in other genetic disorders , we used mental health wellness ( absence of any psychiatric disorder ) as the phenotype in our genome - wide linkage scan of several large multigeneration Old Order Amish pedigrees exhibiting an extremely high incidence of BPAD .","(('To', 'O'), ('determine', 'O'), ('whether', 'O'), ('there', 'O'), ('could', 'O'), ('be', 'O'), ('protective', 'O'), ('alleles', 'O'), ('that', 'O'), ('prevent', 'O'), ('or', 'O'), ('reduce', 'O'), ('the', 'O'), ('risk', 'O'), ('of', 'O'), ('developing', 'O'), ('BPAD', 'B'), (',', 'O'), ('similar', 'O'), ('to', 'O'), ('what', 'O'), ('is', 'O'), ('observed', 'O'), ('in', 'O'), ('other', 'O'), ('genetic', 'B'), ('disorders', 'I'), (',', 'O'), ('we', 'O'), ('used', 'O'), ('mental', 'O'), ('health', 'O'), ('wellness', 'O'), ('(', 'O'), ('absence', 'O'), ('of', 'O'), ('any', 'O'), ('psychiatric', 'B'), ('disorder', 'I'), (')', 'O'), ('as', 'O'), ('the', 'O'), ('phenotype', 'O'), ('in', 'O'), ('our', 'O'), ('genome', 'O'), ('-', 'O'), ('wide', 'O'), ('linkage', 'O'), ('scan', 'O'), ('of', 'O'), ('several', 'O'), ('large', 'O'), ('multigeneration', 'O'), ('Old', 'O'), ('Order', 'O'), ('Amish', 'O'), ('pedigrees', 'O'), ('exhibiting', 'O'), ('an', 'O'), ('extremely', 'O'), ('high', 'O'), ('incidence', 'O'), ('of', 'O'), ('BPAD', 'B'), ('.', 'O'))"
These findings are consistent with the hypothesis that certain alleles could prevent or modify the clinical manifestations of BPAD and perhaps other related affective disorders .,"(('These', 'O'), ('findings', 'O'), ('are', 'O'), ('consistent', 'O'), ('with', 'O'), ('the', 'O'), ('hypothesis', 'O'), ('that', 'O'), ('certain', 'O'), ('alleles', 'O'), ('could', 'O'), ('prevent', 'O'), ('or', 'O'), ('modify', 'O'), ('the', 'O'), ('clinical', 'O'), ('manifestations', 'O'), ('of', 'O'), ('BPAD', 'B'), ('and', 'O'), ('perhaps', 'O'), ('other', 'O'), ('related', 'O'), ('affective', 'B'), ('disorders', 'I'), ('.', 'O'))"
Segregation distortion in myotonic dystrophy .,"(('Segregation', 'O'), ('distortion', 'O'), ('in', 'O'), ('myotonic', 'B'), ('dystrophy', 'I'), ('.', 'O'))"
"Myotonic dystrophy ( DM ) is an autosomal dominant disease which , in the typical pedigree , shows a three generation anticipation cascade .","(('Myotonic', 'B'), ('dystrophy', 'I'), ('(', 'O'), ('DM', 'B'), (')', 'O'), ('is', 'O'), ('an', 'O'), ('autosomal', 'B'), ('dominant', 'I'), ('disease', 'I'), ('which', 'O'), (',', 'O'), ('in', 'O'), ('the', 'O'), ('typical', 'O'), ('pedigree', 'O'), (',', 'O'), ('shows', 'O'), ('a', 'O'), ('three', 'O'), ('generation', 'O'), ('anticipation', 'O'), ('cascade', 'O'), ('.', 'O'))"
This results in infertility and congenital myotonic dystrophy ( CDM ) with the disappearance of DM in that pedigree .,"(('This', 'O'), ('results', 'O'), ('in', 'O'), ('infertility', 'B'), ('and', 'O'), ('congenital', 'B'), ('myotonic', 'I'), ('dystrophy', 'I'), ('(', 'O'), ('CDM', 'B'), (')', 'O'), ('with', 'O'), ('the', 'O'), ('disappearance', 'O'), ('of', 'O'), ('DM', 'B'), ('in', 'O'), ('that', 'O'), ('pedigree', 'O'), ('.', 'O'))"
"The concept of segregation distortion , where there is preferential transmission of the larger allele at the DM locus , has been put forward to explain partially the maintenance of DM in the population .","(('The', 'O'), ('concept', 'O'), ('of', 'O'), ('segregation', 'O'), ('distortion', 'O'), (',', 'O'), ('where', 'O'), ('there', 'O'), ('is', 'O'), ('preferential', 'O'), ('transmission', 'O'), ('of', 'O'), ('the', 'O'), ('larger', 'O'), ('allele', 'O'), ('at', 'O'), ('the', 'O'), ('DM', 'B'), ('locus', 'O'), (',', 'O'), ('has', 'O'), ('been', 'O'), ('put', 'O'), ('forward', 'O'), ('to', 'O'), ('explain', 'O'), ('partially', 'O'), ('the', 'O'), ('maintenance', 'O'), ('of', 'O'), ('DM', 'B'), ('in', 'O'), ('the', 'O'), ('population', 'O'), ('.', 'O'))"
"In a survey of DM in Northern Ireland , 59 pedigrees were ascertained .","(('In', 'O'), ('a', 'O'), ('survey', 'O'), ('of', 'O'), ('DM', 'B'), ('in', 'O'), ('Northern', 'O'), ('Ireland', 'O'), (',', 'O'), ('59', 'O'), ('pedigrees', 'O'), ('were', 'O'), ('ascertained', 'O'), ('.', 'O'))"
Sibships where the status of all the members had been identified were examined to determine the transmission of the DM expansion from affected parents to their offspring .,"(('Sibships', 'O'), ('where', 'O'), ('the', 'O'), ('status', 'O'), ('of', 'O'), ('all', 'O'), ('the', 'O'), ('members', 'O'), ('had', 'O'), ('been', 'O'), ('identified', 'O'), ('were', 'O'), ('examined', 'O'), ('to', 'O'), ('determine', 'O'), ('the', 'O'), ('transmission', 'O'), ('of', 'O'), ('the', 'O'), ('DM', 'B'), ('expansion', 'O'), ('from', 'O'), ('affected', 'O'), ('parents', 'O'), ('to', 'O'), ('their', 'O'), ('offspring', 'O'), ('.', 'O'))"
Studies on meiotic drive in DM have shown increased transmission of the larger allele at the DM locus in non - DM heterozygotes for CTGn .,"(('Studies', 'O'), ('on', 'O'), ('meiotic', 'O'), ('drive', 'O'), ('in', 'O'), ('DM', 'B'), ('have', 'O'), ('shown', 'O'), ('increased', 'O'), ('transmission', 'O'), ('of', 'O'), ('the', 'O'), ('larger', 'O'), ('allele', 'O'), ('at', 'O'), ('the', 'O'), ('DM', 'B'), ('locus', 'O'), ('in', 'O'), ('non', 'O'), ('-', 'O'), ('DM', 'O'), ('heterozygotes', 'O'), ('for', 'O'), ('CTGn', 'O'), ('.', 'O'))"
This study provides further evidence that the DM expansion tends to be transmitted preferentially .,"(('This', 'O'), ('study', 'O'), ('provides', 'O'), ('further', 'O'), ('evidence', 'O'), ('that', 'O'), ('the', 'O'), ('DM', 'B'), ('expansion', 'O'), ('tends', 'O'), ('to', 'O'), ('be', 'O'), ('transmitted', 'O'), ('preferentially', 'O'), ('.', 'O'))"
Diagnosis of hemochromatosis .,"(('Diagnosis', 'O'), ('of', 'O'), ('hemochromatosis', 'B'), ('.', 'O'))"
"If untreated , hemochromatosis can cause serious illness and early death , but the disease is still substantially under - diagnosed .","(('If', 'O'), ('untreated', 'O'), (',', 'O'), ('hemochromatosis', 'B'), ('can', 'O'), ('cause', 'O'), ('serious', 'O'), ('illness', 'O'), ('and', 'O'), ('early', 'B'), ('death', 'I'), (',', 'O'), ('but', 'O'), ('the', 'O'), ('disease', 'O'), ('is', 'O'), ('still', 'O'), ('substantially', 'O'), ('under', 'O'), ('-', 'O'), ('diagnosed', 'O'), ('.', 'O'))"
"Once the diagnosis is suspected , physicians must use serum ferritin levels and hepatic iron stores on liver biopsy specimens to assess patients for the presence of iron overload .","(('Once', 'O'), ('the', 'O'), ('diagnosis', 'O'), ('is', 'O'), ('suspected', 'O'), (',', 'O'), ('physicians', 'O'), ('must', 'O'), ('use', 'O'), ('serum', 'O'), ('ferritin', 'O'), ('levels', 'O'), ('and', 'O'), ('hepatic', 'O'), ('iron', 'O'), ('stores', 'O'), ('on', 'O'), ('liver', 'O'), ('biopsy', 'O'), ('specimens', 'O'), ('to', 'O'), ('assess', 'O'), ('patients', 'O'), ('for', 'O'), ('the', 'O'), ('presence', 'O'), ('of', 'O'), ('iron', 'B'), ('overload', 'I'), ('.', 'O'))"
"Liver biopsy is also used to establish the presence or absence of cirrhosis , which can affect prognosis and management .","(('Liver', 'O'), ('biopsy', 'O'), ('is', 'O'), ('also', 'O'), ('used', 'O'), ('to', 'O'), ('establish', 'O'), ('the', 'O'), ('presence', 'O'), ('or', 'O'), ('absence', 'O'), ('of', 'O'), ('cirrhosis', 'B'), (',', 'O'), ('which', 'O'), ('can', 'O'), ('affect', 'O'), ('prognosis', 'O'), ('and', 'O'), ('management', 'O'), ('.', 'O'))"
"A DNA - based test for the HFE gene is commercially available , but its place in the diagnosis of hemochromatosis is still being evaluated .","(('A', 'O'), ('DNA', 'O'), ('-', 'O'), ('based', 'O'), ('test', 'O'), ('for', 'O'), ('the', 'O'), ('HFE', 'O'), ('gene', 'O'), ('is', 'O'), ('commercially', 'O'), ('available', 'O'), (',', 'O'), ('but', 'O'), ('its', 'O'), ('place', 'O'), ('in', 'O'), ('the', 'O'), ('diagnosis', 'O'), ('of', 'O'), ('hemochromatosis', 'B'), ('is', 'O'), ('still', 'O'), ('being', 'O'), ('evaluated', 'O'), ('.', 'O'))"
"Currently , the most useful role for this test is in the detection of hemochromatosis in the family members of patients with a proven case of the disease .","(('Currently', 'O'), (',', 'O'), ('the', 'O'), ('most', 'O'), ('useful', 'O'), ('role', 'O'), ('for', 'O'), ('this', 'O'), ('test', 'O'), ('is', 'O'), ('in', 'O'), ('the', 'O'), ('detection', 'O'), ('of', 'O'), ('hemochromatosis', 'B'), ('in', 'O'), ('the', 'O'), ('family', 'O'), ('members', 'O'), ('of', 'O'), ('patients', 'O'), ('with', 'O'), ('a', 'O'), ('proven', 'O'), ('case', 'O'), ('of', 'O'), ('the', 'O'), ('disease', 'O'), ('.', 'O'))"
It is crucial to diagnose hemochromatosis before hepatic cirrhosis develops because phlebotomy therapy can avert serious chronic disease and can even lead to normal life expectancy . .,"(('It', 'O'), ('is', 'O'), ('crucial', 'O'), ('to', 'O'), ('diagnose', 'O'), ('hemochromatosis', 'B'), ('before', 'O'), ('hepatic', 'B'), ('cirrhosis', 'I'), ('develops', 'O'), ('because', 'O'), ('phlebotomy', 'O'), ('therapy', 'O'), ('can', 'O'), ('avert', 'O'), ('serious', 'O'), ('chronic', 'O'), ('disease', 'O'), ('and', 'O'), ('can', 'O'), ('even', 'O'), ('lead', 'O'), ('to', 'O'), ('normal', 'O'), ('life', 'O'), ('expectancy', 'O'), ('.', 'O'), ('.', 'O'))"
Prevalence of the I1307K APC gene variant in Israeli Jews of differing ethnic origin and risk for colorectal cancer .,"(('Prevalence', 'O'), ('of', 'O'), ('the', 'O'), ('I1307K', 'O'), ('APC', 'B'), ('gene', 'O'), ('variant', 'O'), ('in', 'O'), ('Israeli', 'O'), ('Jews', 'O'), ('of', 'O'), ('differing', 'O'), ('ethnic', 'O'), ('origin', 'O'), ('and', 'O'), ('risk', 'O'), ('for', 'O'), ('colorectal', 'B'), ('cancer', 'I'), ('.', 'O'))"
"BACKGROUND & AIMS Israeli Jews of European birth , i . e . , Ashkenazim , have the highest colorectal cancer incidence of any Israeli ethnic group .","(('BACKGROUND', 'O'), ('&', 'O'), ('AIMS', 'O'), ('Israeli', 'O'), ('Jews', 'O'), ('of', 'O'), ('European', 'O'), ('birth', 'O'), (',', 'O'), ('i', 'O'), ('.', 'O'), ('e', 'O'), ('.', 'O'), (',', 'O'), ('Ashkenazim', 'O'), (',', 'O'), ('have', 'O'), ('the', 'O'), ('highest', 'O'), ('colorectal', 'B'), ('cancer', 'I'), ('incidence', 'O'), ('of', 'O'), ('any', 'O'), ('Israeli', 'O'), ('ethnic', 'O'), ('group', 'O'), ('.', 'O'))"
The I1307K APC gene variant was found in 6 .,"(('The', 'O'), ('I1307K', 'O'), ('APC', 'B'), ('gene', 'O'), ('variant', 'O'), ('was', 'O'), ('found', 'O'), ('in', 'O'), ('6', 'O'), ('.', 'O'))"
"1 % of American Jews , 28 % of their familial colorectal cancer cases , but not in non - Jews .","(('1', 'O'), ('%', 'O'), ('of', 'O'), ('American', 'O'), ('Jews', 'O'), (',', 'O'), ('28', 'O'), ('%', 'O'), ('of', 'O'), ('their', 'O'), ('familial', 'O'), ('colorectal', 'B'), ('cancer', 'I'), ('cases', 'O'), (',', 'O'), ('but', 'O'), ('not', 'O'), ('in', 'O'), ('non', 'O'), ('-', 'O'), ('Jews', 'O'), ('.', 'O'))"
We assessed the I1307K prevalence in Israeli Jews of differing ethnic origin and risk for colorectal cancer .,"(('We', 'O'), ('assessed', 'O'), ('the', 'O'), ('I1307K', 'O'), ('prevalence', 'O'), ('in', 'O'), ('Israeli', 'O'), ('Jews', 'O'), ('of', 'O'), ('differing', 'O'), ('ethnic', 'O'), ('origin', 'O'), ('and', 'O'), ('risk', 'O'), ('for', 'O'), ('colorectal', 'B'), ('cancer', 'I'), ('.', 'O'))"
"RESULTS In persons at average risk for colorectal cancer , I1307K was found in 5 .","(('RESULTS', 'O'), ('In', 'O'), ('persons', 'O'), ('at', 'O'), ('average', 'O'), ('risk', 'O'), ('for', 'O'), ('colorectal', 'B'), ('cancer', 'I'), (',', 'O'), ('I1307K', 'O'), ('was', 'O'), ('found', 'O'), ('in', 'O'), ('5', 'O'), ('.', 'O'))"
4 % of 52 Ashkenazi Israelis with familial cancer ( P = 0 . 02 ) and was not detected in 51 non - European Jews at increased cancer risk .,"(('4', 'O'), ('%', 'O'), ('of', 'O'), ('52', 'O'), ('Ashkenazi', 'O'), ('Israelis', 'O'), ('with', 'O'), ('familial', 'O'), ('cancer', 'B'), ('(', 'O'), ('P', 'O'), ('=', 'O'), ('0', 'O'), ('.', 'O'), ('02', 'O'), (')', 'O'), ('and', 'O'), ('was', 'O'), ('not', 'O'), ('detected', 'O'), ('in', 'O'), ('51', 'O'), ('non', 'O'), ('-', 'O'), ('European', 'O'), ('Jews', 'O'), ('at', 'O'), ('increased', 'O'), ('cancer', 'B'), ('risk', 'O'), ('.', 'O'))"
"Colorectal neoplasia occurred personally or in the families of 13 of 20 Ashkenazi I1307K carriers , 8 of whom also had a personal or family history of noncolonic neoplasia .","(('Colorectal', 'B'), ('neoplasia', 'I'), ('occurred', 'O'), ('personally', 'O'), ('or', 'O'), ('in', 'O'), ('the', 'O'), ('families', 'O'), ('of', 'O'), ('13', 'O'), ('of', 'O'), ('20', 'O'), ('Ashkenazi', 'O'), ('I1307K', 'O'), ('carriers', 'O'), (',', 'O'), ('8', 'O'), ('of', 'O'), ('whom', 'O'), ('also', 'O'), ('had', 'O'), ('a', 'O'), ('personal', 'O'), ('or', 'O'), ('family', 'O'), ('history', 'O'), ('of', 'O'), ('noncolonic', 'O'), ('neoplasia', 'B'), ('.', 'O'))"
"CONCLUSIONS The I1307K APC variant may represent a susceptibility gene for colorectal , or other , cancers in Ashkenazi Jews , and partially explains the higher incidence of colorectal cancer in European Israelis .","(('CONCLUSIONS', 'O'), ('The', 'O'), ('I1307K', 'O'), ('APC', 'O'), ('variant', 'O'), ('may', 'O'), ('represent', 'O'), ('a', 'O'), ('susceptibility', 'O'), ('gene', 'O'), ('for', 'O'), ('colorectal', 'B'), (',', 'I'), ('or', 'I'), ('other', 'I'), (',', 'I'), ('cancers', 'I'), ('in', 'O'), ('Ashkenazi', 'O'), ('Jews', 'O'), (',', 'O'), ('and', 'O'), ('partially', 'O'), ('explains', 'O'), ('the', 'O'), ('higher', 'O'), ('incidence', 'O'), ('of', 'O'), ('colorectal', 'B'), ('cancer', 'I'), ('in', 'O'), ('European', 'O'), ('Israelis', 'O'), ('.', 'O'))"
Systematic analysis of coproporphyrinogen oxidase gene defects in hereditary coproporphyria and mutation update .,"(('Systematic', 'O'), ('analysis', 'O'), ('of', 'O'), ('coproporphyrinogen', 'O'), ('oxidase', 'O'), ('gene', 'O'), ('defects', 'O'), ('in', 'O'), ('hereditary', 'B'), ('coproporphyria', 'I'), ('and', 'O'), ('mutation', 'O'), ('update', 'O'), ('.', 'O'))"
Hereditary coproporphyria ( HC ) is an acute hepatic porphyria with autosomal dominant inheritance caused by deficient activity of coproporphyrinogen III oxidase ( CPO ) .,"(('Hereditary', 'B'), ('coproporphyria', 'I'), ('(', 'O'), ('HC', 'B'), (')', 'O'), ('is', 'O'), ('an', 'O'), ('acute', 'O'), ('hepatic', 'B'), ('porphyria', 'I'), ('with', 'O'), ('autosomal', 'O'), ('dominant', 'O'), ('inheritance', 'O'), ('caused', 'O'), ('by', 'O'), ('deficient', 'B'), ('activity', 'I'), ('of', 'I'), ('coproporphyrinogen', 'I'), ('III', 'I'), ('oxidase', 'I'), ('(', 'O'), ('CPO', 'O'), (')', 'O'), ('.', 'O'))"
"Clinical manifestations of the disease are characterized by acute attacks of neurological dysfunction often precipitated by drugs , fasting , cyclical hormonal changes , or infectious diseases .","(('Clinical', 'O'), ('manifestations', 'O'), ('of', 'O'), ('the', 'O'), ('disease', 'O'), ('are', 'O'), ('characterized', 'O'), ('by', 'O'), ('acute', 'O'), ('attacks', 'O'), ('of', 'O'), ('neurological', 'B'), ('dysfunction', 'I'), ('often', 'O'), ('precipitated', 'O'), ('by', 'O'), ('drugs', 'O'), (',', 'O'), ('fasting', 'O'), (',', 'O'), ('cyclical', 'O'), ('hormonal', 'O'), ('changes', 'O'), (',', 'O'), ('or', 'O'), ('infectious', 'B'), ('diseases', 'I'), ('.', 'O'))"
Five intragenic dimorphisms are now well characterized and the high degree of allelic heterogeneity in HC is demonstrated with seven new different mutations making a total of nineteen CPO gene defects reported so far . .,"(('Five', 'O'), ('intragenic', 'O'), ('dimorphisms', 'O'), ('are', 'O'), ('now', 'O'), ('well', 'O'), ('characterized', 'O'), ('and', 'O'), ('the', 'O'), ('high', 'O'), ('degree', 'O'), ('of', 'O'), ('allelic', 'O'), ('heterogeneity', 'O'), ('in', 'O'), ('HC', 'B'), ('is', 'O'), ('demonstrated', 'O'), ('with', 'O'), ('seven', 'O'), ('new', 'O'), ('different', 'O'), ('mutations', 'O'), ('making', 'O'), ('a', 'O'), ('total', 'O'), ('of', 'O'), ('nineteen', 'O'), ('CPO', 'O'), ('gene', 'B'), ('defects', 'I'), ('reported', 'O'), ('so', 'O'), ('far', 'O'), ('.', 'O'), ('.', 'O'))"
Coincidence of two novel arylsulfatase A alleles and mutation 459 + 1G > A within a family with metachromatic leukodystrophy : molecular basis of phenotypic heterogeneity .,"(('Coincidence', 'O'), ('of', 'O'), ('two', 'O'), ('novel', 'O'), ('arylsulfatase', 'O'), ('A', 'O'), ('alleles', 'O'), ('and', 'O'), ('mutation', 'O'), ('459', 'O'), ('+', 'O'), ('1G', 'O'), ('>', 'O'), ('A', 'O'), ('within', 'O'), ('a', 'O'), ('family', 'O'), ('with', 'O'), ('metachromatic', 'B'), ('leukodystrophy', 'I'), (':', 'O'), ('molecular', 'O'), ('basis', 'O'), ('of', 'O'), ('phenotypic', 'O'), ('heterogeneity', 'O'), ('.', 'O'))"
"In a family with three siblings , one developed classical late infantile metachromatic leukodystrophy ( MLD ) , fatal at age 5 years , with deficient arylsulfatase A ( ARSA ) activity and increased galactosylsulfatide ( GS ) excretion .","(('In', 'O'), ('a', 'O'), ('family', 'O'), ('with', 'O'), ('three', 'O'), ('siblings', 'O'), (',', 'O'), ('one', 'O'), ('developed', 'O'), ('classical', 'O'), ('late', 'O'), ('infantile', 'O'), ('metachromatic', 'B'), ('leukodystrophy', 'I'), ('(', 'O'), ('MLD', 'B'), (')', 'O'), (',', 'O'), ('fatal', 'O'), ('at', 'O'), ('age', 'O'), ('5', 'O'), ('years', 'O'), (',', 'O'), ('with', 'O'), ('deficient', 'O'), ('arylsulfatase', 'O'), ('A', 'O'), ('(', 'O'), ('ARSA', 'O'), (')', 'O'), ('activity', 'O'), ('and', 'O'), ('increased', 'O'), ('galactosylsulfatide', 'O'), ('(', 'O'), ('GS', 'O'), (')', 'O'), ('excretion', 'O'), ('.', 'O'))"
"The two other siblings , apparently healthy at 12 ( 1 / 2 ) and 15 years , respectively , and their father , apparently healthy as well , presented ARSA and GS values within the range of MLD patients .","(('The', 'O'), ('two', 'O'), ('other', 'O'), ('siblings', 'O'), (',', 'O'), ('apparently', 'O'), ('healthy', 'O'), ('at', 'O'), ('12', 'O'), ('(', 'O'), ('1', 'O'), ('/', 'O'), ('2', 'O'), (')', 'O'), ('and', 'O'), ('15', 'O'), ('years', 'O'), (',', 'O'), ('respectively', 'O'), (',', 'O'), ('and', 'O'), ('their', 'O'), ('father', 'O'), (',', 'O'), ('apparently', 'O'), ('healthy', 'O'), ('as', 'O'), ('well', 'O'), (',', 'O'), ('presented', 'O'), ('ARSA', 'O'), ('and', 'O'), ('GS', 'O'), ('values', 'O'), ('within', 'O'), ('the', 'O'), ('range', 'O'), ('of', 'O'), ('MLD', 'B'), ('patients', 'O'), ('.', 'O'))"
Mutation A464V was not found in 18 unrelated MLD patients and 50 controls .,"(('Mutation', 'O'), ('A464V', 'O'), ('was', 'O'), ('not', 'O'), ('found', 'O'), ('in', 'O'), ('18', 'O'), ('unrelated', 'O'), ('MLD', 'B'), ('patients', 'O'), ('and', 'O'), ('50', 'O'), ('controls', 'O'), ('.', 'O'))"
"A464V , although clearly modifying ARSA and GS levels , apparently bears little significance for clinical manifestation of MLD , mimicking the frequent ARSA pseudodeficiency allele .","(('A464V', 'O'), (',', 'O'), ('although', 'O'), ('clearly', 'O'), ('modifying', 'O'), ('ARSA', 'O'), ('and', 'O'), ('GS', 'O'), ('levels', 'O'), (',', 'O'), ('apparently', 'O'), ('bears', 'O'), ('little', 'O'), ('significance', 'O'), ('for', 'O'), ('clinical', 'O'), ('manifestation', 'O'), ('of', 'O'), ('MLD', 'B'), (',', 'O'), ('mimicking', 'O'), ('the', 'O'), ('frequent', 'O'), ('ARSA', 'O'), ('pseudodeficiency', 'O'), ('allele', 'O'), ('.', 'O'))"
"Our results demonstrate that in certain genetic conditions MLD - like ARSA and GS values need not be paralleled by clinical disease , a finding with serious diagnostic and prognostic implications .","(('Our', 'O'), ('results', 'O'), ('demonstrate', 'O'), ('that', 'O'), ('in', 'O'), ('certain', 'O'), ('genetic', 'O'), ('conditions', 'O'), ('MLD', 'B'), ('-', 'O'), ('like', 'O'), ('ARSA', 'O'), ('and', 'O'), ('GS', 'O'), ('values', 'O'), ('need', 'O'), ('not', 'O'), ('be', 'O'), ('paralleled', 'O'), ('by', 'O'), ('clinical', 'O'), ('disease', 'O'), (',', 'O'), ('a', 'O'), ('finding', 'O'), ('with', 'O'), ('serious', 'O'), ('diagnostic', 'O'), ('and', 'O'), ('prognostic', 'O'), ('implications', 'O'), ('.', 'O'))"
Human MLH1 deficiency predisposes to hematological malignancy and neurofibromatosis type 1 .,"(('Human', 'O'), ('MLH1', 'O'), ('deficiency', 'O'), ('predisposes', 'O'), ('to', 'O'), ('hematological', 'B'), ('malignancy', 'I'), ('and', 'O'), ('neurofibromatosis', 'B'), ('type', 'I'), ('1', 'I'), ('.', 'O'))"
Heterozygous germ - line mutations in the DNA mismatch repair genes lead to hereditary nonpolyposis colorectal cancer .,"(('Heterozygous', 'O'), ('germ', 'O'), ('-', 'O'), ('line', 'O'), ('mutations', 'O'), ('in', 'O'), ('the', 'O'), ('DNA', 'O'), ('mismatch', 'O'), ('repair', 'O'), ('genes', 'O'), ('lead', 'O'), ('to', 'O'), ('hereditary', 'B'), ('nonpolyposis', 'I'), ('colorectal', 'I'), ('cancer', 'I'), ('.', 'O'))"
"We have identified three offspring in a hereditary nonpolyposis colorectal cancer family who developed hematological malignancy at a very early age , and at least two of them displayed signs of neurofibromatosis type 1 ( NF1 ) .","(('We', 'O'), ('have', 'O'), ('identified', 'O'), ('three', 'O'), ('offspring', 'O'), ('in', 'O'), ('a', 'O'), ('hereditary', 'B'), ('nonpolyposis', 'I'), ('colorectal', 'I'), ('cancer', 'I'), ('family', 'O'), ('who', 'O'), ('developed', 'O'), ('hematological', 'B'), ('malignancy', 'I'), ('at', 'O'), ('a', 'O'), ('very', 'O'), ('early', 'O'), ('age', 'O'), (',', 'O'), ('and', 'O'), ('at', 'O'), ('least', 'O'), ('two', 'O'), ('of', 'O'), ('them', 'O'), ('displayed', 'O'), ('signs', 'O'), ('of', 'O'), ('neurofibromatosis', 'B'), ('type', 'I'), ('1', 'I'), ('(', 'O'), ('NF1', 'B'), (')', 'O'), ('.', 'O'))"
"Thus , a homozygous germ - line MLH1 mutation and consequent mismatch repair deficiency results in a mutator phenotype characterized by leukemia and / or lymphoma associated with neurofibromatosis type 1 . .","(('Thus', 'O'), (',', 'O'), ('a', 'O'), ('homozygous', 'O'), ('germ', 'O'), ('-', 'O'), ('line', 'O'), ('MLH1', 'O'), ('mutation', 'O'), ('and', 'O'), ('consequent', 'O'), ('mismatch', 'O'), ('repair', 'O'), ('deficiency', 'O'), ('results', 'O'), ('in', 'O'), ('a', 'O'), ('mutator', 'O'), ('phenotype', 'O'), ('characterized', 'O'), ('by', 'O'), ('leukemia', 'B'), ('and', 'O'), ('/', 'O'), ('or', 'O'), ('lymphoma', 'B'), ('associated', 'O'), ('with', 'O'), ('neurofibromatosis', 'B'), ('type', 'I'), ('1', 'I'), ('.', 'O'), ('.', 'O'))"
Missense mutations in the most ancient residues of the PAX6 paired domain underlie a spectrum of human congenital eye malformations .,"(('Missense', 'O'), ('mutations', 'O'), ('in', 'O'), ('the', 'O'), ('most', 'O'), ('ancient', 'O'), ('residues', 'O'), ('of', 'O'), ('the', 'O'), ('PAX6', 'O'), ('paired', 'O'), ('domain', 'O'), ('underlie', 'O'), ('a', 'O'), ('spectrum', 'O'), ('of', 'O'), ('human', 'O'), ('congenital', 'B'), ('eye', 'I'), ('malformations', 'I'), ('.', 'O'))"
"Mutations of the human PAX6 gene underlie aniridia ( congenital absence of the iris ) , a rare dominant malformation of the eye .","(('Mutations', 'O'), ('of', 'O'), ('the', 'O'), ('human', 'O'), ('PAX6', 'O'), ('gene', 'O'), ('underlie', 'O'), ('aniridia', 'B'), ('(', 'O'), ('congenital', 'B'), ('absence', 'I'), ('of', 'I'), ('the', 'I'), ('iris', 'I'), (')', 'O'), (',', 'O'), ('a', 'O'), ('rare', 'O'), ('dominant', 'O'), ('malformation', 'B'), ('of', 'I'), ('the', 'I'), ('eye', 'I'), ('.', 'O'))"
"The spectrum of PAX6 mutations in aniridia patients is highly biased , with 92 % of all reported mutations leading to premature truncation of the protein ( nonsense , splicing , insertions and deletions ) and just 2 % leading to substitution of one amino acid by another ( missense ) .","(('The', 'O'), ('spectrum', 'O'), ('of', 'O'), ('PAX6', 'O'), ('mutations', 'O'), ('in', 'O'), ('aniridia', 'B'), ('patients', 'O'), ('is', 'O'), ('highly', 'O'), ('biased', 'O'), (',', 'O'), ('with', 'O'), ('92', 'O'), ('%', 'O'), ('of', 'O'), ('all', 'O'), ('reported', 'O'), ('mutations', 'O'), ('leading', 'O'), ('to', 'O'), ('premature', 'O'), ('truncation', 'O'), ('of', 'O'), ('the', 'O'), ('protein', 'O'), ('(', 'O'), ('nonsense', 'O'), (',', 'O'), ('splicing', 'O'), (',', 'O'), ('insertions', 'O'), ('and', 'O'), ('deletions', 'O'), (')', 'O'), ('and', 'O'), ('just', 'O'), ('2', 'O'), ('%', 'O'), ('leading', 'O'), ('to', 'O'), ('substitution', 'O'), ('of', 'O'), ('one', 'O'), ('amino', 'O'), ('acid', 'O'), ('by', 'O'), ('another', 'O'), ('(', 'O'), ('missense', 'O'), (')', 'O'), ('.', 'O'))"
The extraordinary conservation of the PAX6 protein at the amino acid level amongst vertebrates predicts that pathological missense mutations should in fact be common even though they are hardly ever seen in aniridia patients .,"(('The', 'O'), ('extraordinary', 'O'), ('conservation', 'O'), ('of', 'O'), ('the', 'O'), ('PAX6', 'O'), ('protein', 'O'), ('at', 'O'), ('the', 'O'), ('amino', 'O'), ('acid', 'O'), ('level', 'O'), ('amongst', 'O'), ('vertebrates', 'O'), ('predicts', 'O'), ('that', 'O'), ('pathological', 'O'), ('missense', 'O'), ('mutations', 'O'), ('should', 'O'), ('in', 'O'), ('fact', 'O'), ('be', 'O'), ('common', 'O'), ('even', 'O'), ('though', 'O'), ('they', 'O'), ('are', 'O'), ('hardly', 'O'), ('ever', 'O'), ('seen', 'O'), ('in', 'O'), ('aniridia', 'B'), ('patients', 'O'), ('.', 'O'))"
This indicates that there is a heavy ascertainment bias in the selection of patients for PAX6 mutation analysis and that the missing PAX6 missense mutations frequently may underlie phenotypes distinct from textbook aniridia .,"(('This', 'O'), ('indicates', 'O'), ('that', 'O'), ('there', 'O'), ('is', 'O'), ('a', 'O'), ('heavy', 'O'), ('ascertainment', 'O'), ('bias', 'O'), ('in', 'O'), ('the', 'O'), ('selection', 'O'), ('of', 'O'), ('patients', 'O'), ('for', 'O'), ('PAX6', 'O'), ('mutation', 'O'), ('analysis', 'O'), ('and', 'O'), ('that', 'O'), ('the', 'O'), ('missing', 'O'), ('PAX6', 'O'), ('missense', 'O'), ('mutations', 'O'), ('frequently', 'O'), ('may', 'O'), ('underlie', 'O'), ('phenotypes', 'O'), ('distinct', 'O'), ('from', 'O'), ('textbook', 'O'), ('aniridia', 'B'), ('.', 'O'))"
"Here we present four novel PAX6 missense mutations , two in association with atypical phenotypes ectopia pupillae ( displaced pupils ) and congenital nystagmus ( searching gaze ) , and two in association with more recognizable aniridia phenotypes .","(('Here', 'O'), ('we', 'O'), ('present', 'O'), ('four', 'O'), ('novel', 'O'), ('PAX6', 'O'), ('missense', 'O'), ('mutations', 'O'), (',', 'O'), ('two', 'O'), ('in', 'O'), ('association', 'O'), ('with', 'O'), ('atypical', 'O'), ('phenotypes', 'O'), ('ectopia', 'B'), ('pupillae', 'I'), ('(', 'O'), ('displaced', 'B'), ('pupils', 'I'), (')', 'O'), ('and', 'O'), ('congenital', 'B'), ('nystagmus', 'I'), ('(', 'O'), ('searching', 'B'), ('gaze', 'I'), (')', 'O'), (',', 'O'), ('and', 'O'), ('two', 'O'), ('in', 'O'), ('association', 'O'), ('with', 'O'), ('more', 'O'), ('recognizable', 'O'), ('aniridia', 'B'), ('phenotypes', 'O'), ('.', 'O'))"
Our results support the hypothesis that the under - representation of missense mutations is caused by ascertainment bias and suggest that a substantial burden of PAX6 - related disease remains to be uncovered . .,"(('Our', 'O'), ('results', 'O'), ('support', 'O'), ('the', 'O'), ('hypothesis', 'O'), ('that', 'O'), ('the', 'O'), ('under', 'O'), ('-', 'O'), ('representation', 'O'), ('of', 'O'), ('missense', 'O'), ('mutations', 'O'), ('is', 'O'), ('caused', 'O'), ('by', 'O'), ('ascertainment', 'O'), ('bias', 'O'), ('and', 'O'), ('suggest', 'O'), ('that', 'O'), ('a', 'O'), ('substantial', 'O'), ('burden', 'O'), ('of', 'O'), ('PAX6', 'B'), ('-', 'I'), ('related', 'I'), ('disease', 'I'), ('remains', 'O'), ('to', 'O'), ('be', 'O'), ('uncovered', 'O'), ('.', 'O'), ('.', 'O'))"
"The chromosomal order of genes controlling the major histocompatibility complex , properdin factor B , and deficiency of the second component of complement .","(('The', 'O'), ('chromosomal', 'O'), ('order', 'O'), ('of', 'O'), ('genes', 'O'), ('controlling', 'O'), ('the', 'O'), ('major', 'O'), ('histocompatibility', 'O'), ('complex', 'O'), (',', 'O'), ('properdin', 'O'), ('factor', 'O'), ('B', 'O'), (',', 'O'), ('and', 'O'), ('deficiency', 'B'), ('of', 'I'), ('the', 'I'), ('second', 'I'), ('component', 'I'), ('of', 'I'), ('complement', 'I'), ('.', 'O'))"
The relationship of the genes coding for HLA to those coding for properdin Factor B allotypes and for deficiency of the second component of complement ( C2 ) was studied in families of patients with connective tissue disorders .,"(('The', 'O'), ('relationship', 'O'), ('of', 'O'), ('the', 'O'), ('genes', 'O'), ('coding', 'O'), ('for', 'O'), ('HLA', 'O'), ('to', 'O'), ('those', 'O'), ('coding', 'O'), ('for', 'O'), ('properdin', 'O'), ('Factor', 'O'), ('B', 'O'), ('allotypes', 'O'), ('and', 'O'), ('for', 'O'), ('deficiency', 'B'), ('of', 'I'), ('the', 'I'), ('second', 'I'), ('component', 'I'), ('of', 'I'), ('complement', 'I'), ('(', 'O'), ('C2', 'O'), (')', 'O'), ('was', 'O'), ('studied', 'O'), ('in', 'O'), ('families', 'O'), ('of', 'O'), ('patients', 'O'), ('with', 'O'), ('connective', 'O'), ('tissue', 'O'), ('disorders', 'O'), ('.', 'O'))"
Patients were selected because they were heterozygous or homozygous for C2 deficiency .,"(('Patients', 'O'), ('were', 'O'), ('selected', 'O'), ('because', 'O'), ('they', 'O'), ('were', 'O'), ('heterozygous', 'O'), ('or', 'O'), ('homozygous', 'O'), ('for', 'O'), ('C2', 'B'), ('deficiency', 'I'), ('.', 'O'))"
12 families with 15 matings informative for C2 deficiency were found .,"(('12', 'O'), ('families', 'O'), ('with', 'O'), ('15', 'O'), ('matings', 'O'), ('informative', 'O'), ('for', 'O'), ('C2', 'B'), ('deficiency', 'I'), ('were', 'O'), ('found', 'O'), ('.', 'O'))"
"Of 57 informative meioses , two crossovers were noted between the C2 deficiency gene and the HLA - B gene , with a recombinant fraction of 0 .","(('Of', 'O'), ('57', 'O'), ('informative', 'O'), ('meioses', 'O'), (',', 'O'), ('two', 'O'), ('crossovers', 'O'), ('were', 'O'), ('noted', 'O'), ('between', 'O'), ('the', 'O'), ('C2', 'B'), ('deficiency', 'I'), ('gene', 'O'), ('and', 'O'), ('the', 'O'), ('HLA', 'O'), ('-', 'O'), ('B', 'O'), ('gene', 'O'), (',', 'O'), ('with', 'O'), ('a', 'O'), ('recombinant', 'O'), ('fraction', 'O'), ('of', 'O'), ('0', 'O'), ('.', 'O'))"
A lod score of 13 was calculated for linkage between C2 deficiency and HLA - B at a maximum likelihood value of the recombinant fraction of 0 .,"(('A', 'O'), ('lod', 'O'), ('score', 'O'), ('of', 'O'), ('13', 'O'), ('was', 'O'), ('calculated', 'O'), ('for', 'O'), ('linkage', 'O'), ('between', 'O'), ('C2', 'B'), ('deficiency', 'I'), ('and', 'O'), ('HLA', 'O'), ('-', 'O'), ('B', 'O'), ('at', 'O'), ('a', 'O'), ('maximum', 'O'), ('likelihood', 'O'), ('value', 'O'), ('of', 'O'), ('the', 'O'), ('recombinant', 'O'), ('fraction', 'O'), ('of', 'O'), ('0', 'O'), ('.', 'O'))"
"These studies suggest that the genes for Factor B and C2 deficiency are located outside those for HLA , that the order of genese is HLA - A , - B , - D , Factor B allotype , C2 deficiency , that the genes coding for C2 deficiency and Factor B allotypes are approximately 3 - - 5 centimorgans from the HLA - A and HLA - B loci , and that the apparent lack of recombinants between the Factor B gene and C2 deficiency gene suggests that these two genes lie in close proximity to one another .","(('These', 'O'), ('studies', 'O'), ('suggest', 'O'), ('that', 'O'), ('the', 'O'), ('genes', 'O'), ('for', 'O'), ('Factor', 'O'), ('B', 'O'), ('and', 'O'), ('C2', 'B'), ('deficiency', 'I'), ('are', 'O'), ('located', 'O'), ('outside', 'O'), ('those', 'O'), ('for', 'O'), ('HLA', 'O'), (',', 'O'), ('that', 'O'), ('the', 'O'), ('order', 'O'), ('of', 'O'), ('genese', 'O'), ('is', 'O'), ('HLA', 'O'), ('-', 'O'), ('A', 'O'), (',', 'O'), ('-', 'O'), ('B', 'O'), (',', 'O'), ('-', 'O'), ('D', 'O'), (',', 'O'), ('Factor', 'O'), ('B', 'O'), ('allotype', 'O'), (',', 'O'), ('C2', 'B'), ('deficiency', 'I'), (',', 'O'), ('that', 'O'), ('the', 'O'), ('genes', 'O'), ('coding', 'O'), ('for', 'O'), ('C2', 'B'), ('deficiency', 'I'), ('and', 'O'), ('Factor', 'O'), ('B', 'O'), ('allotypes', 'O'), ('are', 'O'), ('approximately', 'O'), ('3', 'O'), ('-', 'O'), ('-', 'O'), ('5', 'O'), ('centimorgans', 'O'), ('from', 'O'), ('the', 'O'), ('HLA', 'O'), ('-', 'O'), ('A', 'O'), ('and', 'O'), ('HLA', 'O'), ('-', 'O'), ('B', 'O'), ('loci', 'O'), (',', 'O'), ('and', 'O'), ('that', 'O'), ('the', 'O'), ('apparent', 'O'), ('lack', 'O'), ('of', 'O'), ('recombinants', 'O'), ('between', 'O'), ('the', 'O'), ('Factor', 'O'), ('B', 'O'), ('gene', 'O'), ('and', 'O'), ('C2', 'B'), ('deficiency', 'I'), ('gene', 'O'), ('suggests', 'O'), ('that', 'O'), ('these', 'O'), ('two', 'O'), ('genes', 'O'), ('lie', 'O'), ('in', 'O'), ('close', 'O'), ('proximity', 'O'), ('to', 'O'), ('one', 'O'), ('another', 'O'), ('.', 'O'))"
Distribution of emerin and lamins in the heart and implications for Emery - Dreifuss muscular dystrophy .,"(('Distribution', 'O'), ('of', 'O'), ('emerin', 'O'), ('and', 'O'), ('lamins', 'O'), ('in', 'O'), ('the', 'O'), ('heart', 'O'), ('and', 'O'), ('implications', 'O'), ('for', 'O'), ('Emery', 'B'), ('-', 'I'), ('Dreifuss', 'I'), ('muscular', 'I'), ('dystrophy', 'I'), ('.', 'O'))"
Emerin is a nuclear membrane protein which is missing or defective in Emery - Dreifuss muscular dystrophy ( EDMD ) .,"(('Emerin', 'O'), ('is', 'O'), ('a', 'O'), ('nuclear', 'O'), ('membrane', 'O'), ('protein', 'O'), ('which', 'O'), ('is', 'O'), ('missing', 'O'), ('or', 'O'), ('defective', 'O'), ('in', 'O'), ('Emery', 'B'), ('-', 'I'), ('Dreifuss', 'I'), ('muscular', 'I'), ('dystrophy', 'I'), ('(', 'O'), ('EDMD', 'B'), (')', 'O'), ('.', 'O'))"
"These results would not be expected if immunostaining at intercalated discs were due to a product of the emerin gene and , therefore , cast some doubt upon the hypothesis that cardiac defects in EDMD are caused by absence of emerin from intercalated discs .","(('These', 'O'), ('results', 'O'), ('would', 'O'), ('not', 'O'), ('be', 'O'), ('expected', 'O'), ('if', 'O'), ('immunostaining', 'O'), ('at', 'O'), ('intercalated', 'O'), ('discs', 'O'), ('were', 'O'), ('due', 'O'), ('to', 'O'), ('a', 'O'), ('product', 'O'), ('of', 'O'), ('the', 'O'), ('emerin', 'O'), ('gene', 'O'), ('and', 'O'), (',', 'O'), ('therefore', 'O'), (',', 'O'), ('cast', 'O'), ('some', 'O'), ('doubt', 'O'), ('upon', 'O'), ('the', 'O'), ('hypothesis', 'O'), ('that', 'O'), ('cardiac', 'B'), ('defects', 'I'), ('in', 'O'), ('EDMD', 'B'), ('are', 'O'), ('caused', 'O'), ('by', 'O'), ('absence', 'O'), ('of', 'O'), ('emerin', 'O'), ('from', 'O'), ('intercalated', 'O'), ('discs', 'O'), ('.', 'O'))"
"This distribution of emerin was similar to that of lamin A , a candidate gene for an autosomal form of EDMD .","(('This', 'O'), ('distribution', 'O'), ('of', 'O'), ('emerin', 'O'), ('was', 'O'), ('similar', 'O'), ('to', 'O'), ('that', 'O'), ('of', 'O'), ('lamin', 'O'), ('A', 'O'), (',', 'O'), ('a', 'O'), ('candidate', 'O'), ('gene', 'O'), ('for', 'O'), ('an', 'O'), ('autosomal', 'O'), ('form', 'O'), ('of', 'O'), ('EDMD', 'B'), ('.', 'O'))"
"In EDMD , the additional absence of lamin B1 from heart and skeletal muscle nuclei which already lack emerin may offer an alternative explanation of why these tissues are particularly affected . .","(('In', 'O'), ('EDMD', 'B'), (',', 'O'), ('the', 'O'), ('additional', 'O'), ('absence', 'O'), ('of', 'O'), ('lamin', 'O'), ('B1', 'O'), ('from', 'O'), ('heart', 'O'), ('and', 'O'), ('skeletal', 'O'), ('muscle', 'O'), ('nuclei', 'O'), ('which', 'O'), ('already', 'O'), ('lack', 'O'), ('emerin', 'O'), ('may', 'O'), ('offer', 'O'), ('an', 'O'), ('alternative', 'O'), ('explanation', 'O'), ('of', 'O'), ('why', 'O'), ('these', 'O'), ('tissues', 'O'), ('are', 'O'), ('particularly', 'O'), ('affected', 'O'), ('.', 'O'), ('.', 'O'))"
"Genetic mapping of the copper toxicosis locus in Bedlington terriers to dog chromosome 10 , in a region syntenic to human chromosome region 2p13 - p16 .","(('Genetic', 'O'), ('mapping', 'O'), ('of', 'O'), ('the', 'O'), ('copper', 'B'), ('toxicosis', 'I'), ('locus', 'O'), ('in', 'O'), ('Bedlington', 'O'), ('terriers', 'O'), ('to', 'O'), ('dog', 'O'), ('chromosome', 'O'), ('10', 'O'), (',', 'O'), ('in', 'O'), ('a', 'O'), ('region', 'O'), ('syntenic', 'O'), ('to', 'O'), ('human', 'O'), ('chromosome', 'O'), ('region', 'O'), ('2p13', 'O'), ('-', 'O'), ('p16', 'O'), ('.', 'O'))"
"Abnormal hepatic copper accumulation is recognized as an inherited disorder in man , mouse , rat and dog .","(('Abnormal', 'O'), ('hepatic', 'B'), ('copper', 'I'), ('accumulation', 'I'), ('is', 'O'), ('recognized', 'O'), ('as', 'O'), ('an', 'O'), ('inherited', 'B'), ('disorder', 'I'), ('in', 'O'), ('man', 'O'), (',', 'O'), ('mouse', 'O'), (',', 'O'), ('rat', 'O'), ('and', 'O'), ('dog', 'O'), ('.', 'O'))"
"The major cause of hepatic copper accumulation in man is a dysfunctional ATP7B gene , causing Wilson disease ( WD ) .","(('The', 'O'), ('major', 'O'), ('cause', 'O'), ('of', 'O'), ('hepatic', 'B'), ('copper', 'I'), ('accumulation', 'I'), ('in', 'O'), ('man', 'O'), ('is', 'O'), ('a', 'O'), ('dysfunctional', 'O'), ('ATP7B', 'O'), ('gene', 'O'), (',', 'O'), ('causing', 'O'), ('Wilson', 'B'), ('disease', 'I'), ('(', 'O'), ('WD', 'B'), (')', 'O'), ('.', 'O'))"
"The ATP7B gene has been excluded in the much rarer human copper overload disease non - Indian childhood cirrhosis , indicating genetic heterogeneity .","(('The', 'O'), ('ATP7B', 'O'), ('gene', 'O'), ('has', 'O'), ('been', 'O'), ('excluded', 'O'), ('in', 'O'), ('the', 'O'), ('much', 'O'), ('rarer', 'O'), ('human', 'O'), ('copper', 'B'), ('overload', 'I'), ('disease', 'O'), ('non', 'B'), ('-', 'I'), ('Indian', 'I'), ('childhood', 'I'), ('cirrhosis', 'I'), (',', 'O'), ('indicating', 'O'), ('genetic', 'O'), ('heterogeneity', 'O'), ('.', 'O'))"
"By investigating the common autosomal recessive copper toxicosis ( CT ) in Bedlington terriers , we have identified a new locus involved in progressive liver disease .","(('By', 'O'), ('investigating', 'O'), ('the', 'O'), ('common', 'O'), ('autosomal', 'O'), ('recessive', 'O'), ('copper', 'B'), ('toxicosis', 'I'), ('(', 'O'), ('CT', 'B'), (')', 'O'), ('in', 'O'), ('Bedlington', 'O'), ('terriers', 'O'), (',', 'O'), ('we', 'O'), ('have', 'O'), ('identified', 'O'), ('a', 'O'), ('new', 'O'), ('locus', 'O'), ('involved', 'O'), ('in', 'O'), ('progressive', 'O'), ('liver', 'B'), ('disease', 'I'), ('.', 'O'))"
"We examined whether the WD gene ATP7B was also causative for CT by investigating the chromosomal co - localization of ATP7B and C04107 , using fluorescence in situ hybridization ( FISH ) .","(('We', 'O'), ('examined', 'O'), ('whether', 'O'), ('the', 'O'), ('WD', 'B'), ('gene', 'O'), ('ATP7B', 'O'), ('was', 'O'), ('also', 'O'), ('causative', 'O'), ('for', 'O'), ('CT', 'B'), ('by', 'O'), ('investigating', 'O'), ('the', 'O'), ('chromosomal', 'O'), ('co', 'O'), ('-', 'O'), ('localization', 'O'), ('of', 'O'), ('ATP7B', 'O'), ('and', 'O'), ('C04107', 'O'), (',', 'O'), ('using', 'O'), ('fluorescence', 'O'), ('in', 'O'), ('situ', 'O'), ('hybridization', 'O'), ('(', 'O'), ('FISH', 'O'), (')', 'O'), ('.', 'O'))"
"However , BAC clones containing ATP7B and C04107 mapped to the canine chromosome regions CFA22q11 and CFA10q26 , respectively , demonstrating that WD cannot be homologous to CT .","(('However', 'O'), (',', 'O'), ('BAC', 'O'), ('clones', 'O'), ('containing', 'O'), ('ATP7B', 'O'), ('and', 'O'), ('C04107', 'O'), ('mapped', 'O'), ('to', 'O'), ('the', 'O'), ('canine', 'O'), ('chromosome', 'O'), ('regions', 'O'), ('CFA22q11', 'O'), ('and', 'O'), ('CFA10q26', 'O'), (',', 'O'), ('respectively', 'O'), (',', 'O'), ('demonstrating', 'O'), ('that', 'O'), ('WD', 'B'), ('cannot', 'O'), ('be', 'O'), ('homologous', 'O'), ('to', 'O'), ('CT', 'B'), ('.', 'O'))"
Molecular analysis of the APC gene in 205 families : extended genotype - phenotype correlations in FAP and evidence for the role of APC amino acid changes in colorectal cancer predisposition .,"(('Molecular', 'O'), ('analysis', 'O'), ('of', 'O'), ('the', 'O'), ('APC', 'B'), ('gene', 'O'), ('in', 'O'), ('205', 'O'), ('families', 'O'), (':', 'O'), ('extended', 'O'), ('genotype', 'O'), ('-', 'O'), ('phenotype', 'O'), ('correlations', 'O'), ('in', 'O'), ('FAP', 'B'), ('and', 'O'), ('evidence', 'O'), ('for', 'O'), ('the', 'O'), ('role', 'O'), ('of', 'O'), ('APC', 'B'), ('amino', 'O'), ('acid', 'O'), ('changes', 'O'), ('in', 'O'), ('colorectal', 'B'), ('cancer', 'I'), ('predisposition', 'O'), ('.', 'O'))"
BACKGROUND / AIMS The development of colorectal cancer and a variable range of extracolonic manifestations in familial adenomatous polyposis ( FAP ) is the result of the dominant inheritance of adenomatous polyposis coli ( APC ) gene mutations .,"(('BACKGROUND', 'O'), ('/', 'O'), ('AIMS', 'O'), ('The', 'O'), ('development', 'O'), ('of', 'O'), ('colorectal', 'B'), ('cancer', 'I'), ('and', 'O'), ('a', 'O'), ('variable', 'O'), ('range', 'O'), ('of', 'O'), ('extracolonic', 'O'), ('manifestations', 'O'), ('in', 'O'), ('familial', 'B'), ('adenomatous', 'I'), ('polyposis', 'I'), ('(', 'O'), ('FAP', 'B'), (')', 'O'), ('is', 'O'), ('the', 'O'), ('result', 'O'), ('of', 'O'), ('the', 'O'), ('dominant', 'O'), ('inheritance', 'O'), ('of', 'O'), ('adenomatous', 'B'), ('polyposis', 'I'), ('coli', 'I'), ('(', 'O'), ('APC', 'B'), (')', 'O'), ('gene', 'O'), ('mutations', 'O'), ('.', 'O'))"
"In this study , direct mutation analysis of the APC gene was performed to determine genotype - phenotype correlations for nine extracolonic manifestations and to investigate the incidence of APC mutations in non - FAP colorectal cancer .","(('In', 'O'), ('this', 'O'), ('study', 'O'), (',', 'O'), ('direct', 'O'), ('mutation', 'O'), ('analysis', 'O'), ('of', 'O'), ('the', 'O'), ('APC', 'B'), ('gene', 'O'), ('was', 'O'), ('performed', 'O'), ('to', 'O'), ('determine', 'O'), ('genotype', 'O'), ('-', 'O'), ('phenotype', 'O'), ('correlations', 'O'), ('for', 'O'), ('nine', 'O'), ('extracolonic', 'O'), ('manifestations', 'O'), ('and', 'O'), ('to', 'O'), ('investigate', 'O'), ('the', 'O'), ('incidence', 'O'), ('of', 'O'), ('APC', 'B'), ('mutations', 'O'), ('in', 'O'), ('non', 'O'), ('-', 'O'), ('FAP', 'O'), ('colorectal', 'B'), ('cancer', 'I'), ('.', 'O'))"
"METHODS The APC gene was analysed in 190 unrelated FAP and 15 non - FAP colorectal cancer patients using denaturing gradient gel electrophoresis , the protein truncation test , and direct sequencing .","(('METHODS', 'O'), ('The', 'O'), ('APC', 'B'), ('gene', 'O'), ('was', 'O'), ('analysed', 'O'), ('in', 'O'), ('190', 'O'), ('unrelated', 'O'), ('FAP', 'B'), ('and', 'O'), ('15', 'O'), ('non', 'O'), ('-', 'O'), ('FAP', 'O'), ('colorectal', 'B'), ('cancer', 'I'), ('patients', 'O'), ('using', 'O'), ('denaturing', 'O'), ('gradient', 'O'), ('gel', 'O'), ('electrophoresis', 'O'), (',', 'O'), ('the', 'O'), ('protein', 'O'), ('truncation', 'O'), ('test', 'O'), (',', 'O'), ('and', 'O'), ('direct', 'O'), ('sequencing', 'O'), ('.', 'O'))"
RESULTS Chain terminating signals were only identified in patients belonging to the FAP group ( 105 patients ) .,"(('RESULTS', 'O'), ('Chain', 'O'), ('terminating', 'O'), ('signals', 'O'), ('were', 'O'), ('only', 'O'), ('identified', 'O'), ('in', 'O'), ('patients', 'O'), ('belonging', 'O'), ('to', 'O'), ('the', 'O'), ('FAP', 'B'), ('group', 'O'), ('(', 'O'), ('105', 'O'), ('patients', 'O'), (')', 'O'), ('.', 'O'))"
"Amino acid changes were identified in four patients , three of whom belonged to the non - FAP group of colorectal cancer patients .","(('Amino', 'O'), ('acid', 'O'), ('changes', 'O'), ('were', 'O'), ('identified', 'O'), ('in', 'O'), ('four', 'O'), ('patients', 'O'), (',', 'O'), ('three', 'O'), ('of', 'O'), ('whom', 'O'), ('belonged', 'O'), ('to', 'O'), ('the', 'O'), ('non', 'O'), ('-', 'O'), ('FAP', 'O'), ('group', 'O'), ('of', 'O'), ('colorectal', 'B'), ('cancer', 'I'), ('patients', 'O'), ('.', 'O'))"
Genotype - phenotype correlations identified significant differences in the nature of certain extracolonic manifestations in FAP patients belonging to three mutation subgroups .,"(('Genotype', 'O'), ('-', 'O'), ('phenotype', 'O'), ('correlations', 'O'), ('identified', 'O'), ('significant', 'O'), ('differences', 'O'), ('in', 'O'), ('the', 'O'), ('nature', 'O'), ('of', 'O'), ('certain', 'O'), ('extracolonic', 'O'), ('manifestations', 'O'), ('in', 'O'), ('FAP', 'B'), ('patients', 'O'), ('belonging', 'O'), ('to', 'O'), ('three', 'O'), ('mutation', 'O'), ('subgroups', 'O'), ('.', 'O'))"
This study also provided evidence for the pathological nature of amino acid changes in APC associated with both FAP and non - FAP colorectal cancer patients . .,"(('This', 'O'), ('study', 'O'), ('also', 'O'), ('provided', 'O'), ('evidence', 'O'), ('for', 'O'), ('the', 'O'), ('pathological', 'O'), ('nature', 'O'), ('of', 'O'), ('amino', 'O'), ('acid', 'O'), ('changes', 'O'), ('in', 'O'), ('APC', 'O'), ('associated', 'O'), ('with', 'O'), ('both', 'O'), ('FAP', 'B'), ('and', 'O'), ('non', 'O'), ('-', 'O'), ('FAP', 'O'), ('colorectal', 'B'), ('cancer', 'I'), ('patients', 'O'), ('.', 'O'), ('.', 'O'))"
Inherited colorectal polyposis and cancer risk of the APC I1307K polymorphism .,"(('Inherited', 'B'), ('colorectal', 'I'), ('polyposis', 'I'), ('and', 'O'), ('cancer', 'B'), ('risk', 'O'), ('of', 'O'), ('the', 'O'), ('APC', 'O'), ('I1307K', 'O'), ('polymorphism', 'O'), ('.', 'O'))"
"Germ - line and somatic truncating mutations of the APC gene are thought to initiate colorectal tumor formation in familial adenomatous polyposis syndrome and sporadic colorectal carcinogenesis , respectively .","(('Germ', 'O'), ('-', 'O'), ('line', 'O'), ('and', 'O'), ('somatic', 'O'), ('truncating', 'O'), ('mutations', 'O'), ('of', 'O'), ('the', 'O'), ('APC', 'B'), ('gene', 'O'), ('are', 'O'), ('thought', 'O'), ('to', 'O'), ('initiate', 'O'), ('colorectal', 'B'), ('tumor', 'I'), ('formation', 'O'), ('in', 'O'), ('familial', 'B'), ('adenomatous', 'I'), ('polyposis', 'I'), ('syndrome', 'I'), ('and', 'O'), ('sporadic', 'O'), ('colorectal', 'O'), ('carcinogenesis', 'O'), (',', 'O'), ('respectively', 'O'), ('.', 'O'))"
"Recently , an isoleucine - - > lysine polymorphism at codon 1307 ( I1307K ) of the APC gene has been identified in 6 % - 7 % of the Ashkenazi Jewish population .","(('Recently', 'O'), (',', 'O'), ('an', 'O'), ('isoleucine', 'O'), ('-', 'O'), ('-', 'O'), ('>', 'O'), ('lysine', 'O'), ('polymorphism', 'O'), ('at', 'O'), ('codon', 'O'), ('1307', 'O'), ('(', 'O'), ('I1307K', 'O'), (')', 'O'), ('of', 'O'), ('the', 'O'), ('APC', 'B'), ('gene', 'O'), ('has', 'O'), ('been', 'O'), ('identified', 'O'), ('in', 'O'), ('6', 'O'), ('%', 'O'), ('-', 'O'), ('7', 'O'), ('%', 'O'), ('of', 'O'), ('the', 'O'), ('Ashkenazi', 'O'), ('Jewish', 'O'), ('population', 'O'), ('.', 'O'))"
"To assess the risk of this common APC allelic variant in colorectal carcinogenesis , we have analyzed a large cohort of unselected Ashkenazi Jewish subjects with adenomatous polyps and . or colorectal cancer , for the APC I1307K polymorphism .","(('To', 'O'), ('assess', 'O'), ('the', 'O'), ('risk', 'O'), ('of', 'O'), ('this', 'O'), ('common', 'O'), ('APC', 'B'), ('allelic', 'O'), ('variant', 'O'), ('in', 'O'), ('colorectal', 'O'), ('carcinogenesis', 'O'), (',', 'O'), ('we', 'O'), ('have', 'O'), ('analyzed', 'O'), ('a', 'O'), ('large', 'O'), ('cohort', 'O'), ('of', 'O'), ('unselected', 'O'), ('Ashkenazi', 'O'), ('Jewish', 'O'), ('subjects', 'O'), ('with', 'O'), ('adenomatous', 'B'), ('polyps', 'I'), ('and', 'O'), ('.', 'O'), ('or', 'O'), ('colorectal', 'B'), ('cancer', 'I'), (',', 'I'), ('for', 'O'), ('the', 'O'), ('APC', 'O'), ('I1307K', 'O'), ('polymorphism', 'O'), ('.', 'O'))"
7 for colorectal neoplasia ( both P = . 01 ) .,"(('7', 'O'), ('for', 'O'), ('colorectal', 'B'), ('neoplasia', 'I'), ('(', 'O'), ('both', 'O'), ('P', 'O'), ('=', 'O'), ('.', 'O'), ('01', 'O'), (')', 'O'), ('.', 'O'))"
"Furthermore , compared with noncarriers , APC I1307K carriers had increased numbers of adenomas and colorectal cancers per patient ( P = . 03 ) , as well as a younger age at diagnosis .","(('Furthermore', 'O'), (',', 'O'), ('compared', 'O'), ('with', 'O'), ('noncarriers', 'O'), (',', 'O'), ('APC', 'O'), ('I1307K', 'O'), ('carriers', 'O'), ('had', 'O'), ('increased', 'O'), ('numbers', 'O'), ('of', 'O'), ('adenomas', 'B'), ('and', 'O'), ('colorectal', 'B'), ('cancers', 'I'), ('per', 'O'), ('patient', 'O'), ('(', 'O'), ('P', 'O'), ('=', 'O'), ('.', 'O'), ('03', 'O'), (')', 'O'), (',', 'O'), ('as', 'O'), ('well', 'O'), ('as', 'O'), ('a', 'O'), ('younger', 'O'), ('age', 'O'), ('at', 'O'), ('diagnosis', 'O'), ('.', 'O'))"
We conclude that the APC I1307K variant leads to increased adenoma formation and directly contributes to 3 % - 4 % of all Ashkenazi Jewish colorectal cancer .,"(('We', 'O'), ('conclude', 'O'), ('that', 'O'), ('the', 'O'), ('APC', 'O'), ('I1307K', 'O'), ('variant', 'O'), ('leads', 'O'), ('to', 'O'), ('increased', 'O'), ('adenoma', 'B'), ('formation', 'O'), ('and', 'O'), ('directly', 'O'), ('contributes', 'O'), ('to', 'O'), ('3', 'O'), ('%', 'O'), ('-', 'O'), ('4', 'O'), ('%', 'O'), ('of', 'O'), ('all', 'O'), ('Ashkenazi', 'O'), ('Jewish', 'O'), ('colorectal', 'B'), ('cancer', 'I'), ('.', 'O'))"
"The estimated relative risk for carriers may justify specific clinical screening for the 360 , 000 Americans expected to harbor this allele , and genetic testing in the setting of long - term - outcome studies may impact significantly on colorectal cancer prevention in this population .","(('The', 'O'), ('estimated', 'O'), ('relative', 'O'), ('risk', 'O'), ('for', 'O'), ('carriers', 'O'), ('may', 'O'), ('justify', 'O'), ('specific', 'O'), ('clinical', 'O'), ('screening', 'O'), ('for', 'O'), ('the', 'O'), ('360', 'O'), (',', 'O'), ('000', 'O'), ('Americans', 'O'), ('expected', 'O'), ('to', 'O'), ('harbor', 'O'), ('this', 'O'), ('allele', 'O'), (',', 'O'), ('and', 'O'), ('genetic', 'O'), ('testing', 'O'), ('in', 'O'), ('the', 'O'), ('setting', 'O'), ('of', 'O'), ('long', 'O'), ('-', 'O'), ('term', 'O'), ('-', 'O'), ('outcome', 'O'), ('studies', 'O'), ('may', 'O'), ('impact', 'O'), ('significantly', 'O'), ('on', 'O'), ('colorectal', 'B'), ('cancer', 'I'), ('prevention', 'O'), ('in', 'O'), ('this', 'O'), ('population', 'O'), ('.', 'O'))"
"Localization of human BRCA1 and its loss in high - grade , non - inherited breast carcinomas .","(('Localization', 'O'), ('of', 'O'), ('human', 'O'), ('BRCA1', 'O'), ('and', 'O'), ('its', 'O'), ('loss', 'O'), ('in', 'O'), ('high', 'O'), ('-', 'O'), ('grade', 'O'), (',', 'O'), ('non', 'B'), ('-', 'I'), ('inherited', 'I'), ('breast', 'I'), ('carcinomas', 'I'), ('.', 'O'))"
"Although the link between the BRCA1 tumour - suppressor gene and hereditary breast and ovarian cancer is established , the role , if any , of BRCA1 in non - familial cancers is unclear .","(('Although', 'O'), ('the', 'O'), ('link', 'O'), ('between', 'O'), ('the', 'O'), ('BRCA1', 'O'), ('tumour', 'B'), ('-', 'O'), ('suppressor', 'O'), ('gene', 'O'), ('and', 'O'), ('hereditary', 'B'), ('breast', 'I'), ('and', 'I'), ('ovarian', 'I'), ('cancer', 'I'), ('is', 'O'), ('established', 'O'), (',', 'O'), ('the', 'O'), ('role', 'O'), (',', 'O'), ('if', 'O'), ('any', 'O'), (',', 'O'), ('of', 'O'), ('BRCA1', 'O'), ('in', 'O'), ('non', 'B'), ('-', 'I'), ('familial', 'I'), ('cancers', 'I'), ('is', 'O'), ('unclear', 'O'), ('.', 'O'))"
"BRCA1 mutations are rare in sporadic cancers , but loss of BRCA1 resulting from reduced expression or incorrect subcellular localization is postulated to be important in non - familial breast and ovarian cancers .","(('BRCA1', 'O'), ('mutations', 'O'), ('are', 'O'), ('rare', 'O'), ('in', 'O'), ('sporadic', 'B'), ('cancers', 'I'), (',', 'O'), ('but', 'O'), ('loss', 'O'), ('of', 'O'), ('BRCA1', 'O'), ('resulting', 'O'), ('from', 'O'), ('reduced', 'O'), ('expression', 'O'), ('or', 'O'), ('incorrect', 'O'), ('subcellular', 'O'), ('localization', 'O'), ('is', 'O'), ('postulated', 'O'), ('to', 'O'), ('be', 'O'), ('important', 'O'), ('in', 'O'), ('non', 'B'), ('-', 'I'), ('familial', 'I'), ('breast', 'I'), ('and', 'I'), ('ovarian', 'I'), ('cancers', 'I'), ('.', 'O'))"
"These reagents detect a 220 - kD protein localized in discrete nuclear foci in all epithelial cell lines , including those derived from breast malignancies .","(('These', 'O'), ('reagents', 'O'), ('detect', 'O'), ('a', 'O'), ('220', 'O'), ('-', 'O'), ('kD', 'O'), ('protein', 'O'), ('localized', 'O'), ('in', 'O'), ('discrete', 'O'), ('nuclear', 'O'), ('foci', 'O'), ('in', 'O'), ('all', 'O'), ('epithelial', 'O'), ('cell', 'O'), ('lines', 'O'), (',', 'O'), ('including', 'O'), ('those', 'O'), ('derived', 'O'), ('from', 'O'), ('breast', 'B'), ('malignancies', 'I'), ('.', 'O'))"
"Immunohistochemical staining of human breast specimens also revealed BRCA1 nuclear foci in benign breast , invasive lobular cancers and low - grade ductal carcinomas .","(('Immunohistochemical', 'O'), ('staining', 'O'), ('of', 'O'), ('human', 'O'), ('breast', 'O'), ('specimens', 'O'), ('also', 'O'), ('revealed', 'O'), ('BRCA1', 'O'), ('nuclear', 'O'), ('foci', 'O'), ('in', 'O'), ('benign', 'O'), ('breast', 'O'), (',', 'O'), ('invasive', 'B'), ('lobular', 'I'), ('cancers', 'I'), ('and', 'O'), ('low', 'B'), ('-', 'I'), ('grade', 'I'), ('ductal', 'I'), ('carcinomas', 'I'), ('.', 'O'))"
"Conversely , BRCA1 expression was reduced or undetectable in the majority of high - grade , ductal carcinomas , suggesting that absence of BRCA1 may contribute to the pathogenesis of a significant percentage of sporadic breast cancers . .","(('Conversely', 'O'), (',', 'O'), ('BRCA1', 'O'), ('expression', 'O'), ('was', 'O'), ('reduced', 'O'), ('or', 'O'), ('undetectable', 'O'), ('in', 'O'), ('the', 'O'), ('majority', 'O'), ('of', 'O'), ('high', 'O'), ('-', 'O'), ('grade', 'O'), (',', 'O'), ('ductal', 'B'), ('carcinomas', 'I'), (',', 'O'), ('suggesting', 'O'), ('that', 'O'), ('absence', 'O'), ('of', 'O'), ('BRCA1', 'O'), ('may', 'O'), ('contribute', 'O'), ('to', 'O'), ('the', 'O'), ('pathogenesis', 'O'), ('of', 'O'), ('a', 'O'), ('significant', 'O'), ('percentage', 'O'), ('of', 'O'), ('sporadic', 'B'), ('breast', 'I'), ('cancers', 'I'), ('.', 'O'), ('.', 'O'))"
